[
  {
    "id": "WO2011111817A1",
    "text": "Benzazepine compound AbstractDisclosed is a compound which is useful as a therapeutic or prophylactic agent for diseases associated with 5-HT2Creceptor, especially for urinary incontinence such as stress urinary incontinence, urge urinary incontinence and mixed urinary incontinence, sexual dysfunction such as erectile dysfunction, obesity and the like.\nStudies have been made on compounds which have a 5-HT2Creceptor agonist action and are thus promising as active ingredients of pharmaceutical compositions for the treatment or prophylaxis of urinary incontinence such as stress urinary incontinence, urge urinary incontinence and mixed urinary incontinence, sexual dysfunction such as erectile dysfunction, obesity and the like, and it is confirmed that a specific benzazepine compound has an excellent 5-HT2Creceptor agonist action. The benzazepine compound has a 5-HT2Creceptor agonist action and can be used as a therapeutic or prophylactic agent for diseases associated with 5-HT2Creceptor, especially for urinary incontinence such as stress urinary incontinence, urge urinary incontinence and mixed urinary incontinence, sexual dysfunction such as erectile dysfunction, obesity and the like. Claims (\n18\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n式（Ｉ）の化合物又はその塩、及び製薬学的に許容される賦形剤を含有する医薬組成物。\n\n\n \n \n\n（式中、\n\nR\n1a\n及びR\n1b\nは、それぞれ同一又は異なって、-H、又はC\n1-6\nアルキルであり、あるいは、一体となってオキソであり、\n\nR\n2a\n及びR\n2b\nは、それぞれ同一又は異なって、-H、又は-O-C\n1-6\nアルキルで置換されていてもよいC\n1-6\nアルキルであり、\n\nR\n3\nは、-H、置換されていてもよいC\n1-6\nアルキル、C\n3-8\nシクロアルキル、置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、又は置換されていてもよいヘテロ環であり、\n\nR\n4\nは、-H、ハロゲン、シアノ、置換されていてもよいC\n1-6\nアルキル、C\n2-6\nアルケニル、置換されていてもよいアリール、置換されていてもよいC\n3-8\nシクロアルキル、芳香族ヘテロ環、又は含酸素ヘテロ環であり、\n\nR\n5\nは、-H、ハロゲン、C\n1-6\nアルキル、C\n3-8\nシクロアルキル、アリール、又は芳香族ヘテロ環であり、\n\nR\n6\n及びR\n7\nは、同一又は異なって、-H、又はC\n1-6\nアルキルであり、\n\nXは、-C(R\nA\n)(R\nB\n)-、又は-O-であり、\n\nR\nA\n及びR\nB\nは、同一又は異なって、-H、又はC\n1-6\nアルキルである。）\n\nA pharmaceutical composition comprising a compound of formula (I) or a salt thereof, and a pharmaceutically acceptable excipient. \n \n \n \n (Where \n R \n1a\n and R \n1b\n are the same or different and are —H or C \n1-6\n alkyl, or oxo together, \n R \n2a\n and R \n2b\n are the same or different and each represent -H or C \n1-6\n alkyl optionally substituted with -OC \n1-6\n alkyl; \n R \n3\n is —H, optionally substituted C \n1-6\n alkyl, C \n3-8\n cycloalkyl, \noptionally\n substituted aryl, —SO \n2\n —C \n1-6\n alkyl, or optionally substituted. A good heterocycle, \n R \n4\n is -H, halogen, cyano, optionally substituted C \n1-6\n alkyl, C \n2-6\n alkenyl, optionally substituted aryl, optionally substituted C \n3-8\n cycloalkyl, An aromatic heterocycle or an oxygen-containing heterocycle, \n R \n5\n is -H, halogen, C \n1-6\n alkyl, C \n3-8\n cycloalkyl, aryl, or an aromatic heterocycle, \n R \n6\n and R \n7\n are the same or different and are —H or C \n1-6\n alkyl; \n X is -C (R \nA\n ) (R \nB\n )-, or -O- \n R \nA\n and R \nB\n are the same or different and are —H or C \n1-6\n alkyl. )\n\n\n\n\n\n\n\n\n\n\n \n\nR\n1a\n及びR\n1b\nが、それぞれ-Hであり、あるいは、一体となってオキソであり、\n\nR\n2a\nが、-H、又はC\n1-6\nアルキルであり、\n\nR\n2b\nが、-Hであり、\n\nR\n3\nが、-H、C\n1-6\nアルキル、ハロゲノC\n1-6\nアルキル、C\n1-6\nアルキレン-OH、(置換されていてもよいC\n1-6\nアルキレン)-O-C\n1-6\nアルキル、C\n1-6\nアルキレン-置換されていてもよいシクロアルキル、C\n1-6\nアルキレン-置換されていてもよいアリール、C\n1-6\nアルキレン-置換されていてもよいヘテロ環基、-CO-C\n1-6\nアルキル、-CO-C\n1-6\nアルキレン-O-C\n1-6\nアルキル、-CO-置換されていてもよいシクロアルキル、-CO-置換されていてもよいアリール、-CO-NR\n8\nR\n9\n、-CO-O-C\n1-6\nアルキル、-CO-O-C\n1-6\nアルキレン-置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、置換されていてもよいアリール、又は、置換されていてもよいヘテロ環であり、\n\nR\n8\n及びR\n9\nが、それぞれ同一又は異なって、-H、又はC\n1-6\nアルキルであり、\n\nR\n4\nが、-H、C\n1-6\nアルキル、ハロゲン、ハロゲノC\n1-6\nアルキル、置換されていてもよいシクロアルキル、又は、置換されていてもよいアリールであり、\n\nR\n5\nが、同一又は異なって、-H、又はC\n1-6\nアルキルである、請求項１に記載の医薬組成物。\n\nR \n1a\n and R \n1b\n are each -H or, together, oxo, \n R \n2a\n is -H or C \n1-6\n alkyl; \n R \n2b\n is -H; \n R \n3\n is -H, C \n1-6\n alkyl, halogeno C \n1-6\n alkyl, C \n1-6\n alkylene-OH, (optionally substituted C \n1-6\n alkylene) -OC \n1-6\n alkyl, C \n1 -6\n alkylene-optionally substituted cycloalkyl, C \n1-6\n alkylene-optionally substituted aryl, C \n1-6\n alkylene-optionally substituted heterocyclic group, -CO-C \n1-6\n Alkyl, -CO-C \n1-6\n alkylene-OC \n1-6\n alkyl, -CO-optionally substituted cycloalkyl, -CO-optionally substituted aryl, -CO-NR \n8\n R \n9\n , -CO -OC \n1-6\n alkyl, -CO-OC \n1-6\n alkylene-optionally substituted aryl, -SO \n2\n -C \n1-6\n alkyl, optionally substituted aryl, or optionally substituted A heterocycle, \n R \n8\n and R \n9\n are the same or different and are —H or C \n1-6\n alkyl; \n R \n4\n is -H, C \n1-6\n alkyl, halogen, halogeno C \n1-6\n alkyl, optionally substituted cycloalkyl, or optionally substituted aryl; \n The pharmaceutical composition according to claim 1, wherein R \n5\n is the same or different and is -H or C \n1-6\n alkyl.\n\n\n\n\n\n\n\n\n\n\n \n\nR\n3\nが、-H、置換されていてもよいC\n1-6\nアルキル、C\n3-8\nシクロアルキル、置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、又は含酸素ヘテロ環であり、\n\nR\n4\nが、-H、ハロゲン、シアノ、置換されていてもよいC\n1-6\nアルキル、C\n2-6\nアルケニル、置換されていてもよいアリール、C\n3-8\nシクロアルキル、芳香族ヘテロ環、又は含酸素ヘテロ環である、請求項１に記載の医薬組成物。\n\nR \n3\n is —H, optionally substituted C \n1-6\n alkyl, C \n3-8\n cycloalkyl, \noptionally\n substituted aryl, —SO \n2\n —C \n1-6\n alkyl, or oxygen-containing heterocycle Yes, \n R \n4\n is -H, halogen, cyano, optionally substituted C \n1-6\n alkyl, C \n2-6\n alkenyl, optionally substituted aryl, C \n3-8\n cycloalkyl, aromatic heterocycle, or The pharmaceutical composition according to claim 1, which is an oxygen-containing heterocycle.\n\n\n\n\n\n\n\n\n\n\n \n\n式（ＩＩ）の化合物又はその塩。\n\n\n \n \n\n（式中、\n\nR\n11a\n及びR\n11b\nは、それぞれ同一又は異なって、-H、又はC\n1-6\nアルキルであり、あるいは、一体となってオキソであり、\n\nR\n21a\n及びR\n21b\nは、それぞれ同一又は異なって、-H、又は-O-C\n1-6\nアルキルで置換されていてもよいC\n1-6\nアルキルであり、\n\nR\n31\nは、-H、置換されていてもよいC\n1-6\nアルキル、C\n3-8\nシクロアルキル、置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、又は置換されていてもよいヘテロ環であり、\n\nR\n41\nは、-H、ハロゲン、シアノ、置換されていてもよいC\n1-6\nアルキル、C\n2-6\nアルケニル、置換されていてもよいアリール、置換されていてもよいC\n3-8\nシクロアルキル、芳香族ヘテロ環、又は含酸素ヘテロ環であり、\n\nR\n51\nは、-H、ハロゲン、C\n1-6\nアルキル、C\n3-8\nシクロアルキル、アリール、又は芳香族ヘテロ環であり、\n\nR\n61\n及びR\n71\nは、同一又は異なって、-H、又はC\n1-6\nアルキルであり、\n\nX\n1\nは、-C(R\nA1\n)(R\nB1\n)-、又は-O-であり、\n\nR\nA1\n及びR\nB1\nは、同一又は異なって、-H、又はC\n1-6\nアルキルである。\n\n但し、\n\n（ｉ）R\n11a\n、R\n11b\n、R\n21a\n、R\n21b\n、R\n41\n、R\n51\n、R\n61\n、及びR\n71\nがそれぞれ-Hであり、X\n1\nが-O-である場合、R\n31\nは、-H、-CO-メチル、又は-SO\n2\n-メチル以外の基であり、\n\n（ｉｉ）R\n11a\n及びR\n11b\nが一体となってオキソであり、R\n21a\n、R\n21b\n、R\n41\n、R\n51\n、R\n61\n、及びR\n71\nがそれぞれ-Hであり、X\n1\nが-O-である場合、R\n31\nは、-H、又はメチル以外の基である。）\n\nA compound of formula (II) or a salt thereof. \n \n \n \n (Where \n R \n11a\n and R \n11b\n are the same or different and are —H or C \n1-6\n alkyl, or oxo as a whole, \n R \n21a\n and R \n21b\n are the same or different and each represent -H or C \n1-6\n alkyl optionally substituted with -OC \n1-6\n alkyl; \n R \n31\n is —H, optionally substituted C \n1-6\n alkyl, C \n3-8\n cycloalkyl, \noptionally\n substituted aryl, —SO \n2\n —C \n1-6\n alkyl, or optionally substituted. A good heterocycle, \n R \n41\n is -H, halogen, cyano, optionally substituted C \n1-6\n alkyl, C \n2-6\n alkenyl, optionally substituted aryl, optionally substituted C \n3-8\n cycloalkyl, An aromatic heterocycle or an oxygen-containing heterocycle, \n R \n51\n is -H, halogen, C \n1-6\n alkyl, C \n3-8\n cycloalkyl, aryl, or an aromatic heterocycle, \n R \n61\n and R \n71\n are the same or different and are —H or C \n1-6\n alkyl; \n X \n1\n is -C (R \nA1\n ) (R \nB1\n )-, or -O- \n R \nA1\n and R \nB1\n are the same or different and are —H or C \n1-6\n alkyl. \n However, \n (I) when R \n11a\n , R \n11b\n , R \n21a\n , R \n21b\n , R \n41\n , R \n51\n , R \n61\n , and R \n71\n are each —H and X \n1\n is —O—, R \n31\n is —H , -CO-methyl, or -SO \n2\n -methyl, \n (Ii) R \n11a\n and R \n11b\n together are oxo, R \n21a\n , R \n21b\n , R \n41\n , R \n51\n , R \n61\n , and R \n71\n are each —H, and X \n1\n is —O—. In this case, R \n31\n is —H or a group other than methyl. )\n\n\n\n\n\n\n\n\n\n\n \n\nR\n11a\n及びR\n11b\nが、それぞれ-Hであり、あるいは、一体となってオキソであり、\n\nR\n21a\nが、-H、又はC\n1-6\nアルキルであり、\n\nR\n21b\nが、-Hであり、\n\nR\n31\nが、-H、C\n1-6\nアルキル、ハロゲノC\n1-6\nアルキル、C\n1-6\nアルキレン-OH、(置換されていてもよいC\n1-6\nアルキレン)-O-C\n1-6\nアルキル、C\n1-6\nアルキレン-置換されていてもよいシクロアルキル、C\n1-6\nアルキレン-置換されていてもよいアリール、C\n1-6\nアルキレン-置換されていてもよいヘテロ環基、-CO-C\n1-6\nアルキル、-CO-C\n1-6\nアルキレン-O-C\n1-6\nアルキル、-CO-置換されていてもよいシクロアルキル、-CO-置換されていてもよいアリール、-CO-NR\n81\nR\n91\n、-CO-O-C\n1-6\nアルキル、-CO-O-C\n1-6\nアルキレン-置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、置換されていてもよいアリール、又は、置換されていてもよいヘテロ環であり、\n\nR\n81\n及びR\n91\nが、それぞれ同一又は異なって、-H、又はC\n1-6\nアルキルであり、\n\nR\n41\nが、-H、C\n1-6\nアルキル、ハロゲン、ハロゲノC\n1-6\nアルキル、置換されていてもよいシクロアルキル、又は、置換されていてもよいアリールであり、\n\nR\n51\nが、同一又は異なって、-H、又はC\n1-6\nアルキルである、請求項４に記載の化合物又はその塩。\n\nR \n11a\n and R \n11b\n are each —H, or together oxo, \n R \n21a\n is -H or C \n1-6\n alkyl; \n R \n21b\n is -H; \n R \n31\n is -H, C \n1-6\n alkyl, halogeno C \n1-6\n alkyl, C \n1-6\n alkylene-OH, (optionally substituted C \n1-6\n alkylene) -OC \n1-6\n alkyl, C \n1 -6\n alkylene-optionally substituted cycloalkyl, C \n1-6\n alkylene-optionally substituted aryl, C \n1-6\n alkylene-optionally substituted heterocyclic group, -CO-C \n1-6\n Alkyl, -CO-C \n1-6\n alkylene-OC \n1-6\n alkyl, -CO-optionally substituted cycloalkyl, -CO-optionally substituted aryl, -CO-NR \n81\n R \n91\n , -CO -OC \n1-6\n alkyl, -CO-OC \n1-6\n alkylene-optionally substituted aryl, -SO \n2\n -C \n1-6\n alkyl, optionally substituted aryl, or optionally substituted A heterocycle, \n R \n81\n and R \n91\n are the same or different and each represents -H or C \n1-6\n alkyl; \n R \n41\n is -H, C \n1-6\n alkyl, halogen, halogeno C \n1-6\n alkyl, optionally substituted cycloalkyl, or optionally substituted aryl; \n The compound or a salt thereof according to claim 4, wherein R \n51\n is the same or different and is —H or C \n1-6\n alkyl.\n\n\n\n\n\n\n\n\n\n\n \n\nR\n31\nが、-H、置換されていてもよいC\n1-6\nアルキル、C\n3-8\nシクロアルキル、置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、又は含酸素ヘテロ環であり、\n\nR\n41\nが、-H、ハロゲン、シアノ、置換されていてもよいC\n1-6\nアルキル、C\n2-6\nアルケニル、置換されていてもよいアリール、C\n3-8\nシクロアルキル、芳香族ヘテロ環、又は含酸素ヘテロ環である、請求項４に記載の化合物又はその塩。\n\nR \n31\n is —H, optionally substituted C \n1-6\n alkyl, C \n3-8\n cycloalkyl, \noptionally\n substituted aryl, —SO \n2\n —C \n1-6\n alkyl, or an oxygen-containing heterocycle. Yes, \n R \n41\n is -H, halogen, cyano, optionally substituted C \n1-6\n alkyl, C \n2-6\n alkenyl, optionally substituted aryl, C \n3-8\n cycloalkyl, aromatic heterocycle, or The compound or a salt thereof according to claim 4, which is an oxygen-containing heterocycle.\n\n\n\n\n\n\n\n\n\n\n \n\nR\n31\nが-H、メチル、-CO-メチル、又は-SO\n2\n-メチル以外の基である、請求項６に記載の化合物又はその塩。\n\nThe compound or a salt thereof according to claim 6, wherein R \n31\n is a group other than -H, methyl, -CO-methyl, or -SO \n2\n -methyl.\n\n\n\n\n\n\n\n\n\n\n \n\nR\n11a\nが、-H又はメチルであり、R\n11b\n、R\n21a\n、R\n21b\n、R\n51\n、R\n61\n、及びR\n71\nがそれぞれ-Hである、請求項７に記載の化合物又はその塩。\n\nThe compound or a salt thereof according to claim 7, wherein R \n11a\n is -H or methyl, and R \n11b\n , R \n21a\n , R \n21b\n , R \n51\n , R \n61\n , and R \n71\n are each -H.\n\n\n\n\n\n\n\n\n\n\n \n\nR\n41\nが、-H、ハロゲン、又はC\n3-8\nシクロアルキルである、請求項８に記載の化合物又はその塩。\n\nThe compound or a salt thereof according to claim 8, wherein R \n41\n is -H, halogen, or C \n3-8\n cycloalkyl.\n\n\n\n\n\n\n\n\n\n\n \n\nR\n41\nが、シクロプロピルである、請求項９に記載の化合物又はその塩。\n\nThe compound or a salt thereof according to claim 9, wherein R \n41\n is cyclopropyl.\n\n\n\n\n\n\n\n\n\n\n \n\nR\n31\nが、（ａ）ハロゲン、（ｂ）-O-C\n1-6\nアルキル、（ｃ）ハロゲン及びシアノからなる群より選択される１以上の基で置換されていてもよいフェノキシ、（ｄ）含酸素ヘテロ環、及び、（ｅ）-O-C\n1-6\nアルキルで置換されていてもよいC\n1-6\nアルキル、ハロゲン、及び-O-C\n1-6\nアルキルからなる群から選択される１以上の基で置換されていてもよいフェニルからなる群より選択される１以上の基で置換されていてもよいC\n1-6\nアルキルである、請求項１０に記載の化合物又はその塩。\n\nR \n31\n is (a) halogen, (b) —OC \n1-6\n alkyl, (c) phenoxy optionally substituted with one or more groups selected from the group consisting of halogen and cyano, (d) oxygen-containing heterocycle, and substituted by one or more groups selected from the group consisting of (e) -OC \n1-6\n alkyl optionally substituted by C \n1-6\n alkyl, halogen, and -OC \n1-6\n alkyl is C \n1-6\n alkyl optionally substituted with one or more groups also selected from the group consisting of phenyl optionally, the compound or a salt thereof according to claim 10.\n\n\n\n\n\n\n\n\n\n\n \n\n11-シクロプロピル-1-(2-メトキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン、\n\n4-(3-メトキシプロピル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-メトキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-エトキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(3-メトキシプロピル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(3-フルオロプロピル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n1-イソブチル-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン、\n\n5-ブロモ-4-(2-メトキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[(2S)-テトラヒドロフラン-2-イルメチル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[(2R)-2-メトキシプロピル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-フルオロベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[(2S)-3-フルオロ-2-メトキシプロピル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n4-(3-クロロベンジル)-5-シクロプロピル-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(テトラヒドロ-2H-ピラン-3-イルメチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2,3-ジヒドロ-1,4-ベンゾジオキシン-2-イルメチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-フェノキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-メチルベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(3-メチルベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2,5-ジフルオロベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[3-(メトキシメチル)ベンジル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n4-(5-クロロ-2-フルオロベンジル)-5-シクロプロピル-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2,3-ジヒドロ-1,4-ベンゾジオキシン-6-イルメチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n(3S)-5-シクロプロピル-4-(2-メトキシエチル)-3-メチル-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n4-[2-(5-シクロプロピル-2,3,7,8,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-4(6H)-イル)エトキシ]-3,5-ジフルオロベンゾニトリル、\n\n5-シクロプロピル-4-(3-メトキシベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(3,5-ジフルオロベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、若しくは、\n\n5-シクロプロピル-4-[(2R)-2-エトキシプロピル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、又はその塩である、請求項４に記載の化合物又はその塩。\n\n11-cyclopropyl-1- (2-methoxyethyl) -2,3,4,6,7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline, \n 4- (3-methoxypropyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (2-methoxyethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (2-ethoxyethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (3-methoxypropyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (3-fluoropropyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline, \n 5-bromo-4- (2-methoxyethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-Cyclopropyl-4-[(2S) -tetrahydrofuran-2-ylmethyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [ 3] Benzazepine, \n 5-Cyclopropyl-4-[(2R) -2-methoxypropyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3 ] Benzazepine, \n 5-cyclopropyl-4- (2-fluorobenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-cyclopropyl-4-[(2S) -3-fluoro-2-methoxypropyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3- h] [3] benzoazepine, \n 4- (3-chlorobenzyl) -5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-Cyclopropyl-4- (tetrahydro-2H-pyran-3-ylmethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [ 3] Benzazepine, \n 5-cyclopropyl-4- (2,3-dihydro-1,4-benzodioxin-2-ylmethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [ 2,3-h] [3] benzazepine, \n 5-cyclopropyl-4- (2-phenoxyethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-cyclopropyl-4- (2-methylbenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (3-methylbenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-Cyclopropyl-4- (2,5-difluorobenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzo Azepine, \n 5-Cyclopropyl-4- [3- (methoxymethyl) benzyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] Benzazepine, \n 4- (5-Chloro-2-fluorobenzyl) -5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3 ] Benzazepine, \n 5-Cyclopropyl-4- (2,3-dihydro-1,4-benzodioxin-6-ylmethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [ 2,3-h] [3] benzazepine, \n (3S) -5-cyclopropyl-4- (2-methoxyethyl) -3-methyl-2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3- h] [3] benzoazepine, \n 4- [2- (5-Cyclopropyl-2,3,7,8,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepin-4 (6H) -yl) Ethoxy] -3,5-difluorobenzonitrile, \n 5-cyclopropyl-4- (3-methoxybenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-Cyclopropyl-4- (3,5-difluorobenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzo Azepine or \n 5-cyclopropyl-4-[(2R) -2-ethoxypropyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3 ] The compound or its salt of Claim 4 which is a benzazepine or its salt.\n\n\n\n\n\n\n\n\n\n\n \n\n請求項４に記載の化合物又はその塩、及び製薬学的に許容される賦形剤を含有する医薬組成物。\n\n\nA pharmaceutical composition comprising the compound according to claim 4 or a salt thereof, and a pharmaceutically acceptable excipient.\n\n\n\n\n\n\n\n\n\n\n\n \n\n請求項４に記載の化合物又はその塩を含有する、5-HT\n2C\n受容体に関係する疾患の予防又は治療用医薬組成物。\n\nA pharmaceutical composition for preventing or treating a disease associated with 5-HT \n2C\n receptor, comprising the compound according to claim 4 or a salt thereof.\n\n\n\n\n\n\n\n\n\n\n \n\n尿失禁の予防又は治療医薬組成物である、請求項１４に記載の医薬組成物。\n\n\nThe pharmaceutical composition according to claim 14, which is a pharmaceutical composition for preventing or treating urinary incontinence.\n\n\n\n\n\n\n\n\n\n\n\n \n\n尿失禁の予防又は治療医薬組成物の製造のための、請求項４に記載の化合物又はその塩の使用。\n\n\nUse of the compound according to claim 4 or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating urinary incontinence.\n\n\n\n\n\n\n\n\n\n\n\n \n\n尿失禁の予防又は治療に使用するための、請求項４に記載の化合物又はその塩。\n\n\nThe compound or a salt thereof according to claim 4, for use in the prevention or treatment of urinary incontinence.\n\n\n\n\n\n\n\n\n\n\n\n \n\n請求項４に記載の化合物又はその塩の有効量を対象に投与することからなる、尿失禁の予防若しくは治療方法。\n\n\nA method for preventing or treating urinary incontinence, comprising administering an effective amount of the compound or salt thereof according to claim 4 to a subject. Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n \nベンゾアゼピン化合物\nBenzazepine compounds\n\n\n\n\n\n\n\n\n \n\n　本発明は医薬組成物、殊に5-HT\n2C\n受容体に関係する疾患、特に、腹圧性尿失禁、切迫性尿失禁、混合型尿失禁等の尿失禁、勃起不全症等の性機能障害、肥満等の治療又は予防用医薬組成物の有効成分として有用なベンゾアゼピン化合物に関する。\n\nThe present invention relates to pharmaceutical compositions, in particular diseases related to 5-HT \n2C\n receptors, in particular urinary incontinence such as stress urinary incontinence, urge incontinence, mixed urinary incontinence, sexual dysfunction such as erectile dysfunction, The present invention relates to a benzazepine compound useful as an active ingredient of a pharmaceutical composition for treating or preventing obesity.\n\n\n\n\n\n\n\n\n\n\n \n\n　セロトニン2C（5-HT\n2C\n）受容体は生体内において種々の生理作用に関わる伝達物質セロトニンの受容体の一つである。主に中枢神経系（脳・脊髄）において発現が認められている。\n\nSerotonin 2C (5-HT \n2C\n ) receptor is one of the receptors for serotonin, a transmitter substance involved in various physiological functions in vivo. Expression is observed mainly in the central nervous system (brain and spinal cord).\n\n\n\n\n\n\n \n\n　中枢5-HT\n2C\n受容体の生理的機能として食欲抑制作用がよく知られており、ラットにおいて種々の5-HT\n2C\n受容体作動薬（アゴニスト）による摂餌量の低下作用が報告されている（非特許文献１、２）。また5-HT\n2C\n受容体アゴニストの食欲抑制作用によって、ヒトにおいて抗肥満作用を示すことが確認されている（非特許文献３）。\n\nAppetite suppression is well known as a physiological function of central 5-HT \n2C\n receptors, and various 5-HT \n2C\n receptor agonists (agonists) have been reported to reduce food intake in rats ( Non-patent documents 1, 2). Further, it has been confirmed that anti-obesity action is shown in humans due to the appetite suppressive action of 5-HT \n2C\n receptor agonists (Non-patent Document 3).\n\n\n\n\n\n\n \n\n　中枢5-HT\n2C\n受容体は末梢神経機能の制御にも関与しており、5-HT\n2C\n受容体アゴニストによりラットの陰茎勃起が誘発され（非特許文献４）、サルの交尾行動試験において挿入から射精までの時間を延長することが報告されている（非特許文献５）。またラットにおいて、5-HT\n2C\n受容体アゴニストは腹圧上昇時の尿道抵抗を高めることが報告されている（非特許文献６）。その他、ラットの神経因性・炎症性疼痛の病態モデルにおいて、5-HT\n2C\n受容体アゴニストの脊髄内投与で有効性を示すことが報告されている（非特許文献７，８）。5-HT\n2C\n受容体アゴニストには多くの臨床応用が考えられ、特に抗肥満薬，男性勃起不全治療薬，早漏治療薬，腹圧性尿失禁治療薬，神経因性・炎症性疼痛治療薬等として期待される。\n\nCentral 5-HT \n2C\n receptor is also involved in the control of peripheral nerve function, and 5-HT \n2C\n receptor agonist induces penile erection in rats (Non-Patent Document 4). It has been reported that the time until ejaculation is extended (Non-patent Document 5). In rats, 5-HT \n2C\n receptor agonists have been reported to increase urethral resistance when abdominal pressure increases (Non-patent Document 6). In addition, it has been reported that 5-HT \n2C\n receptor agonists are effective in the spinal cord in a pathological model of neuropathic / inflammatory pain in rats (Non-patent Documents 7 and 8). 5-HT \n2C\n receptor agonists have many clinical applications, especially as anti-obesity drugs, male erectile dysfunction drugs, premature ejaculation drugs, stress urinary incontinence drugs, neuropathic / inflammatory pain drugs, etc. Be expected.\n\n\n\n\n\n\n \n\n　5-HT\n2C\n受容体アゴニストとしては、ベンゾアゼピン誘導体が報告され、3環性のベンゾアゼピン誘導体として、例えばCompound A（特許文献１）やCompound B（特許文献２）が知られている。\n\n\n \n \n\n\nAs 5-HT \n2C\n receptor agonists, benzoazepine derivatives have been reported, and as tricyclic benzoazepine derivatives, for example, Compound A (Patent Document 1) and Compound B (Patent Document 2) are known. \n \n \n \n \n\n\n\n\n\n\n \n\n　別の5-HT\n2C\n受容体アゴニストとしては、２環性のベンゾアゼピン誘導体が報告されている（特許文献３、特許文献４、特許文献５）。\n\nAs another 5-HT \n2C\n receptor agonist, a bicyclic benzazepine derivative has been reported (Patent Document 3, Patent Document 4, Patent Document 5).\n\n\n\n\n\n\n \n\n　３環性のベンゾアゼピン誘導体である、2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン誘導体や3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン誘導体としては、式(AA)の化合物がDopamine D3 Modulatorであること、及び、中枢性薬物乱用や薬物依存症に有用であることが知られている（特許文献６）。\n\n\n \n \n\n　また、この文献には、式(AA)の合成中間体として以下の化合物が開示されている。\n\n\n \n \n\n\n2,3,4,6,7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline derivatives and 3,4,6,7,9, which are tricyclic benzoazepine derivatives , 10-Hexahydro [1,4] oxazino [2,3-h] [3] benzazepine derivatives include compounds of formula (AA) that are Dopamine D3 Modulators, central drug abuse and drug addiction It is known that it is useful for (patent document 6). \n \n \n \n In addition, this document discloses the following compounds as synthetic intermediates of the formula (AA). \n \n \n \n \n\n\n\n\n\n\n \n\n　また、式(AA)の具体的な化合物の構造活性相関についての報告があり（非特許文献９）、この報告では、以下の化合物が式(AA)の化合物の製造に使用されたことが記載されている。\n\n\n \n \n\n\nIn addition, there is a report on the structure-activity relationship of a specific compound of formula (AA) (Non-Patent Document 9). This report describes that the following compounds were used for the preparation of the compound of formula (AA). Has been. \n \n \n \n \n\n\n\n\n\n\n \n\n　さらに、5-HT\n6\n受容体アンタゴニストに関する報告があり（非特許文献１０）、以下の化合物について、ベンゾアゼピンに縮合する環を５員環から６員環に変換したことで、5-HT\n6\n受容体へのPotencyの消失したことが開示されている。\n\n\n \n \n\n\nFurthermore, there are reports of 5-HT \n6\n receptor antagonists (Non-patent Document 10), for the following compounds, by converting the ring fused to the benzo azepine to 6-membered ring from 5-membered ring, 5-HT \n6\n receptor It is disclosed that the potency to the body has disappeared. \n \n \n \n \n\n\n\n\n\n\n \n\n　しかし、これら３環性ベンゾアゼピン誘導体を開示する文献には、2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン誘導体や3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン誘導体の5-HT\n2C\n受容体アゴニスト活性の開示はない。\n\nHowever, references disclosing these tricyclic benzoazepine derivatives include 2,3,4,6,7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline derivatives and 3,4 5,7,9,10-Hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine derivatives do not disclose 5-HT \n2C\n receptor agonist activity.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n国際公開第WO 2002/074746号パンフレット\nInternational Publication No. WO 2002/074746 Pamphlet\n\n\n\n\n\n\n\n\n\n\n \n国際公開第WO 2003/086306号パンフレット\nInternational Publication No. WO 2003/086306 Pamphlet\n\n\n\n\n\n\n\n\n\n\n \n国際公開第WO 2005/042490号パンフレット\nInternational Publication No. WO 2005/042490 pamphlet\n\n\n\n\n\n\n\n\n\n\n \n国際公開第WO 2005/042491号パンフレット\nInternational Publication No. WO 2005/042491 Pamphlet\n\n\n\n\n\n\n\n\n\n\n \n国際公開第WO 2005/003096号パンフレット\nInternational Publication No. WO 2005/003096 Pamphlet\n\n\n\n\n\n\n\n\n\n\n \n国際公開第WO 2005/118549号パンフレット\nInternational Publication No. WO 2005/118549 Pamphlet\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nObesity、2008年、第17巻、494-503ページ\nObesity, 2008, 17, 17, 494-503\n\n\n\n\n\n\n\n\n\n\n \nProgress in Neuro-Psychopharmacology and Biological Psychiatry、2002年、第26巻、441-449ページ\nProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 441-449\n\n\n\n\n\n\n\n\n\n\n \nJournal of Pharmacology and Experimental Therapeutics、2008年、第325巻、577-587ページ\nJournal of Pharmacology and Experimental Therapeutics, 2008, 325, 577-587\n\n\n\n\n\n\n\n\n\n\n \nEuropean Journal of Pharmacology、2004年、第483巻、37-43ページ\nEuropean Journal of Pharmacy, 2004, 483, 37-43\n\n\n\n\n\n\n\n\n\n\n \nPsychopharmacology、1993年、第111巻、47-54ページ\nPsychopharmacology, 1993, 111, 47-54\n\n\n\n\n\n\n\n\n\n\n \nAmerican Journal of Physiology : Renal Physiology、2009年、第297巻、1024-1031ページ\nAmerican Journal of Physiology: Renal Physiology, 2009, 297, 1024-1031\n\n\n\n\n\n\n\n\n\n\n \nPain、2004年、第108巻、163-169ページ\nPain, 2004, 108, 163-169\n\n\n\n\n\n\n\n\n\n\n \nAnesthesia and Analgesia、2003年、第96巻、1072-1078ページ\nAnesthesia and Analgesia, 2003, 96, 1072-1078\n\n\n\n\n\n\n\n\n\n\n \nBioorganic & Medicinal Chemistry Letters、2008年、18巻、901-907ページ\nBioorganic & Medicinal Chemistry Letters, 2008, 18, 901-907\n\n\n\n\n\n\n\n\n\n\n \nBioorganic & Medicinal Chemistry Letters、2008年、18巻、5698-5700ページ\nBioorganic & Medicinal Chemistry Letters, 2008, 18, 5698-5700\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n　医薬組成物、殊に5-HT\n2C\n受容体に関係する疾患、特に、腹圧性尿失禁、切迫性尿失禁、混合型尿失禁等の尿失禁、勃起不全症等の性機能障害、肥満等の治療又は予防用医薬組成物の有効成分として有用なベンゾアゼピン化合物を提供する。\n\nPharmaceutical composition, especially diseases related to 5-HT \n2C\n receptor, especially urinary incontinence such as stress urinary incontinence, urge incontinence, mixed urinary incontinence, sexual dysfunction such as erectile dysfunction, obesity etc. A benzazepine compound useful as an active ingredient of a therapeutic or prophylactic pharmaceutical composition is provided.\n\n\n\n\n\n\n\n\n\n\n \n\n　本発明者らは、5-HT\n2C\n受容体アゴニスト作用を有する化合物について鋭意検討した結果、本発明のベンゾアゼピン化合物が5-HT\n2C\n受容体アゴニスト作用を有することを知見して本発明を完成した。\n\nThe present inventors have, 5-HT \n2C\n receptor a result of intensive studies on compounds having agonist activity, and completed the present invention by finding that the benzazepine compounds of the present invention has a 5-HT \n2C\n receptor agonist activity .\n\n\n\n\n\n\n \n\n　即ち、本発明は、式（Ｉ）の化合物又はその塩、及び製薬学的に許容される賦形剤を含有する医薬組成物に関する。\n\n\n \n \n\n（式中、\n\nR\n1a\n及びR\n1b\nは、それぞれ同一又は異なって、-H、又はC\n1-6\nアルキルであり、あるいは、一体となってオキソであり、\n\nR\n2a\n及びR\n2b\nは、それぞれ同一又は異なって、-H、又は-O-C\n1-6\nアルキルで置換されていてもよいC\n1-6\nアルキルであり、\n\nR\n3\nは、-H、置換されていてもよいC\n1-6\nアルキル、C\n3-8\nシクロアルキル、置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、又は置換されていてもよいヘテロ環であり、\n\nR\n4\nは、-H、ハロゲン、シアノ、置換されていてもよいC\n1-6\nアルキル、C\n2-6\nアルケニル、置換されていてもよいアリール、置換されていてもよいC\n3-8\nシクロアルキル、芳香族ヘテロ環、又は含酸素ヘテロ環であり、\n\nR\n5\nは、-H、ハロゲン、C\n1-6\nアルキル、C\n3-8\nシクロアルキル、アリール、又は芳香族ヘテロ環であり、\n\nR\n6\n及びR\n7\nは、同一又は異なって、-H、又はC\n1-6\nアルキルであり、\n\nXは、-C(R\nA\n)(R\nB\n)-、又は-O-であり、\n\nR\nA\n及びR\nB\nは、同一又は異なって、-H、又はC\n1-6\nアルキルである。）\n\nThat is, the present invention relates to a pharmaceutical composition containing a compound of formula (I) or a salt thereof, and a pharmaceutically acceptable excipient. \n \n \n \n (Where \n R \n1a\n and R \n1b\n are the same or different and are —H or C \n1-6\n alkyl, or oxo together, \n R \n2a\n and R \n2b\n are the same or different and each represent -H or C \n1-6\n alkyl optionally substituted with -OC \n1-6\n alkyl; \n R \n3\n is —H, optionally substituted C \n1-6\n alkyl, C \n3-8\n cycloalkyl, \noptionally\n substituted aryl, —SO \n2\n —C \n1-6\n alkyl, or optionally substituted. A good heterocycle, \n R \n4\n is -H, halogen, cyano, optionally substituted C \n1-6\n alkyl, C \n2-6\n alkenyl, optionally substituted aryl, optionally substituted C \n3-8\n cycloalkyl, An aromatic heterocycle or an oxygen-containing heterocycle, \n R \n5\n is -H, halogen, C \n1-6\n alkyl, C \n3-8\n cycloalkyl, aryl, or an aromatic heterocycle, \n R \n6\n and R \n7\n are the same or different and are —H or C \n1-6\n alkyl; \n X is -C (R \nA\n ) (R \nB\n )-, or -O- \n R \nA\n and R \nB\n are the same or different and are —H or C \n1-6\n alkyl. )\n\n\n\n\n\n\n \n\n　また、本発明は、式（ＩＩ）の化合物又はその塩に関する。\n\n\n \n \n\n（式中、\n\nR\n11a\n及びR\n11b\nは、それぞれ同一又は異なって、-H、又はC\n1-6\nアルキルであり、あるいは、一体となってオキソであり、\n\nR\n21a\n及びR\n21b\nは、それぞれ同一又は異なって、-H、又は-O-C\n1-6\nアルキルで置換されていてもよいC\n1-6\nアルキルであり、\n\nR\n31\nは、-H、置換されていてもよいC\n1-6\nアルキル、C\n3-8\nシクロアルキル、置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、又は置換されていてもよいヘテロ環であり、\n\nR\n41\nは、-H、ハロゲン、シアノ、置換されていてもよいC\n1-6\nアルキル、C\n2-6\nアルケニル、置換されていてもよいアリール、置換されていてもよいC\n3-8\nシクロアルキル、芳香族ヘテロ環、又は含酸素ヘテロ環であり、\n\nR\n51\nは、-H、ハロゲン、C\n1-6\nアルキル、C\n3-8\nシクロアルキル、アリール、又は芳香族ヘテロ環であり、\n\nR\n61\n及びR\n71\nは、同一又は異なって、-H、又はC\n1-6\nアルキルであり、\n\nX\n1\nは、-C(R\nA1\n)(R\nB1\n)-、又は-O-であり、\n\nR\nA1\n及びR\nB1\nは、同一又は異なって、-H、又はC\n1-6\nアルキルである。\n\n但し、\n\n（ｉ）R\n11a\n、R\n11b\n、R\n21a\n、R\n21b\n、R\n41\n、R\n51\n、R\n61\n、及びR\n71\nがそれぞれ-Hであり、X\n1\nが-O-である場合、R\n31\nは、-H、-CO-メチル、又は-SO\n2\n-メチル以外の基であり、\n\n（ｉｉ）R\n11a\n及びR\n11b\nが一体となってオキソであり、R\n21a\n、R\n21b\n、R\n41\n、R\n51\n、R\n61\n、及びR\n71\nがそれぞれ-Hであり、X\n1\nが-O-である場合、R\n31\nは、-H、又はメチル以外の基である。）\n\nThe present invention also relates to a compound of formula (II) or a salt thereof. \n \n \n \n (Where \n R \n11a\n and R \n11b\n are the same or different and are —H or C \n1-6\n alkyl, or oxo as a whole, \n R \n21a\n and R \n21b\n are the same or different and each represent -H or C \n1-6\n alkyl optionally substituted with -OC \n1-6\n alkyl; \n R \n31\n is —H, optionally substituted C \n1-6\n alkyl, C \n3-8\n cycloalkyl, \noptionally\n substituted aryl, —SO \n2\n —C \n1-6\n alkyl, or optionally substituted. A good heterocycle, \n R \n41\n is -H, halogen, cyano, optionally substituted C \n1-6\n alkyl, C \n2-6\n alkenyl, optionally substituted aryl, optionally substituted C \n3-8\n cycloalkyl, An aromatic heterocycle or an oxygen-containing heterocycle, \n R \n51\n is -H, halogen, C \n1-6\n alkyl, C \n3-8\n cycloalkyl, aryl, or an aromatic heterocycle, \n R \n61\n and R \n71\n are the same or different and are —H or C \n1-6\n alkyl; \n X \n1\n is -C (R \nA1\n ) (R \nB1\n )-, or -O- \n R \nA1\n and R \nB1\n are the same or different and are —H or C \n1-6\n alkyl. \n However, \n (I) when R \n11a\n , R \n11b\n , R \n21a\n , R \n21b\n , R \n41\n , R \n51\n , R \n61\n , and R \n71\n are each —H and X \n1\n is —O—, R \n31\n is —H , -CO-methyl, or -SO \n2\n -methyl, \n (Ii) R \n11a\n and R \n11b\n together are oxo, R \n21a\n , R \n21b\n , R \n41\n , R \n51\n , R \n61\n , and R \n71\n are each —H, and X \n1\n is —O—. In this case, R \n31\n is —H or a group other than methyl. )\n\n\n\n\n\n\n \n\n　なお、特に記載がない限り、本明細書のある化学式中の記号が他の化学式においても用いられる場合、同一の記号は同一の意味を示す。\n\n\nUnless otherwise specified, when a symbol in a chemical formula in this specification is also used in another chemical formula, the same symbol has the same meaning.\n\n\n\n\n\n\n\n \n\n　また、本発明は、式（Ｉ）の化合物又はその塩、あるいは、式（ＩＩ）の化合物又はその塩を含有する5-HT\n2C\n受容体に関係する疾患の予防又は治療用医薬組成物に関する。なお、この医薬組成物は、式（Ｉ）の化合物又はその塩、あるいは、式（ＩＩ）の化合物又はその塩を含有する5-HT\n2C\n受容体に関係する疾患の予防又は治療剤を包含する。\n\n　また、本発明は、5-HT\n2C\n受容体に関係する疾患の予防又は治療用医薬組成物の製造のための式（Ｉ）の化合物又はその塩、若しくは、式（ＩＩ）の化合物又はその塩の使用；5-HT\n2C\n受容体に関係する疾患の予防又は治療に使用するための式（Ｉ）の化合物又はその塩、若しくは、式（ＩＩ）の化合物又はその塩；並びに、式（Ｉ）の化合物又はその塩、若しくは、式（ＩＩ）の化合物又はその塩の有効量を対象に投与することからなる5-HT\n2C\n受容体に関係する疾患の予防又は治療方法に関する。なお、「対象」とは、その予防又は治療を必要とするヒト又はその他の動物であり、ある態様としては、その予防又は治療を必要とするヒトである。\n\nThe present invention also relates to a pharmaceutical composition for preventing or treating a disease associated with a 5-HT \n2C\n receptor comprising a compound of formula (I) or a salt thereof, or a compound of formula (II) or a salt thereof. The pharmaceutical composition includes a prophylactic or therapeutic agent for a disease related to 5-HT \n2C\n receptor, which contains a compound of formula (I) or a salt thereof, or a compound of formula (II) or a salt thereof. . \n The present invention also relates to a compound of formula (I) or a salt thereof, or a compound of formula (II) or a salt thereof for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with 5-HT \n2C\n receptor. A compound of formula (I) or a salt thereof, or a compound of formula (II) or a salt thereof for use in the prevention or treatment of a disease associated with 5-HT \n2C\n receptor; and formula (I) Or a salt thereof, or a method for preventing or treating a disease associated with 5-HT \n2C\n receptor, comprising administering an effective amount of a compound of formula (II) or a salt thereof to a subject. The “subject” is a human or other animal that needs the prevention or treatment, and as a certain aspect, it is a human that needs the prevention or treatment.\n\n\n\n\n\n\n \n\n　なお、式（ＩＩ）の化合物又はその塩は、式（Ｉ）の化合物又はその塩に包含される。従って、本明細書において、式（Ｉ）の化合物の説明は、式（ＩＩ）の化合物の説明も包含する。\n\n\nThe compound of formula (II) or a salt thereof is encompassed by the compound of formula (I) or a salt thereof. Accordingly, in this specification, the description of the compound of formula (I) includes the description of the compound of formula (II).\n\n\n\n\n\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物又はその塩、あるいは、式（ＩＩ）の化合物又はその塩は、5-HT\n2C\n受容体アゴニスト作用を有し、5-HT\n2C\n受容体に関係する疾患の予防及び又は治療剤として使用できる。\n\n　ここで、5-HT\n2C\n受容体に関係する疾患としては、腹圧性尿失禁、切迫性尿失禁、混合型尿失禁等の尿失禁、勃起不全症等の性機能障害、肥満等が挙げられる。\n\nThe compound of formula (I) or a salt thereof, or the compound of formula (II) or a salt thereof has a 5-HT \n2C\n receptor agonistic action and prevents and / or treats a disease related to 5-HT \n2C\n receptor Can be used as an agent. \n Here, diseases related to 5-HT \n2C\n receptor include urinary incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, sexual dysfunction such as erectile dysfunction, obesity and the like.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n　以下、本発明を詳細に説明する。\n\n\nHereinafter, the present invention will be described in detail.\n\n\n\n\n\n\n\n \n\n　本明細書において、「アルキル」とは、直鎖状のアルキル及び分枝状のアルキルを含む。従って、「C\n1-6\nアルキル」とは、直鎖又は分枝状の炭素数１～６のアルキルであり、具体的には例えば、メチル、エチル、プロピル、イソプロピル、ブチル、tert-ブチル、ペンチル、ヘキシル等であり、別の態様としては、メチル、エチル、プロピル、イソプロピルであり、さらに別の態様としては、メチル、エチルであり、さらに別の態様としてはメチルであり、さらに別の態様としてはエチルである。\n\nIn the present specification, “alkyl” includes linear alkyl and branched alkyl. Accordingly, “C \n1-6\n alkyl” is linear or branched alkyl having 1 to 6 carbon atoms, specifically, for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl. Hexyl and the like, and in another aspect, methyl, ethyl, propyl, isopropyl, and in yet another aspect, methyl and ethyl, and in still another aspect, methyl, Is ethyl.\n\n\n\n\n\n\n \n\n　「アルキレン」とは、上記「アルキル」の任意の水素原子１個を除去してなる二価基である。従って、「C\n1-6\nアルキレン」とは、直鎖又は分枝状の炭素数１～６のアルキレンであり、具体的には例えば、メチレン、エチレン、トリメチレン、テトラメチレン、ペンタメチレン、ヘキサメチレン、メチルメチレン、ジメチルメチレン、エチルメチレン、メチルエチレン、ジメチルエチレン、エチルエチレン等であり、別の態様としてはメチレン、エチレンであり、さらに別の態様としてはメチレンである。\n\n“Alkylene” is a divalent group formed by removing any one hydrogen atom of the above “alkyl”. Accordingly, “C \n1-6\n alkylene” is linear or branched alkylene having 1 to 6 carbon atoms, and specifically includes, for example, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, Examples thereof include methylmethylene, dimethylmethylene, ethylmethylene, methylethylene, dimethylethylene, ethylethylene and the like. In another embodiment, methylene and ethylene are used, and in another embodiment, methylene is used.\n\n\n\n\n\n\n \n\n　「アリール」とは、炭素数６～１４の単環乃至三環式芳香族炭化水素環基である。具体的には例えば、フェニル、ナフチルであり、別の態様としてはフェニルであり、さらに別の態様としてはナフチルである。\n\n\n“Aryl” is a monocyclic to tricyclic aromatic hydrocarbon ring group having 6 to 14 carbon atoms. Specifically, for example, phenyl and naphthyl, another embodiment is phenyl, and still another embodiment is naphthyl.\n\n\n\n\n\n\n\n \n\n　「シクロアルキル」とは、飽和炭化水素環基であり、当該シクロアルキルは架橋を有していてもよく、ベンゼン環と縮合していてもよく、一部の結合が不飽和であってもよい。従って、「C\n3-8\nシクロアルキル」とは、具体的には例えば、シクロプロピル、シクロブチル、シクロペンチル、シクロヘキシル、シクロヘキセニル、シクロヘプチル、シクロオクチル、シクロオクタジエニル、ノルボルニル、ビシクロ[2.2.2]オクチル、インダニル、インデニル、1,2-ジヒドロナフチル、1,2,3,4-テトラヒドロナフチル等が挙げられる。\n\n“Cycloalkyl” is a saturated hydrocarbon ring group, and the cycloalkyl may have a bridge, may be condensed with a benzene ring, and some of the bonds may be unsaturated. . Accordingly, “C \n3-8\n cycloalkyl” specifically includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclooctadienyl, norbornyl, bicyclo [2.2.2] Examples include octyl, indanyl, indenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl and the like.\n\n\n\n\n\n\n \n\n　「ヘテロ環」とは、酸素、硫黄及び窒素から選択されるヘテロ原子を１～４個含有する３～１５員の、別の態様としては５～１０員の単環乃至三環式ヘテロ環の一価基であり、飽和環、芳香環、及びその部分的に水素化された環基を包含する。環原子である硫黄又は窒素が酸化されオキシドやジオキシドを形成してもよい。具体的には例えば、ピロリル、フリル、チエニル、ピラゾリル、イミダゾリル、オキサゾリル、イソオキサゾリル、チアゾリル、イソチアゾリル、トリアゾリル、オキサジアゾリル、チアジアゾリル、テトラゾリル、ピリジル、ピリダジニル、ピリミジニル、ピラジニル、トリアジニル等の単環式芳香族ヘテロ環、インドリル、イソインドリル、ベンゾフラニル、ベンゾチエニル、インダゾリル、ベンゾイミダゾリル、ベンゾオキサゾリル、ベンゾイソオキサゾリル、ベンゾチアゾリル、ベンゾイソチアゾリル、キノリル、イソキノリル、キノキサリニル、キナゾリニル、フタラジニル、ベンゾチアジアゾリル等の二環式芳香族ヘテロ環、カルバゾリル、ジベンゾ[b,d]フラニル、ジベンゾ[b,d]チエニル等の三環式芳香族ヘテロ環、アゼチジニル、ピロリジニル、ピペリジル、ピペラジニル、アゼパニル、ジアゼパニル、モルホリニル、チオモルホリニル、テトラヒドロピリジニル、オキセタニル、テトラヒドロフラニル、テトラヒドロピラニル、ジオキソラニル、ジオキサニル、テトラヒドロチオピラニル等の単環式非芳香族ヘテロ環、インドリニル、テトラヒドロキノリル、テトラヒドロイソキノリル、ジヒドロベンゾイミダゾリル、テトラヒドロベンゾイミダゾリル、テトラヒドロキノキサリニル、ジヒドロキノキサリニル、ジヒドロベンゾキサゾリル、ジヒドロベンゾオキサジニル、ジヒドロベンゾフリル、クロマニル、クロメニル、メチレンジオキシフェニル、エチレンジオキシフェニル等の二環式非芳香族ヘテロ環、キヌクリジニル等の架橋ヘテロ環等が包含される。別の態様としては、５～１０員の単環乃至二環式へテロ環であり、さらに別の態様としては、５～６員の単環式へテロ環基であり、またさらに別の態様としては、５～６員の単環式芳香族ヘテロ環である。\n\n\n“Heterocycle” means a 3- to 15-membered, or in another embodiment, a 5- to 10-membered monocyclic to tricyclic heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen. It is a monovalent group and includes saturated rings, aromatic rings, and partially hydrogenated ring groups thereof. Ring atoms such as sulfur or nitrogen may be oxidized to form oxides or dioxides. Specifically, monocyclic aromatic heterocycles such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc. , Indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl, benzothiadiazolyl, etc. Aromatic heterocycles, carbazolyl, tribenzoaromatic heterocycles such as dibenzo [b, d] furanyl, dibenzo [b, d] thienyl, azetidinyl Monocyclic non-aromatic heterocycles such as pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, tetrahydropyridinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, tetrahydrothiopyranyl, indolinyl, Tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzimidazolyl, tetrahydrobenzoimidazolyl, tetrahydroquinoxalinyl, dihydroquinoxalinyl, dihydrobenzoxazolyl, dihydrobenzoxazinyl, dihydrobenzofuryl, chromanyl, chromenyl, methylenedioxy Bicyclic non-aromatic heterocycles such as phenyl and ethylenedioxyphenyl, bridged heterocycles such as quinuclidinyl and the like are included. Another embodiment is a 5- to 10-membered monocyclic to bicyclic heterocycle, and yet another embodiment is a 5- to 6-membered monocyclic heterocyclic group, and still another embodiment. Is a 5- to 6-membered monocyclic aromatic heterocycle.\n\n\n\n\n\n\n\n \n\n　「芳香族ヘテロ環」とは、上記「ヘテロ環」のうち、５～１０員の単環乃至二環式芳香族へテロ環であり、具体的には例えば、ピロリル、フリル、チエニル、ピラゾリル、イミダゾリル、オキサゾリル、チアゾリル、トリアゾリル、オキサジアゾリル、チアジアゾリル、テトラゾリル、ピリジル、ピリダジニル、ピリミジニル、ピラジニル、トリアジニル、インドリル、イソインドリル、ベンゾフラニル、ベンゾチエニル、インダゾリル、ベンゾイミダゾリル、ベンゾオキサゾリル、ベンゾイソオキサゾリル、ベンゾチアゾリル、ベンゾイソチアゾリル、キノリル、イソキノリル、キノキサリニル、キナゾリニル、フタラジニル等が挙げられる。別の態様としては、フリル、チエニル、ピラゾリル、チアゾリル、ピリジル、ピリミジニル、ピラジルである。\n\n\nThe “aromatic heterocycle” is a 5- to 10-membered monocyclic to bicyclic aromatic heterocycle among the above “heterocycle”, and specifically includes, for example, pyrrolyl, furyl, thienyl, pyrazolyl, Imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl Examples include benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl and the like. Another embodiment is furyl, thienyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazyl.\n\n\n\n\n\n\n\n \n\n　「環状アミノ」とは、上記「ヘテロ環」のうち、窒素原子上に結合手を有する、５～７員の非芳香族ヘテロ環であって、具体的には例えば、ピロリジニル、ピペリジル、ピペラジニル、アゼパニル、ジアゼパニル、モルホリニル、チオモルホリニルが挙げられる。\n\n\n“Cyclic amino” is a 5- to 7-membered non-aromatic heterocycle having a bond on a nitrogen atom among the above “heterocycle”, and specifically includes, for example, pyrrolidinyl, piperidyl, piperazinyl, Azepanyl, diazepanyl, morpholinyl, thiomorpholinyl are mentioned.\n\n\n\n\n\n\n\n \n\n　「含酸素ヘテロ環」とは、１つ若しくは２つの酸素原子を環構成原子として有する、ベンゼン環と縮合していてもよい非芳香族の５～６員環の一価基である。具体的には例えば、テトラヒドロフラニル、テトラヒドロピラニル、ジオキソラニル、ジオキサニル、ジヒドロベンゾフラニル、ジヒドロクロメニル、ベンゾジオキソリル、ベンゾジオキシニル、ジヒドロジオキシニル、ジヒドロベンゾジオキシニル、ジヒドロピラニル、ジオキシニル、クロメニル、ベンゾジオキシニルが挙げられる。\n\n\nThe “oxygen-containing heterocycle” is a monovalent group of a non-aromatic 5- to 6-membered ring which has one or two oxygen atoms as ring constituent atoms and may be condensed with a benzene ring. Specifically, for example, tetrahydrofuranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, dihydrobenzofuranyl, dihydrochromenyl, benzodioxolyl, benzodioxinyl, dihydrodioxinyl, dihydrobenzodioxinyl, dihydropyranyl , Dioxynyl, chromenyl, benzodioxinyl.\n\n\n\n\n\n\n\n \n\n　「ハロゲン」とは、-F、-Cl、-Br、-Iを意味し、別の態様としては、-F、-Cl、-Brである。\n\n\n“Halogen” means —F, —Cl, —Br, —I, and in another embodiment, —F, —Cl, —Br.\n\n\n\n\n\n\n\n \n\n　「ハロゲノC\n1-6\nアルキル」とは、１つ以上のハロゲンで置換されたC\n1-6\nアルキルであり、具体的には例えば、フルオロメチル、ジフルオロメチル、トリフルオロメチル、トリフルオロエチル、フルオロエチル、クロロエチル、ブロモエチル、フルオロプロピル、ジクロロプロピル、フルオロクロロプロピル等が挙げられる。別の態様としてはジフルオロメチル、トリフルオロメチル、ジフルオロエチル、トリフルオロエチル、フルオロプロピルである。\n\nThe \"halogeno C \n1-6\n alkyl\" is a C \n1-6\n alkyl substituted with one or more halogen, specifically, for example, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, fluoroethyl , Chloroethyl, bromoethyl, fluoropropyl, dichloropropyl, fluorochloropropyl and the like. Another embodiment is difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, fluoropropyl.\n\n\n\n\n\n\n \n\n　本明細書において、「置換されていてもよい」とは、無置換、若しくは置換基を１～５個有していることを意味する。なお、複数個の置換基を有する場合、それらの置換基は同一であっても、互いに異なっていてもよい。\n\n\nIn the present specification, “optionally substituted” means unsubstituted or having 1 to 5 substituents. In addition, when it has a some substituent, those substituents may be the same or may mutually differ.\n\n\n\n\n\n\n\n \n\n　R\n3\n及びR\n4\nの「置換されていてもよいC\n1-6\nアルキル」、「置換されていてもよいC\n1-6\nアルキレン」、「置換されていてもよい（C\n3-8\n）シクロアルキル」、「置換されていてもよいアリール」、「置換されていてもよいヘテロ環」における置換基としては、具体的には例えば、アミノ、ニトロ、シアノ、ハロゲン、C\n1-6\nアルキル、ハロゲノC\n1-6\nアルキル、-OH、-C\n1-6\nアルキレン-OH、-O-C\n1-6\nアルキル、-C\n1-6\nアルキレン-O-C\n1-6\nアルキル、-C\n1-6\nアルキレン-シクロアルキル、-C\n1-6\nアルキレン-アリール、-C\n1-6\nアルキレン-ヘテロ環、-CO-C\n1-6\nアルキル、-CO-C\n1-6\nアルキレン-O-C\n1-6\nアルキル、-CO-シクロアルキル、-CO-アリール、-CO-NR\n8\nR\n9\n、-CO-O-C\n1-6\nアルキル、-CO-O-C\n1-6\nアルキレン-アリール、-SO\n2\n-C\n1-6\nアルキル、アリール、ヘテロ環等が挙げられる。\n\n　ここで、R\n8\n及びR\n9\nは、それぞれ同一又は異なって、-H、又はC\n1-6\nアルキルである。\n\nR \n3\n and R \n4\n “optionally substituted C \n1-6\n alkyl”, “optionally substituted C \n1-6\n alkylene”, “optionally substituted (C \n3-8\n ) cycloalkyl” , \"Optionally substituted aryl\" and \"optionally substituted heterocycle\" include, for example, amino, nitro, cyano, halogen, C \n1-6\n alkyl, halogeno C \n1 -6\n alkyl, -OH, -C \n1-6\n alkylene-OH, -OC \n1-6\n alkyl, -C \n1-6\n alkylene-OC \n1-6\n alkyl, -C \n1-6\n alkylene-cycloalkyl, -C \n1- 6\n alkylene-aryl, -C \n1-6\n alkylene-heterocycle, -CO-C \n1-6\n alkyl, -CO-C \n1-6\n alkylene-OC \n1-6\n alkyl, -CO-cycloalkyl, -CO-aryl, -CO-NR \n8\n R \n9\n , -CO-OC \n1-6\n alkyl, -CO-OC \n1-6\n alkylene-aryl, -SO \n2\n -C \n1-6\n alkyl, aryl, heterocycle and the like can be mentioned. \n Here, R \n8\n and R \n9\n are the same or different and are —H or C \n1-6\n alkyl.\n\n\n\n\n\n\n \n\n　また、別の態様として、R\n3\nにおける「置換されていてもよいC\n1-6\nアルキル」の置換基としては、\n\n（１）ハロゲン、\n\n（２）オキソ、-OH、-O-R\nZ\n、\n\n（３）-O-(R\nZ\n、-O-R\nZ\n、ハロゲン、及びシアノからなる群より選択される１つ以上の基で置換されていてもよいフェニル)、\n\n（４）-O-芳香族ヘテロ環、\n\n（５）１つ若しくは２つのR\nZ\nで置換されていてもよいアミノ、\n\n（６）R\nZ\n、-O-R\nZ\n、ハロゲン、及びシアノからなる群より選択される１つ以上の基で置換されていてもよいフェニル、\n\n（７）R\nZ\nで置換されていてもよいC\n3-8\nシクロアルキル、\n\n（８）ハロゲンで置換されていてもよい含酸素ヘテロ環、\n\n（９）R\nZ\nで置換されていてもよい環状アミノ、及び、\n\n（１０）芳香族ヘテロ環、\n\nが挙げられ、当該C\n1-6\nアルキルは１つ以上の置換基で置換されていてもよい。\n\nIn another embodiment, the substituent of “optionally substituted C \n1-6\n alkyl” in R \n3\n is: \n (1) halogen, \n (2) Oxo, —OH, —OR \nZ\n , \n (3) —O— (phenyl optionally substituted with one or more groups selected from the group consisting of R \nZ\n , —OR \nZ\n , halogen, and cyano), \n (4) -O-aromatic heterocycle, \n (5) amino optionally substituted with one or two R \nZ\n , \n (6) phenyl optionally substituted with one or more groups selected from the group consisting of R \nZ\n , —OR \nZ\n , halogen, and cyano; \n (7) C \n3-8\n cycloalkyl \noptionally\n substituted by R \nZ\n \n (8) an oxygen-containing heterocycle optionally substituted with halogen, \n (9) a cyclic amino optionally substituted with R \nZ\n , and \n (10) an aromatic heterocycle, \n And the C \n1-6\n alkyl may be substituted with one or more substituents.\n\n\n\n\n\n\n \n\n　なお、ここでR\nZ\nとは、ハロゲン、-O-C\n1-6\nアルキル、C\n3-8\nシクロアルキル、及びフェニル（当該フェニルは、ハロゲン、及び-O-C\n1-6\nアルキルからなる群より選択される１以上の基で置換されていてもよい。）からなる群より選択される１以上の基で置換されていてもよいC\n1-6\nアルキルを示す。\n\nHere, R \nZ\n is halogen, —OC \n1-6\n alkyl, C \n3-8\n cycloalkyl, and phenyl (the phenyl is one or more selected from the group consisting of halogen and —OC \n1-6\n alkyl) And C \n1-6\n alkyl which may be substituted with one or more groups selected from the group consisting of:\n\n\n\n\n\n\n \n\n　また、別の態様として、R\n3\nにおける「置換されていてもよいアリール」の置換基としては、ハロゲンが挙げられ、当該アリールは１つ以上の置換基で置換されていてもよい。\n\nIn another embodiment, the substituent of “optionally substituted aryl” in R \n3\n includes halogen, and the aryl may be substituted with one or more substituents.\n\n\n\n\n\n\n \n\n　また、別の態様として、R\n4\nにおける「置換されていてもよいC\n1-6\nアルキル」の置換基としては、ハロゲン、アリールが挙げられ、当該C\n1-6\nアルキルは１つ以上の置換基で置換されていてもよい。\n\nIn another embodiment, examples of the substituent of “ \noptionally\n substituted C \n1-6\n alkyl” in R \n4\n include halogen and aryl, and the C \n1-6\n alkyl is one or more substituents. May be substituted.\n\n\n\n\n\n\n \n\n　また、別の態様として、R\n4\nにおける「置換されていてもよいアリール」の置換基としては、ハロゲン、C\n1-6\nアルキル、-O-C\n1-6\nアルキルが挙げられ、当該アリールは１つ以上の置換基で置換されていてもよい。\n\nIn another embodiment, the substituent of “optionally substituted aryl” in R \n4\n includes halogen, C \n1-6\n alkyl, —OC \n1-6\n alkyl, and the aryl includes one or more aryls. It may be substituted with a substituent.\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物又はその塩のある態様を以下に示す。\n\n\nCertain embodiments of the compound of formula (I) or a salt thereof are shown below.\n\n\n\n\n\n\n\n \n\n（１）R\n1a\n及びR\n1b\nがそれぞれ同一又は異なって-H又はメチルである化合物又はその塩。別の態様として、R\n1a\n及びR\n1b\nがそれぞれ-Hである化合物又はその塩。さらに別の態様として、R\n1a\nが-Hであり、R\n1b\nがメチルである化合物又はその塩。さらに別の態様として、R\n1a\n及びR\n1b\nが一体となってオキソである化合物又はその塩。\n\n(1) A compound or a salt thereof, wherein R \n1a\n and R \n1b\n are the same or different and are —H or methyl. In another embodiment, the compound or a salt thereof, wherein R \n1a\n and R \n1b\n are each —H. In still another embodiment, the compound or a salt thereof, wherein R \n1a\n is —H and R \n1b\n is methyl. In still another embodiment, a compound or a salt thereof, wherein R \n1a\n and R \n1b\n are oxo together.\n\n\n\n\n\n\n \n\n（２）R\n2a\nが-Hであり、R\n2b\nが-H又はC\n1-6\nアルキルである化合物又はその塩。別の態様として、R\n2a\nが-Hであり、R\n2b\nが-H又はメチルである化合物又はその塩。さらに別の態様として、R\n2a\n及びR\n2b\nがそれぞれ-Hである化合物又はその塩。\n\n(2) A compound or a salt thereof, wherein R \n2a\n is —H and R \n2b\n is —H or C \n1-6\n alkyl. In another embodiment, the compound or a salt thereof, wherein R \n2a\n is —H and R \n2b\n is —H or methyl. In still another embodiment, the compound or a salt thereof, wherein R \n2a\n and R \n2b\n are each —H.\n\n\n\n\n\n\n \n\n（３）R\n3\nが、以下の（ａ）～（ｅ）からなる群より選択される１以上の基で置換されていてもよいC\n1-6\nアルキルである化合物又はその塩。\n\n（ａ）ハロゲン、（ｂ）-O-C\n1-6\nアルキル、（ｃ）ハロゲン及びシアノからなる群より選択される１以上の基で置換されていてもよいフェノキシ、（ｄ）含酸素ヘテロ環、（ｅ）-O-C\n1-6\nアルキルで置換されていてもよいC\n1-6\nアルキル、ハロゲン、及び-O-C\n1-6\nアルキルからなる群から選択される１以上の基で置換されていてもよいフェニル。\n\n別の態様として、R\n3\nが、以下の（ｆ）～（ｊ）からなる群より選択される１以上の基で置換されていてもよいC\n1-6\nアルキルである化合物又はその塩。\n\n（ｆ）フルオロ、（ｇ）メトキシ、エトキシ、（ｈ）フルオロ及びシアノからなる群より選択される１以上の基で置換されていてもよいフェノキシ、（ｉ）テトラヒドロフラニル、テトラヒドロピラニル、ジヒドロベンゾジオキシニル、（ｊ）フルオロ、クロロ、メチル、及びメトキシメチルからなる群から選択される１以上の基で置換されていてもよいフェニル。\n\nさらに別の態様として、R\n3\nがイソブチルである化合物又はその塩。さらに別の態様として、R\n3\nがフルオロ、メトキシ、及びエトキシからなる群より選択される１以上の基でそれぞれ置換されたエチル若しくはプロピルである化合物又はその塩。さらに別の態様として、R\n3\nがフルオロ及びシアノからなる群より選択される１以上の基で置換されていてもよいフェノキシで置換されたエチルである化合物又はその塩。さらに別の態様として、R\n3\nがテトラヒドロフラニル、テトラヒドロピラニル、及びジヒドロベンゾジオキシニルからなる群より選択される基で置換されたメチルである化合物又はその塩。さらに別の態様として、R\n3\nがフルオロ、クロロ、メチル、及びメトキシメチルからなる群から選択される１以上の基で置換されていてもよいフェニルで置換されたメチルである化合物又はその塩。\n\n(3) A compound or a salt thereof, wherein R \n3\n is C \n1-6\n alkyl optionally substituted with one or more groups selected from the group consisting of the following (a) to (e). \n (A) halogen, (b) —OC \n1-6\n alkyl, (c) phenoxy optionally substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing heterocycle, ( e) -OC \n1-6\n alkyl optionally substituted by C \n1-6\n alkyl, halogen, and 1 or more phenyl which may be substituted with a group selected from the group consisting of -OC \n1-6\n alkyl. \n In another embodiment, the compound or a salt thereof, wherein R \n3\n is C \n1-6\n alkyl optionally substituted with one or more groups selected from the group consisting of the following (f) to (j). \n (F) fluoro, (g) methoxy, ethoxy, (h) phenoxy optionally substituted with one or more groups selected from the group consisting of fluoro and cyano, (i) tetrahydrofuranyl, tetrahydropyranyl, dihydrobenzo Phenyl optionally substituted with one or more groups selected from the group consisting of dioxynyl, (j) fluoro, chloro, methyl, and methoxymethyl. \n Yet another embodiment is a compound or a salt thereof, wherein R \n3\n is isobutyl. In yet another embodiment, the compound or a salt thereof, wherein R \n3\n is ethyl or propyl each substituted with one or more groups selected from the group consisting of fluoro, methoxy, and ethoxy. In still another embodiment, the compound or a salt thereof, wherein R \n3\n is ethyl substituted with phenoxy optionally substituted with one or more groups selected from the group consisting of fluoro and cyano. In yet another embodiment, the compound or a salt thereof, wherein R \n3\n is methyl substituted with a group selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, and dihydrobenzodioxinyl. In yet another embodiment, the compound or a salt thereof, wherein R \n3\n is methyl substituted with phenyl optionally substituted with one or more groups selected from the group consisting of fluoro, chloro, methyl, and methoxymethyl.\n\n\n\n\n\n\n \n\n（４）R\n4\nが-H、ハロゲン、C\n3-8\nシクロアルキルである化合物又はその塩。別の態様として、R\n4\nが-H、ブロモ、シクロプロピルである化合物又はその塩。さらに別の態様として、R\n4\nが-Hである化合物又はその塩。さらに別の態様として、R\n4\nがブロモである化合物又はその塩。さらに別の態様として、R\n4\nがシクロプロピルである化合物又はその塩。\n\n(4) A compound or a salt thereof, wherein R \n4\n is —H, halogen, C \n3-8\n cycloalkyl. In another embodiment, the compound or a salt thereof, wherein R \n4\n is —H, bromo, cyclopropyl. In yet another embodiment, the compound or a salt thereof, wherein R \n4\n is —H. In yet another embodiment, the compound or a salt thereof, wherein R \n4\n is bromo. In yet another embodiment, the compound or a salt thereof, wherein R \n4\n is cyclopropyl.\n\n\n\n\n\n\n \n\n（５）R\n5\nが-H又はC\n1-6\nアルキルである化合物又はその塩。別の態様として、R\n5\nが-H又はメチルである化合物又はその塩。さらに別の態様として、R\n5\nが-Hである化合物又はその塩。\n\n(5) A compound or a salt thereof, wherein R \n5\n is —H or C \n1-6\n alkyl. In another embodiment, the compound or a salt thereof, wherein R \n5\n is —H or methyl. In yet another embodiment, the compound or a salt thereof, wherein R \n5\n is —H.\n\n\n\n\n\n\n \n\n（６）R\n6\n及びR\n7\nがそれぞれ同一又は異なって-H又はメチルである化合物又はその塩。別の態様として、R\n6\nがメチルであり、R\n7\nが-Hである化合物又はその塩。さらに別の態様として、R\n6\nが-Hであり、R\n7\nがメチルである化合物又はその塩。さらに別の態様として、R\n6\n及びR\n7\nがそれぞれ-Hである化合物又はその塩。\n\n(6) A compound or a salt thereof, wherein R \n6\n and R \n7\n are the same or different and are —H or methyl. In another embodiment, the compound or a salt thereof, wherein R \n6\n is methyl and R \n7\n is —H. In still another embodiment, the compound or a salt thereof, wherein R \n6\n is —H and R \n7\n is methyl. In still another embodiment, the compound or a salt thereof, wherein R \n6\n and R \n7\n are each —H.\n\n\n\n\n\n\n \n\n（７）Xが-CH\n2\n-又は-O-である化合物又はその塩。別の態様として、Xが-CH\n2\n-である化合物又はその塩。さらに別の態様として、Xが-O-である化合物又はその塩。\n\n(7) A compound or a salt thereof, wherein X is —CH \n2\n — or —O—. In another embodiment, the compound or a salt thereof, wherein X is —CH \n2\n —. In still another embodiment, the compound or a salt thereof, wherein X is —O—.\n\n\n\n\n\n\n \n\n（８）上記（１）～（７）に記載の基の二以上の組み合わせである化合物又はその塩。\n\n\n(8) A compound or a salt thereof, which is a combination of two or more of the groups described in (1) to (7) above.\n\n\n\n\n\n\n\n \n\n　本発明には、上記（８）に記載したような、上記（１）～（７）に記載の基の二以上の組み合わせである化合物又はその塩が包含されるが、その具体例を含めて、以下の態様も挙げられる。\n\n\nThe present invention includes a compound or a salt thereof which is a combination of two or more groups described in (1) to (7) as described in (8) above, including specific examples thereof. The following embodiments are also included.\n\n\n\n\n\n\n\n \n\n（９）R\n3\nが、-H、置換されていてもよいC\n1-6\nアルキル、C\n3-8\nシクロアルキル、置換されていてもよいアリール、-SO\n2\n-C\n1-6\nアルキル、又は含酸素ヘテロ環であり、R\n4\nが、-H、ハロゲン、シアノ、置換されていてもよいC\n1-6\nアルキル、C\n2-6\nアルケニル、置換されていてもよいアリール、C\n3-8\nシクロアルキル、芳香族ヘテロ環、又は含酸素ヘテロ環である化合物又はその塩。\n\n(9) R \n3\n is —H, optionally substituted C \n1-6\n alkyl, C \n3-8\n cycloalkyl, \noptionally\n substituted aryl, —SO \n2\n —C \n1-6\n alkyl, or oxygen-containing A heterocycle, wherein R \n4\n is —H, halogen, cyano, optionally substituted C \n1-6\n alkyl, C \n2-6\n alkenyl, optionally substituted aryl, C \n3-8\n cycloalkyl, aromatic Or a salt thereof, which is a group heterocycle or an oxygen-containing heterocycle.\n\n\n\n\n\n\n \n\n（１０）R\n3\nが-H、メチル、-CO-メチル、又は-SO\n2\n-メチル以外の基である、（９）に記載の化合物又はその塩。\n\n(10) The compound or salt thereof according to (9), wherein R \n3\n is a group other than —H, methyl, —CO-methyl, or —SO \n2\n -methyl.\n\n\n\n\n\n\n \n\n（１１）R\n1a\nが、-H又はメチルであり、R\n1b\n、R\n2a\n、R\n2b\n、R\n5\n、R\n6\n、及びR\n7\nがそれぞれ-Hである、（１０）に記載の化合物又はその塩。\n\n(11) The compound or salt thereof according to (10), wherein R \n1a\n is —H or methyl, and R \n1b\n , R \n2a\n , R \n2b\n , R \n5\n , R \n6\n , and R \n7\n are each —H.\n\n\n\n\n\n\n \n\n（１２）R\n4\nが、-H、ハロゲン、又はC\n3-8\nシクロアルキルである、（１１）に記載の化合物又はその塩。\n\n(12) The compound or salt thereof according to (11), wherein R \n4\n is —H, halogen, or C \n3-8\n cycloalkyl.\n\n\n\n\n\n\n \n\n（１３）R\n4\nが、シクロプロピルである、（１２）に記載の化合物又はその塩。\n\n(13) The compound or salt thereof according to (12), wherein R \n4\n is cyclopropyl.\n\n\n\n\n\n\n \n\n（１４）R\n3\nが、（ａ）ハロゲン、（ｂ）-O-C\n1-6\nアルキル、（ｃ）ハロゲン及びシアノからなる群より選択される１以上の基で置換されていてもよいフェノキシ、（ｄ）含酸素ヘテロ環、及び、（ｅ）-O-C\n1-6\nアルキルで置換されていてもよいC\n1-6\nアルキル、ハロゲン、及び-O-C\n1-6\nアルキルからなる群から選択される１以上の基で置換されていてもよいフェニルからなる群より選択される１以上の基で置換されていてもよいC\n1-6\nアルキルである、（１３）に記載の化合物又はその塩。\n\n(14) R \n3\n is (a) halogen, (b) —OC \n1-6\n alkyl, (c) phenoxy optionally substituted with one or more groups selected from the group consisting of halogen and cyano, (d ) oxygen-containing heterocycle, and, (e) -OC \n1-6\n alkyl optionally substituted by C \n1-6\n alkyl, one or more groups selected from halogen, and from the group consisting of -OC \n1-6\n alkyl The compound or a salt thereof according to (13), which is C \n1-6\n alkyl optionally substituted with one or more groups selected from the group consisting of phenyl optionally substituted with.\n\n\n\n\n\n\n \n\n（１５）Xが-CH\n2\n-又は-O-である、（１）～（１４）のいずれかに記載の化合物又はその塩。別の態様として、Xが-O-である、（１）～（１４）のいずれかに記載の化合物又はその塩。さらに別の態様として、Xが-CH\n2\n-である、（１）～（１４）のいずれかに記載の化合物又はその塩。\n\n(15) The compound or salt thereof according to any one of (1) to (14), wherein X is —CH \n2\n — or —O—. In another embodiment, the compound or a salt thereof according to any one of (1) to (14), wherein X is —O—. In still another embodiment, the compound or a salt thereof according to any one of (1) to (14), wherein X is —CH \n2\n —.\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物又はその塩に包含される具体的化合物の例として、以下の化合物が挙げられる。\n\n11-シクロプロピル-1-(2-メトキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン、\n\n4-(3-メトキシプロピル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-メトキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-エトキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(3-メトキシプロピル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(3-フルオロプロピル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n1-イソブチル-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン、\n\n5-ブロモ-4-(2-メトキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[(2S)-テトラヒドロフラン-2-イルメチル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[(2R)-2-メトキシプロピル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-フルオロベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[(2S)-3-フルオロ-2-メトキシプロピル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n4-(3-クロロベンジル)-5-シクロプロピル-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(テトラヒドロ-2H-ピラン-3-イルメチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2,3-ジヒドロ-1,4-ベンゾジオキシン-2-イルメチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-フェノキシエチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2-メチルベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(3-メチルベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2,5-ジフルオロベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[3-(メトキシメチル)ベンジル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n4-(5-クロロ-2-フルオロベンジル)-5-シクロプロピル-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(2,3-ジヒドロ-1,4-ベンゾジオキシン-6-イルメチル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n(3S)-5-シクロプロピル-4-(2-メトキシエチル)-3-メチル-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n4-[2-(5-シクロプロピル-2,3,7,8,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-4(6H)-イル)エトキシ]-3,5-ジフルオロベンゾニトリル、\n\n5-シクロプロピル-4-(3-メトキシベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-(3,5-ジフルオロベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、\n\n5-シクロプロピル-4-[(2R)-2-エトキシプロピル]-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン、及びこれらの塩。\n\nExamples of specific compounds included in the compound of formula (I) or a salt thereof include the following compounds. \n 11-cyclopropyl-1- (2-methoxyethyl) -2,3,4,6,7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline, \n 4- (3-methoxypropyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (2-methoxyethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (2-ethoxyethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (3-methoxypropyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (3-fluoropropyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline, \n 5-bromo-4- (2-methoxyethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-Cyclopropyl-4-[(2S) -tetrahydrofuran-2-ylmethyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [ 3] Benzazepine, \n 5-Cyclopropyl-4-[(2R) -2-methoxypropyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3 ] Benzazepine, \n 5-cyclopropyl-4- (2-fluorobenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-cyclopropyl-4-[(2S) -3-fluoro-2-methoxypropyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3- h] [3] benzoazepine, \n 4- (3-chlorobenzyl) -5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-Cyclopropyl-4- (tetrahydro-2H-pyran-3-ylmethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [ 3] Benzazepine, \n 5-cyclopropyl-4- (2,3-dihydro-1,4-benzodioxin-2-ylmethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [ 2,3-h] [3] benzazepine, \n 5-cyclopropyl-4- (2-phenoxyethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-cyclopropyl-4- (2-methylbenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzoazepine, \n 5-cyclopropyl-4- (3-methylbenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-Cyclopropyl-4- (2,5-difluorobenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzo Azepine, \n 5-Cyclopropyl-4- [3- (methoxymethyl) benzyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] Benzazepine, \n 4- (5-Chloro-2-fluorobenzyl) -5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3 ] Benzazepine, \n 5-Cyclopropyl-4- (2,3-dihydro-1,4-benzodioxin-6-ylmethyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [ 2,3-h] [3] benzazepine, \n (3S) -5-cyclopropyl-4- (2-methoxyethyl) -3-methyl-2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3- h] [3] benzoazepine, \n 4- [2- (5-Cyclopropyl-2,3,7,8,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepin-4 (6H) -yl) Ethoxy] -3,5-difluorobenzonitrile, \n 5-cyclopropyl-4- (3-methoxybenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzazepine, \n 5-Cyclopropyl-4- (3,5-difluorobenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] benzo Azepine, \n 5-cyclopropyl-4-[(2R) -2-ethoxypropyl] -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3 ] Benzazepines and their salts.\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物には、置換基の種類によって互変異性体や幾何異性体が存在しうる。本明細書中、式（Ｉ）の化合物が異性体の一形態のみで記載されることがあるが、本発明はそれ以外の異性体も包含し、異性体の分離されたもの、あるいはそれらの混合物も包含する。\n\n　また、式（Ｉ）の化合物には不斉炭素原子や軸不斉を有する場合があり、これに基づく光学異性体が存在しうる。本発明は、式（Ｉ）の化合物の光学異性体の分離されたもの、あるいはそれらの混合物も包含する。\n\nIn the compound of the formula (I), tautomers and geometric isomers may exist depending on the type of substituent. In the present specification, the compound of the formula (I) may be described in only one form of an isomer, but the present invention includes other isomers, separated isomers, or those isomers. Also includes mixtures. \n In addition, the compound of formula (I) may have an asymmetric carbon atom or axial asymmetry, and optical isomers based on this may exist. The present invention also includes separated optical isomers of the compound of formula (I) or a mixture thereof.\n\n\n\n\n\n\n \n\n　さらに、本発明は式（Ｉ）の化合物の製薬学的に許容されるプロドラッグも包含する。製薬学的に許容されるプロドラッグとは、加溶媒分解により又は生理学的条件下で、アミノ基、水酸基、カルボキシル等に変換されうる基を有する化合物である。プロドラッグを形成する基としては、例えばProg. Med., 5, 2157-2161 (1985)や「医薬品の開発」（廣川書店、1990年）第７巻　分子設計163-198に記載の基が挙げられる。\n\n\nFurthermore, the present invention includes pharmaceutically acceptable prodrugs of the compound of formula (I). Pharmaceutically acceptable prodrugs are compounds having groups that can be converted to amino groups, hydroxyl groups, carboxyls, etc. by solvolysis or under physiological conditions. Examples of groups that form prodrugs include those described in Prog. Med., 5, 2157-2161 (1985) and “Development of Pharmaceuticals” (Yodogawa Shoten, 1990), Volume 7, Molecular Design 163-198. It is done.\n\n\n\n\n\n\n\n \n\n　また、式（Ｉ）の化合物の塩とは、式（Ｉ）の化合物の製薬学的に許容される塩であり、置換基の種類によって、酸付加塩又は塩基との塩を形成する場合がある。具体的には、塩酸、臭化水素酸、ヨウ化水素酸、硫酸、硝酸、リン酸等の無機酸や、ギ酸、酢酸、プロピオン酸、シュウ酸、マロン酸、コハク酸、フマル酸、マレイン酸、乳酸、リンゴ酸、マンデル酸、酒石酸、ジベンゾイル酒石酸、ジトルオイル酒石酸、クエン酸、メタンスルホン酸、エタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸、アスパラギン酸、グルタミン酸等の有機酸との酸付加塩、ナトリウム、カリウム、マグネシウム、カルシウム、アルミニウム等の無機塩基、メチルアミン、エチルアミン、エタノールアミン、リシン、オルニチン等の有機塩基との塩、アセチルロイシン等の各種アミノ酸及びアミノ酸誘導体との塩やアンモニウム塩等が挙げられる。\n\n\nThe salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I), and may form an acid addition salt or a salt with a base depending on the type of substituent. is there. Specifically, inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid Acid addition with organic acids such as lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, ditoluoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid Salts, salts with inorganic bases such as sodium, potassium, magnesium, calcium and aluminum, salts with organic bases such as methylamine, ethylamine, ethanolamine, lysine and ornithine, salts with various amino acids and amino acid derivatives such as acetylleucine and ammonium salts Etc.\n\n\n\n\n\n\n\n \n\n　さらに、本発明は式（Ｉ）の化合物及びその塩の各種の水和物や溶媒和物、及び結晶多形の物質も包含する。また、本発明は種々の放射性又は非放射性同位体でラベルされた化合物も包含する。\n\n\nFurthermore, the present invention also includes various hydrates and solvates of the compound of formula (I) and salts thereof, and polymorphic substances. The present invention also includes compounds labeled with various radioactive or non-radioactive isotopes.\n\n\n\n\n\n\n\n \n\n（製造法）\n\n　式（Ｉ）の化合物及びその塩は、その基本構造あるいは置換基の種類に基づく特徴を利用し、種々の公知の合成法を適用して製造することができる。その際、官能基の種類によっては、当該官能基を原料から中間体へ至る段階で適当な保護基（容易に当該官能基に転化可能な基）に置き換えておくことが製造技術上効果的な場合がある。このような保護基としては、例えばウッツ(P. G. M. Wuts)及びグリーン(T. W. Greene)著、「Greene's Protective Groups in Organic Synthesis（第４版、２００６年）」に記載の保護基等を挙げることができ、これらの反応条件に応じて適宜選択して用いればよい。このような方法では、当該保護基を導入して反応を行ったあと、必要に応じて保護基を除去することにより、所望の化合物を得ることができる。\n\n　また、式（Ｉ）の化合物のプロドラッグは、上記保護基と同様、原料から中間体へ至る段階で特定の基を導入、あるいは得られた式（Ｉ）の化合物を用いてさらに反応を行うことで製造できる。反応は通常のエステル化、アミド化、脱水等、当業者に公知の方法を適用することにより行うことができる。\n\n(Production method) \n The compound of the formula (I) and a salt thereof can be produced by applying various known synthesis methods utilizing characteristics based on the basic structure or the type of substituent. In this case, depending on the type of functional group, it is effective in terms of production technology to replace the functional group with an appropriate protecting group (a group that can be easily converted into the functional group) at the stage from the raw material to the intermediate. There is a case. Examples of such protecting groups include protecting groups described in “Greene's Protective Groups in Organic Synthesis (4th edition, 2006)” by PGM Wuts and TW Greene, What is necessary is just to select suitably according to these reaction conditions. In such a method, after carrying out the reaction by introducing the protective group, the desired compound can be obtained by removing the protective group as necessary. \n Moreover, the prodrug of the compound of the formula (I) introduces a specific group at the stage from the raw material to the intermediate as in the case of the protective group, or further reacts with the obtained compound of the formula (I). Can be manufactured. The reaction can be carried out by applying a method known to those skilled in the art, such as ordinary esterification, amidation, dehydration and the like.\n\n\n\n\n\n\n \n\n　以下、式（Ｉ）の化合物の代表的な製造法を説明する。各製法は、当該説明に付した参考文献を参照して行うこともできる。なお、本発明の製造法は以下に示した例には限定されない。\n\n\nHereinafter, representative production methods of the compound of the formula (I) will be described. Each manufacturing method can also be performed with reference to the reference attached to the said description. In addition, the manufacturing method of this invention is not limited to the example shown below.\n\n\n\n\n\n\n\n \n \n \n \n\n　式（Ｉ）の化合物は、アミノ基の保護基であるPを除去することにより得ることができる。Pにおける保護基としては、当業者が通常用いるアミノ基の保護基であればいずれでもよく、トリフルオロアセチル等のカルボニル；ｔ-ブチルカルボキシル、エチルカルボキシル、ベンジルカルボキシル等のオキシカルボニル；メタンスルホニル、ｐ-トルエンスルホニル、トリフルオロメタンスルホニル、ｐ－ニトロフェニルスルホニル、2,4-ジニトロフェニルスルホニル等のスルホニルが好適に用いられる。\n\n \n \n \n The compound of the formula (I) can be obtained by removing P which is a protecting group for an amino group. The protecting group for P may be any amino-protecting group commonly used by those skilled in the art, such as carbonyl such as trifluoroacetyl; oxycarbonyl such as t-butylcarboxyl, ethylcarboxyl and benzylcarboxyl; methanesulfonyl, p -Sulfonylsulfonyl, trifluoromethanesulfonyl, p-nitrophenylsulfonyl, 2,4-dinitrophenylsulfonyl and the like are preferably used.\n\n\n\n\n\n\n \n\n　本工程の脱保護は当業者が通常用いる脱保護の条件を適用することができる。例えば、酸処理、加水分解、加水素分解等により製造することができる。酸処理では、例えば、トリフルオロ酢酸、塩酸ガス、硫酸等を用いることができる。アルカリ加水分解の場合、無機塩基（例えばNaOH、KOH、NaHCO\n3\n、Cs\n2\nCO\n3\n等）を用いることが出来る。酸加水分解の場合は、塩酸等を用いることができる。いずれも反応温度は氷冷下から還流条件下で基質が分解しない条件で反応を行なうことができる。溶媒としては、ジオキサン、テトラヒドロフラン、ジクロロメタン、クロロホルム、酢酸エチル、アルコール類（MeOH、EtOH等）、N,N-ジメチルホルムアミド（DMF）、ジメチルスルホキシド（DMSO）、水、若しくはこれらの混合溶媒等が用いられるが、これらに限定されるものではない。加水素分解の場合、通常、パラジウム触媒の存在下、水素雰囲気下で反応させることができる。通常、室温から還流条件下で、基質が分解しない条件で反応を行なうことができる。溶媒としては、DMFやアルコール類（MeOH、EtOH等）が用いられるがこれらに限定されるものではない。また、前記の「Greene's Protective Groups in Organic Synthesis（第４版、２００６年）」に記載の脱カルボキサミド反応、脱カルバマート反応、脱スルホナミド反応の条件を適用することができる。\n\nDeprotection conditions commonly used by those skilled in the art can be applied to the deprotection in this step. For example, it can be produced by acid treatment, hydrolysis, hydrogenolysis and the like. In the acid treatment, for example, trifluoroacetic acid, hydrochloric acid gas, sulfuric acid or the like can be used. In the case of alkaline hydrolysis, an inorganic base (for example, NaOH, KOH, NaHCO \n3\n , Cs \n2\n CO \n3\n etc.) can be used. In the case of acid hydrolysis, hydrochloric acid or the like can be used. In either case, the reaction can be carried out under conditions where the substrate does not decompose under ice-cooling to reflux conditions. Dioxane, tetrahydrofuran, dichloromethane, chloroform, ethyl acetate, alcohols (MeOH, EtOH, etc.), N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), water, or a mixed solvent thereof are used as the solvent. However, it is not limited to these. In the case of hydrogenolysis, the reaction can be usually carried out in the presence of a palladium catalyst in a hydrogen atmosphere. Usually, the reaction can be carried out from room temperature to reflux conditions under which the substrate does not decompose. As the solvent, DMF and alcohols (MeOH, EtOH, etc.) are used, but are not limited thereto. In addition, the conditions of decarboxamide reaction, decarbamate reaction, and desulfonamide reaction described in the above-mentioned “Greene's Protective Groups in Organic Synthesis (4th edition, 2006)” can be applied.\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物における基R\n1a\n、R\n1b\n、R\n2a\n、R\n2b\n、R\n3\n、R\n4\n、R\n5\n、R\n6\n、及びR\n7\nとして定義された種々の置換基は、式（Ｉ）の化合物を原料として、又は式（Ｉ）の化合物の合成中間体を原料として、後述の実施例記載の反応、当業者にとって自明である反応、又はこれらの変法を用いることにより、他の官能基へと容易に変換することができる。例えば、O-アルキル化、N-アルキル化、還元、加水分解、アミド化等、当業者が通常採用し得る工程を任意に組み合わせて行うことができる。\n\nThe various substituents defined as groups R \n1a\n , R \n1b\n , R \n2a\n , R \n2b\n , R \n3\n , R \n4\n , R \n5\n , R \n6\n , and R \n7\n in the compounds of formula (I) are of formula (I) By using the compound as a raw material or the synthetic intermediate of the compound of formula (I) as a raw material, the reaction described in the examples below, the reaction obvious to those skilled in the art, or a modification thereof, other functional groups Can be easily converted into For example, the steps that can be usually employed by those skilled in the art, such as O-alkylation, N-alkylation, reduction, hydrolysis, amidation and the like, can be carried out in any combination.\n\n\n\n\n\n\n \n\n（原料化合物の製造）\n\n　上記製造法における原料化合物は、例えば下記の方法、後述の製造例に記載の方法、公知の方法、あるいはそれらの変法を用いて製造することができる。\n\n(Manufacture of raw material compounds) \n The raw material compound in the said manufacturing method can be manufactured using the following method, the method as described in the below-mentioned manufacture example, a well-known method, or those modified methods, for example.\n\n\n\n\n\n\n \n\n（原料合成１）\n\n\n \n \n\n　一般式(2)の化合物の合成原料である一般式(1)で表される化合物は、市販で入手可能であるか、または、当業者に公知の手段により製造される。次に、一般式(1)の化合物をニトロ化することにより一般式(2)の化合物を製造することができる。例えばいくつかの公知のニトロ化反応を使用することができ、酸溶媒中で硝酸、発煙硝酸または硝酸カリウム等を使用する方法や、テトラフルオロほう酸ニトロニウムを使用する方法などが挙げられる。次に、一般式(2)の化合物のニトロ基をアミノ基に還元することにより、一般式(3)の化合物を製造することができる。例えばいくつかの公知の還元方法を使用することができ、水素化リチウムアルミニウム等の金属水素化物を使用する方法や、還元鉄等を使用する方法などが挙げられる。また、ラネーニッケル、パラジウム、ルテニウム、ロジウムまたは白金等の貴金属触媒を使用する接触水素化も使用することができる。\n\n(Raw material synthesis 1) \n \n \n \n The compound represented by the general formula (1), which is a raw material for synthesizing the compound of the general formula (2), is commercially available or is produced by means known to those skilled in the art. Next, the compound of the general formula (2) can be produced by nitration of the compound of the general formula (1). For example, several known nitration reactions can be used, and examples thereof include a method using nitric acid, fuming nitric acid or potassium nitrate in an acid solvent, a method using nitronium tetrafluoroborate, and the like. Next, the compound of general formula (3) can be produced by reducing the nitro group of the compound of general formula (2) to an amino group. For example, several known reduction methods can be used, and examples thereof include a method using a metal hydride such as lithium aluminum hydride and a method using reduced iron. Catalytic hydrogenation using a noble metal catalyst such as Raney nickel, palladium, ruthenium, rhodium or platinum can also be used.\n\n\n\n\n\n\n \n\n（原料合成２）\n\n\n \n \n\n（ここでR\nXa\nはC\n1-6\nアルキルである）\n\n　一般式(3)の化合物をハロゲン化することにより一般式(4)の化合物を製造することができる。例えばいくつかの公知のハロゲン化反応を使用することができ、N-ブロモスクシンイミドやN-クロロスクシンイミドを使用する方法などが挙げられる。次に、一般式(4)の化合物から、遷移金属触媒を使用したカップリング反応により、一般式(5)の化合物を製造することができる。カップリング反応としては、例えばHeck反応を挙げることができる。Heck反応の反応条件は、使用される原料、溶媒及び遷移金属触媒によって異なるが、当業者に公知の手法を使用することができる。好ましい溶媒としてはアセトニトリル、テトラヒドロフラン、1,4-ジオキサン、又はDMF等が挙げられるが、これらに限定されるものではない。好ましい遷移金属触媒としてはパラジウム錯体であり、より好ましくは酢酸パラジウム(II)、ジクロロビス(トリフェニルホスフィン)パラジウム(II)、テトラキス(トリフェニルホスフィン)パラジウム(0)などの公知のパラジウム錯体が挙げられる。さらに、本反応は良好な結果を得るためにリン配位子（好ましくはトリフェニルホスフィン、トリ-o-トリルホスフィン、トリ-tert-ブチルホスフィン、又は2-(ジ-tert-ブチルホスフィノ)ビフェニル等）を添加してもよい。また、本反応は、塩基の存在下で好ましい結果を与えることができ、この際使用する塩基は、本反応様のカップリング反応で使用されたものであれば特に限定されないが、好ましくは、トリエチルアミン、又はN,N-ジイソプロピルエチルアミンなどである。\n\n(Raw material synthesis 2) \n \n \n \n (Where R \nXa\n is C \n1-6\n alkyl) \n The compound of the general formula (4) can be produced by halogenating the compound of the general formula (3). For example, several known halogenation reactions can be used, and examples thereof include a method using N-bromosuccinimide and N-chlorosuccinimide. Next, the compound of the general formula (5) can be produced from the compound of the general formula (4) by a coupling reaction using a transition metal catalyst. An example of the coupling reaction is a Heck reaction. The reaction conditions for the Heck reaction vary depending on the raw material, solvent and transition metal catalyst used, but techniques known to those skilled in the art can be used. Preferred solvents include, but are not limited to acetonitrile, tetrahydrofuran, 1,4-dioxane, DMF, and the like. Preferable transition metal catalyst is a palladium complex, more preferably a known palladium complex such as palladium acetate (II), dichlorobis (triphenylphosphine) palladium (II), tetrakis (triphenylphosphine) palladium (0). . In addition, the reaction may be performed with a phosphorus ligand (preferably triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine, or 2- (di-tert-butylphosphino) biphenyl to obtain good results. Etc.) may be added. In addition, this reaction can give a preferable result in the presence of a base, and the base used in this case is not particularly limited as long as it is used in this reaction-like coupling reaction, but preferably triethylamine. Or N, N-diisopropylethylamine.\n\n\n\n\n\n\n \n\n（原料合成３）\n\n\n \n \n\n　一般式（ＩＩＩａ）の化合物は、一般式(5)の化合物のα,β-不飽和エステルの二重結合の水素添加反応を行なうことにより、分子内アミド縮合環化反応を進行させて得ることができる。この反応では、水素雰囲気下、反応に不活性な溶媒中、一般式(5)の化合物を金属触媒存在下で、通常１時間～５日間撹拌する。この反応は、通常、冷却下から加熱下、好ましくは室温で行われる。ここで用いられる溶媒の例としては、特に限定されないが、メタノール、エタノール、2-プロパノール等のアルコール類、ジエチルエーテル、テトラヒドロフラン、ジオキサン、ジメトキシエタン等のエーテル類、水、酢酸エチル、DMF、DMSO、及びこれらの混合物が挙げられる。金属触媒としては、パラジウム炭素、パラジウム黒、水酸化パラジウム等のパラジウム触媒、白金板、酸化白金等の白金触媒、還元ニッケル、ラネーニッケル等のニッケル触媒、テトラキストリフェニルホスフィンクロロロジウム等のロジウム触媒、還元鉄等の鉄触媒等が好適に用いられる。水素ガスの代わりに、一般式(5)の化合物に対し等量～過剰量のギ酸、又はギ酸アンモニウムを水素源として用いることもできる。\n\n　なお、R\n2b\nが-H以外である化合物については、化合物（ＩＩＩａ）に対して、塩基を用いたカルボニルのα位への求電子置換反応を用いて、あるいは、当業者が通常採用しうる方法により所望の位置に-H以外のR\n2b\n基を導入することができる。\n\n〔文献〕\n\nM. Hudlicky著、「Reductions in Organic Chemistry, 2nd ed (ACS Monograph :188)」、ACS、1996年\n\n(Raw material synthesis 3) \n \n \n \n The compound of the general formula (IIIa) is obtained by proceeding the intramolecular amide condensation cyclization reaction by carrying out the hydrogenation reaction of the double bond of the α, β-unsaturated ester of the compound of the general formula (5). Can do. In this reaction, the compound of the general formula (5) is usually stirred for 1 hour to 5 days in the presence of a metal catalyst in a hydrogen atmosphere in a solvent inert to the reaction. This reaction is usually carried out under cooling to heating, preferably at room temperature. Examples of the solvent used here are not particularly limited, but alcohols such as methanol, ethanol and 2-propanol, ethers such as diethyl ether, tetrahydrofuran, dioxane and dimethoxyethane, water, ethyl acetate, DMF, DMSO, And mixtures thereof. As metal catalysts, palladium catalysts such as palladium carbon, palladium black and palladium hydroxide, platinum catalysts such as platinum plate and platinum oxide, nickel catalysts such as reduced nickel and Raney nickel, rhodium catalysts such as tetrakistriphenylphosphine chlororhodium, reduction An iron catalyst such as iron is preferably used. Instead of hydrogen gas, an equivalent to excess amount of formic acid or ammonium formate relative to the compound of general formula (5) can also be used as the hydrogen source. \n For compounds in which R \n2b\n is other than —H, a method that can be commonly employed by those skilled in the art using an electrophilic substitution reaction to the α-position of the carbonyl using a base with respect to the compound (IIIa). Can introduce an R \n2b\n group other than —H at a desired position. \n [Reference] \n M. Hudlicky, \"Reductions in Organic Chemistry, 2nd ed (ACS Monograph: 188)\", ACS, 1996\n\n\n\n\n\n\n \n\n（原料合成４）\n\n\n \n \n\n　一般式（ＩＩＩｂ）の化合物は、一般式（ＩＩＩａ）の化合物のカルボニル基の還元を行なうことにより得ることができる。この反応は、通常、溶媒中で還元剤の存在下に行なわれる。ここで用いられる溶媒の例としては、特に限定されないが、ジエチルエーテル、テトラヒドロフラン、ジオキサン、ジメトキシエタン等のエーテル類、ベンゼン、トルエン、キシレン等の芳香族炭化水素類が挙げられる。還元剤としては、水素化アルミニウムリチウムやナトリウムビス(2-メトキシエトキシ)アルミニウムヒドリド等の水素化アルミニウム化合物、水素化ホウ素ナトリウム、ジボラン、ボランテトラヒドロフラン錯体等の水素化ホウ素化合物が挙げられる。\n\n(Raw material synthesis 4) \n \n \n \n The compound of the general formula (IIIb) can be obtained by reducing the carbonyl group of the compound of the general formula (IIIa). This reaction is usually performed in a solvent in the presence of a reducing agent. Examples of the solvent used here are not particularly limited, but include ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane, and aromatic hydrocarbons such as benzene, toluene, and xylene. Examples of the reducing agent include aluminum hydride compounds such as lithium aluminum hydride and sodium bis (2-methoxyethoxy) aluminum hydride, and borohydride compounds such as sodium borohydride, diborane, and borane tetrahydrofuran complex.\n\n\n\n\n\n\n \n\n（原料合成５）\n\n\n \n \n\n（ここでR\n4a\nは、C\n1-6\nアルキル、ハロゲノC\n1-6\nアルキル、置換されていてもよいシクロアルキル、又は置換されていてもよいアリールであり、Halはハロゲンである。）\n\n　一般式（ＩＩＩｄ）の化合物は、一般式（ＩＩＩｃ）の化合物のカップリング反応により得ることができる。例えば、下記文献記載のスズキ（Suzuki）カップリング、上記原料合成２に記載のHeck反応等を適用することができる。\n\n〔文献〕\n\nChemical Reviews, vol.95, No.7, p2457 (1995)、Journal of American Chemical Society, vol.127, p4685 (2005)、Synlett, No.13, p2327 (2004)、Tetrahedron letters, No. 41, p4363 (2000)、又は、Tetrahedron letters, No.43, p2695 (2002)\n\n(Raw material synthesis 5) \n \n \n \n (Wherein R \n4a\n is C \n1-6\n alkyl, halogeno-C \n1-6\n alkyl, optionally substituted cycloalkyl, or optionally substituted aryl, Hal is halogen.) \n The compound of the general formula (IIId) can be obtained by a coupling reaction of the compound of the general formula (IIIc). For example, the Suzuki coupling described in the following literature, the Heck reaction described in the raw material synthesis 2, and the like can be applied. \n [Reference] \n Chemical Reviews, vol.95, No.7, p2457 (1995), Journal of American Chemical Society, vol.127, p4685 (2005), Synlett, No.13, p2327 (2004), Tetrahedron letters, No. 41, p4363 (2000) or Tetrahedron letters, No. 43, p2695 (2002)\n\n\n\n\n\n\n \n\n　一般式（ＩＩＩｄ）の化合物は、後述の実施例に記載の方法により得ることもできる。\n\n\nThe compound of the general formula (IIId) can also be obtained by the method described in Examples below.\n\n\n\n\n\n\n\n \n\n（原料合成６）\n\n\n \n \n\n（ここでR\n3a\nは、R\n3\nとして定義された基のうち-H以外の基である。）\n\n　一般式（ＩＩＩｅ）の化合物は、一般式（ＩＩＩｂ）の化合物のアルキル化やアシル化等により得ることができる。具体的な反応条件は、下記文献に記載された条件を適用することができる。\n\n〔文献〕\n\nS. R. Sandler及びW. Karo著、「Organic Functional Group Preparations」、第2版、第1巻、Academic Press Inc.、1991年\n\n日本化学会編「実験化学講座(第5版)」14巻(2005年)(丸善)\n\n(Raw material synthesis 6) \n \n \n \n (Here, R \n3a\n is a group other than —H among the groups defined as R \n3.\n ) \n The compound of the general formula (IIIe) can be obtained by alkylation or acylation of the compound of the general formula (IIIb). As specific reaction conditions, the conditions described in the following documents can be applied. \n [Reference] \n SR Sandler and W. Karo, “Organic Functional Group Preparations”, 2nd edition, 1st volume, Academic Press Inc. (Maruzen)\n\n\n\n\n\n\n \n\n　一般式（ＩＩＩｅ）の化合物は、後述の実施例に記載の方法及び上記原料合成４に記載の方法により得ることもできる。\n\n\nThe compound of the general formula (IIIe) can also be obtained by the method described in Examples below and the method described in the above raw material synthesis 4.\n\n\n\n\n\n\n\n \n\n（原料合成７）\n\n\n \n \n\n　一般式(8)の化合物は、一般式(6)の化合物と一般式(7)の化合物との反応により得ることができる。ここで、L\n1\nの脱離基の例には、ハロゲン、メタンスルホニルオキシ、p-トルエンスルホニルオキシ基等が含まれる。\n\n　この反応では、一般式(6)の化合物と一般式(7)の化合物とを等量若しくは一方を過剰量用い、これらの混合物を、塩基の存在下、反応に不活性な溶媒中、冷却下から加熱還流下、好ましくは0℃から80℃において、通常0.1時間～５日間撹拌する。ここで用いられる溶媒の例としては、特に限定はされないが、ベンゼン、トルエン、キシレン等の芳香族炭化水素類、ジエチルエーテル、テトラヒドロフラン、ジオキサン、ジメトキシエタン等のエーテル類、ジクロロメタン、1,2-ジクロロエタン、クロロホルム等のハロゲン化炭化水素類、DMF、DMSO、酢酸エチル、アセトニトリル、及びこれらの混合物が挙げられる。塩基の例には、トリエチルアミン、N,N-ジイソプロピルエチルアミン、1,8-ジアザビシクロ[5.4.0]-7-ウンデセン、n-ブチルリチウム等の有機塩基、炭酸ナトリウム、炭酸カリウム、水素化ナトリウム、カリウム tert-ブトキシド等の無機塩基が含まれる。塩化テトラ-n-ブチルアンモニウム等の相間移動触媒の存在下で反応を行うことが有利な場合がある。\n\n　一般式（ＩＩＩｆ）の化合物は上記原料合成３に記載の方法により、一般式（ＩＩＩｇ）の化合物は上記原料合成４に記載の方法により、それぞれ得ることができる。\n\n〔文献〕\n\nS. R. Sandler及びW. Karo著、「Organic Functional Group Preparations」、第2版、第1巻、Academic Press Inc.、1991年\n\n日本化学会編「実験化学講座(第5版)」14巻(2005年)(丸善)\n\n(Raw material synthesis 7) \n \n \n \n The compound of the general formula (8) can be obtained by reacting the compound of the general formula (6) with the compound of the general formula (7). Here, examples of the leaving group for L \n1\n include halogen, methanesulfonyloxy, p-toluenesulfonyloxy group and the like. \n In this reaction, the compound of the general formula (6) and the compound of the general formula (7) are used in the same amount or in excess, and the mixture is cooled in a solvent inert to the reaction in the presence of a base. From 0 to 80 ° C., usually for 0.1 to 5 days. Examples of the solvent used here include, but are not limited to, aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as diethyl ether, tetrahydrofuran, dioxane and dimethoxyethane, dichloromethane and 1,2-dichloroethane. , Halogenated hydrocarbons such as chloroform, DMF, DMSO, ethyl acetate, acetonitrile, and mixtures thereof. Examples of bases include triethylamine, N, N-diisopropylethylamine, 1,8-diazabicyclo [5.4.0] -7-undecene, organic bases such as n-butyllithium, sodium carbonate, potassium carbonate, sodium hydride, potassium Inorganic bases such as tert-butoxide are included. It may be advantageous to carry out the reaction in the presence of a phase transfer catalyst such as tetra-n-butylammonium chloride. \n The compound of the general formula (IIIf) can be obtained by the method described in the raw material synthesis 3, and the compound of the general formula (IIIg) can be obtained by the method described in the raw material synthesis 4. \n [Reference] \n SR Sandler and W. Karo, “Organic Functional Group Preparations”, 2nd edition, 1st volume, Academic Press Inc. (Maruzen)\n\n\n\n\n\n\n \n\n（原料合成８）\n\n\n \n \n\n（ここでR\n3b\nは、R\n3\nとして定義された基のうち、置換されていてもよいC\n1-6\nアルキル、C\n3-8\nシクロアルキル、置換されていてもよいアリール、置換されていてもよいヘテロ環である。なお、この置換されていてもよいC\n1-6\nアルキルのうち、R\n3b\nが結合する窒素原子に直接結合する炭素原子上にオキソが置換しているものは除く。）\n\n　一般式(10)の化合物は一般式(9)の化合物と適当なアルデヒド又はケトン化合物とを等量用い、これらの混合物を、還元剤の存在下、反応に不活性な溶媒中、-45℃から加熱還流下、好ましくは0℃～室温において、通常0.1時間～５日間撹拌することで、得ることができる。ここで用いられる溶媒の例としては、特に限定されないが、メタノール、エタノール等のアルコール類、ジエチルエーテル、テトラヒドロフラン、ジオキサン、ジメトキシエタン等のエーテル類、及びこれらの混合物が挙げられる。還元剤としては、シアン化水素化ホウ素ナトリウム、トリアセトキシ水素化ホウ素ナトリウム、水素化ホウ素ナトリウム等が挙げられる。モレキュラーシーブス等の脱水剤、又は酢酸、塩酸、チタニウム(IV)イソプロポキシド錯体等の酸存在下で反応を行うことが好ましい場合がある。また、前記還元剤での処理の代わりに、メタノール、エタノール、酢酸エチル等の溶媒中、酢酸、塩酸等の酸の存在下又は非存在下で、還元触媒（例えば、パラジウム炭素、ラネーニッケル等）を用いて反応を行うこともできる。この場合、反応を常圧から50気圧の水素雰囲気下で、冷却下から加熱下で行うことが好ましい。　一般式（ＩＩＩｈ）の化合物は、一般式(10)の化合物と適当なハロゲノカルボン酸エステルとを用いて、塩基の存在下反応させることにより得ることができる。\n\n　一般式（ＩＩＩｉ）の化合物は、上記原料合成４に記載の方法を用いて、一般式（ＩＩＩｈ）の化合物のカルボニル基の還元を行なうことにより得ることができる。\n\n〔文献〕\n\nA. R. Katritzky及びR. J. K. Taylor著、「Comprehensive Organic Functional Group Transformations II」、第2巻、Elsevier Pergamon、2005年\n\n日本化学会編「実験化学講座(第5版)」14巻(2005年)(丸善)\n\n(Raw material synthesis 8) \n \n \n \n (Here, R \n3b\n is an \noptionally\n substituted C \n1-6\n alkyl, C \n3-8\n cycloalkyl, \noptionally\n substituted aryl among the groups defined as R \n3\n , and \noptionally\n substituted. (It is a heterocycle, except for the optionally substituted C \n1-6\n alkyl in which oxo is substituted on the carbon atom directly bonded to the nitrogen atom to which R \n3b\n is bonded.) \n For the compound of the general formula (10), an equal amount of the compound of the general formula (9) and an appropriate aldehyde or ketone compound is used, and a mixture thereof is -45 ° C in a solvent inert to the reaction in the presence of a reducing agent. To 0.degree. C. to room temperature, usually for 0.1 hour to 5 days. Examples of the solvent used here include, but are not limited to, alcohols such as methanol and ethanol, ethers such as diethyl ether, tetrahydrofuran, dioxane and dimethoxyethane, and mixtures thereof. Examples of the reducing agent include sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride and the like. It may be preferable to carry out the reaction in the presence of a dehydrating agent such as molecular sieves or an acid such as acetic acid, hydrochloric acid, titanium (IV) isopropoxide complex. Further, instead of the treatment with the reducing agent, a reduction catalyst (for example, palladium carbon, Raney nickel, etc.) is used in a solvent such as methanol, ethanol, ethyl acetate, in the presence or absence of an acid such as acetic acid or hydrochloric acid. Can also be used to carry out the reaction. In this case, it is preferable to carry out the reaction in a hydrogen atmosphere at normal pressure to 50 atm and under cooling to heating. The compound of the general formula (IIIh) can be obtained by reacting the compound of the general formula (10) with an appropriate halogenocarboxylic acid ester in the presence of a base. \n The compound of the general formula (IIIi) can be obtained by reducing the carbonyl group of the compound of the general formula (IIIh) using the method described in the raw material synthesis 4. \n [Reference] \n A. R. Katritzky and R. J. K. Taylor, `` Comprehensive Organic Functional Group Transformations II '', Volume 2, Elsevier Pergamon, 2005 The Chemical Society of Japan `` Experimental Chemistry Course (5th Edition) '' Volume 14 (2005) (Maruzen)\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物は、遊離化合物、その塩、水和物、溶媒和物、あるいは結晶多形の物質として単離され、精製される。式（Ｉ）の化合物の塩は、常法の造塩反応に付すことにより製造できる。\n\n　単離、精製は、抽出、分別結晶化、各種分画クロマトグラフィー等、通常の科学捜査を適用して行われる。\n\n　各種の異性体は、適当な原料化合物を選択することにより製造でき、あるいは異性体間の物理化学的性質の差を利用して分離することができる。例えば、光学異性体は、ラセミ体の一般的な光学分割法（例えば、光学活性な塩基又は酸とのジアステレオマー塩に導く分別結晶化や、キラルカラム等を用いたクロマトグラフィー等）により得られ、また、適当な光学活性な原料から製造することもできる。\n\nThe compounds of formula (I) are isolated and purified as free compounds, their salts, hydrates, solvates or polymorphic substances. The salt of the compound of the formula (I) can be produced by subjecting it to a conventional salt formation reaction. \n Isolation and purification are carried out by applying ordinary forensic investigations such as extraction, fractional crystallization, and various fractional chromatography. \n Various isomers can be produced by selecting an appropriate raw material compound, or can be separated by utilizing a difference in physicochemical properties between isomers. For example, optical isomers can be obtained by general optical resolution of racemates (for example, fractional crystallization leading to diastereomeric salts with optically active bases or acids, chromatography using chiral columns, etc.). It can also be produced from a suitable optically active raw material.\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物の薬理活性は、以下の試験により確認した。\n\n\nThe pharmacological activity of the compound of formula (I) was confirmed by the following test.\n\n\n\n\n\n\n\n \n\n試験例１　5-HT\n2C\n受容体アゴニスト活性の評価\n\n　式（Ｉ）の化合物の5-HT\n2C\n受容体に対するアゴニスト活性は、下記に示す方法により確認した。\n\n　ヒト5-HT\n2C\n受容体アゴニスト活性は、リガンド依存的な細胞内カルシウム濃度の上昇を指標にして測定した。ヒト5-HT\n2C\n受容体を安定的に発現させたCHO細胞を用いた。受容体発現細胞は、ヒト5-HT\n2C\n受容体の遺伝子（Accession numbers：AF498983(5-HT\n2C\n)）を、pEF-BOSベクター（Nucleic Acids Research, Vol.18, No.17）を用いてCHO細胞（ジヒドロ葉酸欠損株、DSファーマバイオメディカル株式会社）にトランスフェクションすることにより作製した。5-HT\n2C\nに関しては転写後、RNAエディティングを受けて、3種のアミノ酸に違いが生じ、14個の受容体アイソフォームができる。これらのうち、エディティングを受けていないINI型の5-HT\n2C\n受容体を安定的に発現する細胞を用いた。評価に用いるための細胞の培養は37℃、5%二酸化炭素下にて、10%ウシ胎児血清（FBS）を含む培地（商品名：α-MEM、インビトロジェン社）にて行った。評価前日、8mM L-glutamine（商品名：L-glutamine 200mM、インビトロジェン社、使用時の濃度が8mMとなるように培地に添加）を含む無血清培地（商品名：CD-CHO、インビトロジェン社）に懸濁して4×104細胞／ウェル（well）となるように、96ウェルポリ-D-リジン-コートプレート（商品名：バイオコートPDL96Wブラック/クリアー、日本べクトンディッキンソン社）に分注し、37℃、5%二酸化炭素下にて一晩培養した。洗浄溶液（ハンクスバランス塩溶液（HBSS）-水酸化ナトリウム（NaOH）、20mM 2-[4-(2-ヒドロキシエチル)-1-ピペラジニル]エタンスルホン酸（HEPES）-水酸化ナトリウム（NaOH）、2.5mM プロベネシド、及び0.1%ウシ血清アルブミン（BSA）の混合物）と4μMの蛍光標識試薬（商品名：Fluo4-AM、同仁堂社）を含む溶液をローディングバッファーとし、一晩培養した96ウェルプレートの培地をローディングバッファーに置き換えた。室温で3時間静置（遮光）した後、洗浄溶液をセットしたプレートウォッシャー（商品名：ELx405、バイオテック（BIO-TEK）インスツルメント社）にて細胞を洗浄した。洗浄した細胞のプレートを、細胞内カルシウム（Ca）濃度測定システム（商品名：FLIPR、モレキュラーデバイス社）にセットした。本装置内で、ジメチルスルホキシドで溶解し洗浄溶液で所定の濃度に希釈した試験化合物を添加し、細胞内Ca濃度変化を測定した。細胞内Ca濃度変化の最大値と最小値の差を算出し、測定データとして保存した。\n\n　アゴニスト活性は5-HTによる最大反応（5-HT 10μM 添加時のアゴニスト作用）を100%及び溶媒のみの反応を0%とし、5-HTの最大反応に対する本発明化合物の活性化作用(Emax（％）)を求め、logistic回帰法により効力（EC50（nM））を算出した。\n\nTest Example 1 Evaluation of 5-HT \n2C\n receptor agonist activity The agonist activity of the compound of formula (I) on 5-HT \n2C\n receptor was confirmed by the method shown below. \n Human 5-HT \n2C\n receptor agonist activity was measured using an increase in intracellular calcium concentration dependent on the ligand as an index. CHO cells stably expressing the human 5-HT \n2C\n receptor were used. Receptor-expressing cells can be obtained by using the human 5-HT \n2C\n receptor gene (Accession numbers: AF498983 (5-HT \n2C\n )) using the pEF-BOS vector (Nucleic Acids Research, Vol. 18, No. 17). It was prepared by transfecting cells (dihydrofolate deficient strain, DS Pharma Biomedical Co., Ltd.). As for 5-HT \n2C\n , after transcription, RNA editing is performed, and three amino acids differ, resulting in 14 receptor isoforms. Among these, cells that stably expressed the INI-type 5-HT \n2C\n receptor not subjected to editing were used. The cells used for evaluation were cultured in a medium (trade name: α-MEM, Invitrogen) containing 10% fetal bovine serum (FBS) at 37 ° C. and 5% carbon dioxide. The day before the evaluation, a serum-free medium (trade name: CD-CHO, Invitrogen) containing 8 mM L-glutamine (trade name: L-glutamine 200 mM, Invitrogen, added to the medium so that the concentration at use is 8 mM) Dispensed into a 96-well poly-D-lysine-coated plate (trade name: Biocoat PDL96W Black / Clear, Nippon Becton Dickinson) at 37 ° C so that it becomes 4 x 104 cells / well. And cultured overnight under 5% carbon dioxide. Wash solution (Hanks balanced salt solution (HBSS) -sodium hydroxide (NaOH), 20 mM 2- [4- (2-hydroxyethyl) -1-piperazinyl] ethanesulfonic acid (HEPES) -sodium hydroxide (NaOH), 2.5 Using a solution containing mM probenecid and 0.1% bovine serum albumin (BSA) and 4 μM fluorescent labeling reagent (trade name: Fluo4-AM, Dojindo) as a loading buffer, culture the medium in a 96-well plate overnight. Replaced with loading buffer. After standing at room temperature (light-shielded) for 3 hours, the cells were washed with a plate washer (trade name: ELx405, Biotech (BIO-TEK) Instruments) in which a washing solution was set. The washed cell plate was set in an intracellular calcium (Ca) concentration measurement system (trade name: FLIPR, Molecular Devices). In this apparatus, a test compound dissolved in dimethyl sulfoxide and diluted to a predetermined concentration with a washing solution was added, and changes in intracellular Ca concentration were measured. The difference between the maximum value and the minimum value of intracellular Ca concentration change was calculated and stored as measurement data. \n Agonist activity is 100% for the maximum response due to 5-HT (agonist effect when 10 μM of 5-HT is added) and 0% for the response of only the solvent, and the activating effect of the compound of the present invention on the maximum response of 5-HT (Emax ( %)) And the efficacy (EC50 (nM)) was calculated by logistic regression.\n\n\n\n\n\n\n \n\n　いくつかの化合物の結果を表１に示す。表中、Exは後記の実施例化合物番号を示す。\n\n\nThe results for several compounds are shown in Table 1. In the table, Ex represents an example compound number described later.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n試験例２　外尿道括約筋筋電図の測定\n\n　式（Ｉ）の化合物の尿道括約筋筋電図に対する活性化作用は、下記に示す方法により確認した。\n\n　体重250-350gのHartley系雌性モルモットをウレタン（シグマ）で麻酔した。モルモットを仰臥位で固定し、被験化合物投与用カテーテル（PE-50;Clay Adams）を頚静脈に留置した。また膀胱頂部から膀胱内へ、生理食塩水のインフュージョン及び膀胱内圧測定用のカテーテル（PE-160;Clay Adams）を挿入して留置した。さらに外尿道括約筋筋電図を測定するため、尿道口の左右両脇から尿道括約筋部分に電極を２本挿入した。ベース電圧を測定するための電極は後肢の皮下に留置した。膀胱カテーテルは三方活栓を介して分岐させ、一方はインフュージョンポンプ（テルモ）に固定した50mLシリンジ（テルモ）を連結した。もう一方は圧トランスデューサー（DX-100;日本光電）に接続し、トランスデューサーの信号をアンプ（AP-630G;日本光電）、データ収録装置（PowerLab;ADInstruments）を介してコンピューターへ送り、ハードディスク上に記録した。筋電図測定用の電極はコントロールユニット（JB-101J;日本光電）に接続し、信号をアンプ（AB-651J;日本光電）、データ収録装置（PowerLab;ADInstruments）を介してコンピュータへ送り、ハードディスク上に記録した。また、データはソフトウェア（Chart;ADInstruments）を用いてコンピューター上で解析した。インフュージョンポンプを用いて膀胱内に生理食塩水を時速18mLの速度で連続的に注入し、安定して排尿反射が誘発されることを確認した。筋電図活性は、安定化期間において最も低い電位振幅を基準とし、その基準の振幅を超える発火回数を指標として解析した。各々の排尿の間（蓄尿期）の尿道括約筋筋電図活性を解析し、その平均値を算出した。安定化期間の後、溶媒及び被験化合物を頸静脈に留置したカテーテルを介して40分間隔で増加用量にて投与した。溶媒投与後の尿道括約筋筋電活性を100％とし、被験化合物投与後の尿道括約筋筋電活性を溶媒投与後の筋電活性に対する割合（％）で表記した。\n\nTest Example 2 Measurement of external urethral sphincter electromyogram The activation action of the compound of formula (I) on the urethral sphincter electromyogram was confirmed by the method described below. \n Hartley female guinea pigs weighing 250-350 g were anesthetized with urethane (Sigma). The guinea pig was fixed in the supine position, and a test compound administration catheter (PE-50; Clay Adams) was placed in the jugular vein. A catheter (PE-160; Clay Adams) for infusion of physiological saline and measurement of intravesical pressure was inserted from the top of the bladder into the bladder. Furthermore, in order to measure the external urethral sphincter electromyogram, two electrodes were inserted into the urethral sphincter from both the left and right sides of the urethral orifice. The electrode for measuring the base voltage was placed subcutaneously in the hind limb. The bladder catheter was branched through a three-way stopcock, and one was connected to a 50 mL syringe (Terumo) fixed to an infusion pump (Terumo). The other is connected to a pressure transducer (DX-100; Nihon Kohden), and the transducer signal is sent to a computer via an amplifier (AP-630G; Nihon Kohden) and a data recording device (PowerLab; ADInstruments). Recorded. Electrodes for measuring electromyogram are connected to a control unit (JB-101J; Nihon Kohden), and signals are sent to a computer via an amplifier (AB-651J; Nihon Kohden) and a data recording device (PowerLab; ADInstruments). Recorded above. The data was analyzed on a computer using software (Chart; ADInstruments). Using an infusion pump, physiological saline was continuously infused into the bladder at a rate of 18 mL per hour, and it was confirmed that the urination reflex was induced stably. The electromyogram activity was analyzed using the lowest potential amplitude in the stabilization period as a reference and the number of firings exceeding the reference amplitude as an index. The urethral sphincter electromyogram activity during each urination (urine accumulation phase) was analyzed, and the average value was calculated. After the stabilization period, vehicle and test compound were administered at increasing doses at 40 minute intervals via a catheter placed in the jugular vein. The urethral sphincter myoelectric activity after administration of the solvent was taken as 100%, and the urethral sphincter myoelectric activity after administration of the test compound was expressed as a ratio (%) to the myoelectric activity after administration of the solvent.\n\n\n\n\n\n\n \n\n　その結果、後記に示す実施例８１、実施例５９、実施例８８、実施例１０４、実施例１０６、実施例１４１、実施例３８、実施例１３５、実施例２１５、実施例２４３、実施例２６５、実施例２８７、実施例２５８、実施例２６３、実施例２６７、実施例２６８、実施例２７６、実施例２７７、実施例２８３、実施例２８８、実施例２９０、実施例２９１、実施例２９２、実施例２９７、実施例２９９、実施例３１３、実施例３１５の化合物は、3mg/kg静脈内投与で、200%以上の外尿道括約筋筋電活性を示した。\n\n\nAs a result, Example 81, Example 59, Example 88, Example 104, Example 106, Example 141, Example 38, Example 135, Example 215, Example 243, Example 265, described later, Example 287, Example 258, Example 263, Example 267, Example 268, Example 276, Example 277, Example 283, Example 288, Example 290, Example 291, Example 292, Example The compounds of 297, Example 299, Example 313, and Example 315 showed an external urinary sphincter myoelectric activity of 200% or more after intravenous administration at 3 mg / kg.\n\n\n\n\n\n\n\n \n\n　上記の各試験の結果、式（Ｉ）の化合物は5-HT\n2C\n受容体アゴニスト活性を有することが確認され、式（Ｉ）の化合物は、医薬品として、5-HT\n2C\n受容体に関係する疾患、特に、腹圧性尿失禁、切迫性尿失禁、混合型尿失禁等の尿失禁、勃起不全症等の性機能障害、肥満等の治療又は予防に使用できる。\n\n　上記試験で得られた結果によれば、5-HT\n2C\n受容体アゴニスト活性を有しており、抗肥満薬として開発中のLorcaserinの活性値とほぼ同等かそれ以上であると考えられる（The Journal of Pharmacology and Experimental Therapeutics Vol 325, No.2 p577-587(2008)）。\n\nAs a result of the above tests, the compound of formula (I) was confirmed to have 5-HT \n2C\n receptor agonist activity, and the compound of formula (I) was used as a pharmaceutical for diseases related to 5-HT \n2C\n receptor. In particular, it can be used for the treatment or prevention of urinary incontinence such as stress urinary incontinence, urge incontinence, mixed urinary incontinence, sexual dysfunction such as erectile dysfunction, obesity and the like. \n According to the results obtained in the above test, it has 5-HT \n2C\n receptor agonist activity and is considered to be almost equal to or higher than the activity value of Lorcaserin under development as an anti-obesity drug (The Journal of Pharmacology and Experimental Therapeutics Vol 325, No. 2 p577-587 (2008)).\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物又はその塩の１種又は２種以上を有効成分として含有する医薬組成物は、当分野において通常用いられている賦形剤、即ち薬剤用賦形剤や薬剤用担体等を用いて、通常使用されている方法によって調製することができる。\n\n　投与は錠剤、丸剤、カプセル剤、顆粒剤、散剤、液剤等による経口投与、又は関節内、静脈内、筋肉内等の注射剤、坐剤、点眼剤、眼軟膏、経皮用液剤、軟膏剤、経皮用貼付剤、経粘膜液剤、経粘膜貼付剤、吸入剤等による非経口投与のいずれの形態であってもよい。\n\nA pharmaceutical composition containing one or more compounds of the formula (I) or a salt thereof as an active ingredient is an excipient normally used in the art, that is, a pharmaceutical excipient, a pharmaceutical carrier, etc. Can be prepared by a commonly used method. \n Administration is oral by tablet, pill, capsule, granule, powder, liquid, etc., or injection such as intraarticular, intravenous, intramuscular, suppository, eye drops, ophthalmic ointment, transdermal solution, ointment Any form of parenteral administration using an agent, a transdermal patch, a transmucosal solution, a transmucosal patch, an inhalant, etc. may be used.\n\n\n\n\n\n\n \n\n　経口投与のための固体組成物としては、錠剤、散剤、顆粒剤等が用いられる。このような固体組成物においては、１種又は２種以上の有効成分を、少なくとも１種の不活性な賦形剤と混合される。組成物は、常法に従って、不活性な添加剤、例えば滑沢剤や崩壊剤、安定化剤、溶解補助剤を含有していてもよい。錠剤又は丸剤は必要により糖衣又は胃溶性若しくは腸溶性物質のフィルムで被膜してもよい。\n\n　経口投与のための液体組成物は、薬剤的に許容される乳濁剤、溶液剤、懸濁剤、シロップ剤又はエリキシル剤等を含み、一般的に用いられる不活性な希釈剤、例えば精製水又はエタノールを含む。当該液体組成物は不活性な希釈剤以外に可溶化剤、湿潤剤、懸濁剤のような補助剤、甘味剤、風味剤、芳香剤、防腐剤を含有していてもよい。\n\nAs a solid composition for oral administration, tablets, powders, granules and the like are used. In such a solid composition, one or more active ingredients are mixed with at least one inert excipient. The composition may contain an inert additive such as a lubricant, a disintegrant, a stabilizer and a solubilizing agent according to a conventional method. If necessary, tablets or pills may be coated with a sugar coating or a film of a gastric or enteric substance. \n Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs and the like, and commonly used inert diluents such as purified water. Or it contains ethanol. In addition to the inert diluent, the liquid composition may contain solubilizers, wetting agents, auxiliaries such as suspending agents, sweeteners, flavors, fragrances, and preservatives.\n\n\n\n\n\n\n \n\n　非経口投与のための注射剤は、無菌の水性若しくは非水性の溶剤、懸濁剤、又は乳濁剤を含有する。水性の溶剤としては、例えば注射用蒸留水又は生理食塩液が含まれる。非水性の溶剤としては、例えばエタノールのようなアルコール類がある。このような組成物は、さらに等張化剤、防腐剤、湿潤剤、乳化剤、分散剤、安定化剤、又は溶解補助剤を含んでもよい。これらは例えばバクテリア保留フィルターを通す濾過、殺菌剤の配合、又は照射によって無菌化される。また、これらは無菌の固体組成物を製造し、使用前に無菌水又は無菌の注射用溶媒に溶解又は懸濁して使用することもできる。\n\n\nThe injection for parenteral administration contains a sterile aqueous or non-aqueous solvent, suspension, or emulsion. Examples of the aqueous solvent include distilled water for injection or physiological saline. Non-aqueous solvents include alcohols such as ethanol. Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizing agents. These are sterilized by, for example, filtration through a bacteria-retaining filter, blending with a bactericide, or irradiation. These can also be used by producing a sterile solid composition and dissolving or suspending it in sterile water or a sterile solvent for injection before use.\n\n\n\n\n\n\n\n \n\n　外用剤としては、軟膏剤、硬膏剤、クリーム剤、ゼリー剤、パップ剤、噴霧剤、ローション剤、点眼剤、眼軟膏等を包含する。一般に用いられる軟膏基剤、ローション基剤、水性又は非水性の液剤、懸濁剤、乳剤等を含有する。\n\n\nExternal preparations include ointments, plasters, creams, jellies, poultices, sprays, lotions, eye drops, eye ointments and the like. Contains commonly used ointment bases, lotion bases, aqueous or non-aqueous solutions, suspensions, emulsions, and the like.\n\n\n\n\n\n\n\n \n\n　吸入剤や経鼻剤等の経粘膜剤は固体、液体又は半固体状のものが用いられ、従来公知の方法に従って製造することができる。例えば公知の賦形剤や、更に、pH調整剤、防腐剤、界面活性剤、滑沢剤、安定剤や増粘剤等が適宜添加されていてもよい。投与は、適当な吸入又は吹送のためのデバイスを使用することができる。例えば、計量投与吸入デバイス等の公知のデバイスや噴霧器を使用して、化合物を単独で又は処方された混合物の粉末として、若しくは医薬的に許容し得る担体と組み合わせて溶液又は懸濁液として投与することができる。乾燥粉末吸入器等は、単回又は多数回の投与用のものであってもよく、乾燥粉末又は粉末含有カプセルを利用することができる。あるいは、適当な駆出剤、例えばクロロフルオロアルカン、ヒドロフルオロアルカン、又は二酸化炭素等の好適な気体を使用した加圧エアゾールスプレー等の形態であってもよい。\n\n\nA transmucosal agent such as an inhalant or a nasal agent is used in a solid, liquid or semi-solid form, and can be produced according to a conventionally known method. For example, known excipients, and further pH adjusters, preservatives, surfactants, lubricants, stabilizers, thickeners and the like may be appropriately added. For administration, an appropriate device for inhalation or insufflation can be used. For example, using a known device such as a metered dose inhalation device or a nebulizer, the compound is administered alone or as a powder in a formulated mixture or as a solution or suspension in combination with a pharmaceutically acceptable carrier. be able to. The dry powder inhaler or the like may be for single or multiple administration, and a dry powder or a powder-containing capsule can be used. Alternatively, it may be in the form of a pressurized aerosol spray using a suitable propellant such as chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide.\n\n\n\n\n\n\n\n \n\n　通常経口投与の場合、１日の投与量は、体重当たり約0.001～100 mg/kg、好ましくは0.1～30 mg/kg、更に好ましくは0.1～10 mg/kgが適当であり、これを１回であるいは２回～４回に分けて投与する。静脈内投与される場合は、１日の投与量は、体重当たり約0.0001～10 mg/kgが適当で、１日１回～複数回に分けて投与する。また、経粘膜剤としては、体重当たり約0.001～100 mg/kgを１日１回～複数回に分けて投与する。投与量は症状、年令、性別等を考慮して個々の場合に応じて適宜決定される。\n\n\nIn the case of oral administration, the appropriate daily dose is about 0.001 to 100 mg / kg, preferably 0.1 to 30 mg / kg, more preferably 0.1 to 10 mg / kg per body weight. Or in 2 to 4 divided doses. In the case of intravenous administration, the daily dose is suitably about 0.0001 to 10 mg / kg per body weight, and is administered once to several times a day. As a transmucosal agent, about 0.001 to 100 mg / kg per body weight is administered once to several times a day. The dose is appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.\n\n\n\n\n\n\n\n \n\n　投与経路、剤型、投与部位、賦形剤や添加剤の種類によって異なるが、本発明の医薬組成物は、0.01～100重量％、ある態様としては0.01～50重量％の有効成分である１種またはそれ以上の式（Ｉ）の化合物又はその塩を含有する。\n\n\nThe pharmaceutical composition of the present invention is an active ingredient in an amount of 0.01 to 100% by weight, and in some embodiments 0.01 to 50% by weight, although it varies depending on the route of administration, dosage form, administration site, excipient and additive. Contains one or more compounds of formula (I) or salts thereof.\n\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物は、前述の式（Ｉ）の化合物が有効性を示すと考えられる疾患の種々の治療又は予防剤と併用することができる。当該併用は、同時投与、あるいは別個に連続して、若しくは所望の時間間隔をおいて投与してもよい。同時投与製剤は、別個に製剤化されていても、前述の式（Ｉ）の化合物が有効性を示すと考えられる疾患の種々の治療剤又は予防剤と式（Ｉ）の化合物とを含む医薬組成物であってもよい。\n\n\nThe compound of formula (I) can be used in combination with various therapeutic or prophylactic agents for diseases for which the compound of formula (I) is considered to be effective. The combination may be administered simultaneously, separately separately, or at desired time intervals. The pharmaceutical preparation containing various therapeutic or prophylactic agents for the diseases for which the compound of the above formula (I) is considered to be effective and the compound of the formula (I), even if the coadministration preparation is formulated separately It may be a composition.\n\n\n\n\n\n\n\n\n\n \n\n　以下、実施例に基づき、式（Ｉ）の化合物及びその原料化合物の製造法をさらに詳細に説明する。なお本発明は、下記実施例に記載の化合物に限定されるものではない。また、原料化合物の製法を製造例に示す。また、式（Ｉ）の化合物の製造法は、以下に示される具体的実施例の製造法のみに限定されるものではなく、式（Ｉ）の化合物はこれらの製造法の組み合わせ、あるいは当業者に自明である方法によっても製造されうる。\n\n\nHereinafter, based on an Example, the manufacturing method of the compound of Formula (I) and its raw material compound is demonstrated in detail. In addition, this invention is not limited to the compound as described in the following Example. Moreover, the manufacturing method of a raw material compound is shown to a manufacture example. Further, the production method of the compound of the formula (I) is not limited to the production methods of the specific examples shown below, and the compound of the formula (I) may be a combination of these production methods or a person skilled in the art. It can also be produced by methods that are self-evident.\n\n\n\n\n\n\n\n \n\n　また、製造例、実施例、及び後記表中において、以下の略号を用いることがある。\n\nPEx：製造例番号、Ex：実施例番号、PSyn：同様の方法で製造した製造例番号、Syn：同様の方法で製造した実施例番号、No：化合物番号、Str：構造式、Dat：物理化学的データ、EI：質量分析におけるm/z値(イオン化法EI、断りのない場合(M)\n+\nを表す)、ESI+：質量分析におけるm/z値(イオン化法ESI、断りのない場合(M+H)\n+\nを表す)、ESI-：質量分析におけるm/z値(イオン化法ESI、断りのない場合(M-H)\n-\nを表す)、FAB+：質量分析におけるm/z値(イオン化法FAB、断りのない場合(M+H)\n+\nを表す)、FAB-：質量分析におけるm/z値(イオン化法FAB、断りのない場合(M-H)\n-\nを表す)、APCI+：質量分析におけるm/z値(イオン化法APCI、断りのない場合(M+H)\n+\nを表す)、NMR：DMSO-d\n6\n中の\n1\nH NMRにおけるδ(ppm)、NMR-A：DMSO-d\n6\n中の\n1\nH NMRにおけるδ(ppm)(トリフルオロ酢酸を添加)、NMR-C：CDCl\n3\n中の\n1\nH NMRにおけるδ(ppm)、s：一重線（スペクトル）、d：二重線（スペクトル）、t：三重線（スペクトル）、q：四重線（スペクトル）、br：幅広線（スペクトル）（例：br-s）、mp：融点（℃）。\n\nMe：メチル、Et：エチル、nPr：ノルマルプロピル、iPr：イソプロピル、nBu：ノルマルブチル、iBu：イソブチル、t-Bu：tert-ブチル、cPr：シクロプロピル、cBu：シクロブチル、cPen：シクロペンチル、cHex：シクロヘキシル、Bz：ベンジル、Boc：ｔ-ブトキシカルボニル、MeOH：メタノール、EtOH：エタノール、EtOAc：酢酸エチル、HEX：n-ヘキサン、DMF：N,N-ジメチルホルムアミド、TFA：トリフルオロ酢酸、THF：テトラヒドロフラン、DPPA：ジフェニルホスホリルアジド、HOBt：1-ヒドロキシベンゾトリアゾール。\n\nIn addition, the following abbreviations may be used in Production Examples, Examples, and Tables below. \n PEx: Production example number, Ex: Example number, PSyn: Production example number produced by the same method, Syn: Example number produced by the same method, No: Compound number, Str: Structural formula, Dat: Physical chemistry Data, EI: m / z value in mass spectrometry (ionization method EI, unless otherwise noted (M) \n+\n ), ESI +: m / z value in mass spectrometry (ionization method ESI, unless otherwise noted (M + H) represents \n+\n ), ESI-: m / z value in mass spectrometry (ionization method ESI, unless otherwise indicated (MH) \n-\n ), FAB +: m / z value in mass analysis (ionization method FAB, not shown) Without (represents M + H) \n+\n ), FAB-: m / z value in mass spectrometry (ionization method FAB, unless otherwise indicated (represents MH) \n-\n ), APCI +: m / z value in mass spectrometry (ionization) law APCI, if otherwise stated represents the \n(M + H) +),\n NMR: δ (ppm in \n1\n H NMR in \nDMSO-d 6), NMR-\n a: δ in \n1\n H NMR in DMSO-d \n6\n ( ppm) (added trifluoroacetic acid), NMR-C: in \n1\n H NMR in CDCl \n3\n (ppm), s: single line (spectrum), d: double line (spectrum), t: triple line (spectrum), q: quadruple line (spectrum), br: wide line (spectrum) (example: br- s), mp: melting point (° C.). \n Me: methyl, Et: ethyl, nPr: normal propyl, iPr: isopropyl, nBu: normal butyl, iBu: isobutyl, t-Bu: tert-butyl, cPr: cyclopropyl, cBu: cyclobutyl, cPen: cyclopentyl, cHex: cyclohexyl , Bz: benzyl, Boc: t-butoxycarbonyl, MeOH: methanol, EtOH: ethanol, EtOAc: ethyl acetate, HEX: n-hexane, DMF: N, N-dimethylformamide, TFA: trifluoroacetic acid, THF: tetrahydrofuran, DPPA: diphenylphosphoryl azide, HOBt: 1-hydroxybenzotriazole.\n\n\n\n\n\n\n \n\n　構造式中のHClはその実施例化合物が塩酸塩として単離されたことを示す。また、構造式中にフマル酸の構造式が併記してある場合、その実施例化合物がフマル酸塩として単離されたことを示す。また、構造式中にシュウ酸の構造式が併記してある場合、その実施例化合物がシュウ酸塩として単離されたことを示す。また、構造式中にコハク酸の構造式が併記してある場合、その実施例化合物がコハク酸塩として単離されたことを示す。\n\n　なお、HClの前に数字が付されている場合、その化合物と塩酸のモル比を示す。例えば、2HClは二塩酸塩であることを示す。また、構造式中にフマル酸の構造式が併記してある実施例化合物において、その実施例番号の下に「M」が記載されているものは、その実施例化合物がモノフマル酸塩として単離されたことを、「H」が記載されているものは、その実施例化合物がヘミフマル酸塩として単離されたことを、「S」が記載されているものは、その実施例化合物がセスキフマル酸塩として単離されたことを示す。また、実施例２６７の「T」は0.75フマル酸塩として単離されたことを示す。また、これら「M」、「H」、「S」の記載は、構造式中にシュウ酸の構造式が併記してある実施例化合物、構造式中にコハク酸の構造式が併記してある実施例化合物においても、同様の意味を有する。\n\nHCl in the structural formula indicates that the example compound was isolated as the hydrochloride salt. Moreover, when the structural formula of fumaric acid is written in the structural formula, it indicates that the example compound was isolated as a fumarate salt. Moreover, when the structural formula of oxalic acid is written in the structural formula, it indicates that the example compound was isolated as an oxalate. Moreover, when the structural formula of succinic acid is written in the structural formula, it indicates that the example compound was isolated as a succinate. \n In addition, when the number is attached | subjected before HCl, the molar ratio of the compound and hydrochloric acid is shown. For example, 2HCl indicates dihydrochloride. In addition, in the example compounds in which the structural formula of fumaric acid is also written in the structural formula, those in which “M” is described under the example number are isolated as the monofumarate salt. \"H\" indicates that the example compound was isolated as a hemifumarate, and \"S\" indicates that the example compound is sesquifumaric acid. It is isolated as a salt. In addition, “T” in Example 267 indicates that it was isolated as a 0.75 fumarate salt. In addition, the description of “M”, “H”, and “S” is an example compound in which the structural formula of oxalic acid is written in the structural formula, and the structural formula of succinic acid is written in the structural formula. In the example compounds, it has the same meaning.\n\n\n\n\n\n\n \n\n　また、便宜上、濃度mol/lをMとして表す。例えば、1M水酸化ナトリウム水溶液は1mol/lの水酸化ナトリウム水溶液であることを意味する。\n\n\nFor convenience, the concentration mol / l is expressed as M. For example, a 1M aqueous sodium hydroxide solution means a 1 mol / l aqueous sodium hydroxide solution.\n\n\n\n\n\n\n\n \n\n製造例１\n\n　3-クロロ-o-キシレン27.11gの四塩化炭素300ml溶液に、N-ブロモスクシンイミド75gおよびアザイソブチロニトリル0.81gを加え、2時間加熱還流した。反応混合物を水および飽和炭酸水素ナトリウムにて洗浄し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮して1,2-ビス(ブロモメチル)-3-クロロベンゼン63.297gを赤橙色油状物として得た。\n\nProduction Example 1 \n To a solution of 27.11 g of 3-chloro-o-xylene in 300 ml of carbon tetrachloride was added 75 g of N-bromosuccinimide and 0.81 g of azaisobutyronitrile, and the mixture was heated to reflux for 2 hours. The reaction mixture was washed with water and saturated sodium bicarbonate, the organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain 63.297 g of 1,2-bis (bromomethyl) -3-chlorobenzene as red. Obtained as an orange oil.\n\n\n\n\n\n\n \n\n製造例２\n\n　シアン化ナトリウム9.5gの水120ml溶液に、1,2-ビス(ブロモメチル)-3-クロロベンゼン57.533gのEtOH 120ml溶液を加え、30分間加熱還流した。反応混合物を氷に注いで攪拌し、析出固体を濾取して2,2’-(3-クロロ-1,2-フェニレン)ジアセトニトリル32.941gを黄褐色固体として得た。\n\nProduction Example 2 \n To a 120 ml water solution of 9.5 g of sodium cyanide was added a 120 ml EtOH solution of 57.533 g of 1,2-bis (bromomethyl) -3-chlorobenzene, and the mixture was heated to reflux for 30 minutes. The reaction mixture was poured into ice and stirred, and the precipitated solid was collected by filtration to obtain 32.941 g of 2,2 ′-(3-chloro-1,2-phenylene) diacetonitrile as a tan solid.\n\n\n\n\n\n\n \n\n製造例３\n\n　2,2’-(3-クロロ-1,2-フェニレン)ジアセトニトリル32.94gの酢酸100ml懸濁液に、33%臭化水素-酢酸溶液100mlを、内温を20℃以下に保ちながら1.5時間にわたり滴下した。反応混合物を室温にて3時間攪拌後、反応混合物にジエチルエーテルおよびアセトンを加えた。生じた黒褐色飴状の固形物と懸濁液を分離し、懸濁液を減圧下濃縮し、飴状物質はアセトン中にて粉砕して懸濁液とした。濃縮残渣とアセトン懸濁液を合わせて減圧下濃縮し、残渣にEtOAcを加えて攪拌した。固体を濾取した。得られた固体を80℃に熱した水400ml中に懸濁させ、酢酸ナトリウム31.2gを加えて90℃にて3時間攪拌した。反応混合物を室温まで冷却後、固体を濾取し、6-クロロ-1H-3-ベンゾアゼピン-2,4(3H,5H)-ジオン22.506gを褐色固体として得た。\n\nProduction Example 3 \n A suspension of 32.94 g of 2,2 ′-(3-chloro-1,2-phenylene) diacetonitrile in 100 ml of acetic acid was added with 100 ml of 33% hydrogen bromide-acetic acid solution for 1.5 hours while maintaining the internal temperature at 20 ° C. or lower. It was dripped over. After stirring the reaction mixture at room temperature for 3 hours, diethyl ether and acetone were added to the reaction mixture. The resulting black-brown candy-like solid and suspension were separated, the suspension was concentrated under reduced pressure, and the candy-like substance was pulverized in acetone to give a suspension. The concentrated residue and the acetone suspension were combined and concentrated under reduced pressure, and EtOAc was added to the residue and stirred. The solid was collected by filtration. The obtained solid was suspended in 400 ml of water heated to 80 ° C., 31.2 g of sodium acetate was added, and the mixture was stirred at 90 ° C. for 3 hours. The reaction mixture was cooled to room temperature, and the solid was collected by filtration to obtain 22.506 g of 6-chloro-1H-3-benzazepine-2,4 (3H, 5H) -dione as a brown solid.\n\n\n\n\n\n\n \n\n製造例４\n\n　6-クロロ-1H-3-ベンゾアゼピン-2,4(3H,5H)-ジオン22.5gのTHF 200ml溶液に、10Mボラン-ジメチルスルフィド錯体38mlを0℃にて20分にわたり滴下し2.5時間攪拌した。反応混合物を加熱還流してさらに攪拌した。反応混合物に氷冷下MeOH 30mlを滴下して攪拌した後、4M塩酸30mlを滴下し、気泡の発生がほぼ収まった後に1時間加熱還流した。混合物にアンモニア水および1M水酸化ナトリウム水溶液を加えてアルカリ性とし、クロロホルムにて抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過した。濾液を減圧下濃縮し、残渣をEtOHに溶解させ、活性炭を加えて加熱還流した後、アミノシリカゲルにて濾過し、濾液を減圧下濃縮した。得られた残渣18.7gのジクロロメタン180ml溶液にピリジン17mlを加えて氷冷し、クロロ炭酸エチル13mlを滴下して1.5時間攪拌した。反応混合物を減圧下濃縮し、残渣をEtOAcにて希釈した後1M塩酸および水で洗浄し、無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮した。残さをシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、エチル　6-クロロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート9.653gを赤褐色油状物として得た。\n\nProduction Example 4 \n To 200 ml of THF solution of 22.5 g of 6-chloro-1H-3-benzazepine-2,4 (3H, 5H) -dione, 38 ml of 10M borane-dimethyl sulfide complex was added dropwise at 0 ° C. over 20 minutes and stirred for 2.5 hours. . The reaction mixture was heated to reflux and further stirred. To the reaction mixture, 30 ml of MeOH was added dropwise with stirring under ice-cooling, and then 30 ml of 4M hydrochloric acid was added dropwise. The mixture was made alkaline with aqueous ammonia and 1M aqueous sodium hydroxide solution, extracted with chloroform, and the organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, the residue was dissolved in EtOH, activated charcoal was added and the mixture was heated to reflux, filtered through amino silica gel, and the filtrate was concentrated under reduced pressure. 17 ml of pyridine was added to a solution of 18.7 g of the obtained residue in 180 ml of dichloromethane and the mixture was ice-cooled, and 13 ml of ethyl chlorocarbonate was added dropwise and stirred for 1.5 hours. The reaction mixture was concentrated under reduced pressure, the residue was diluted with EtOAc, washed with 1M hydrochloric acid and water, dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate (9.653 g) was reddish brown oil Obtained as a thing.\n\n\n\n\n\n\n \n\n製造例５\n\n　エチル　6-クロロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート11.86gのクロロホルム30ml溶液を氷冷し、内温を10℃以下に保って濃塩酸60mlを加えた後、濃硝酸32mlを滴下し、30分間攪拌した。反応混合物を氷に注ぎ、クロロホルムにて抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、エチル　6-クロロ-7-ニトロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート6.442gを赤橙色粘稠性物質として、エチル　6-クロロ-9-ニトロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート5.201gを淡黄色固体として得た。\n\nProduction Example 5 \n Ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 11.86 g of chloroform in 30 ml of chloroform is ice-cooled, and the internal temperature is kept below 10 ° C., and 60 ml of concentrated hydrochloric acid is added. After the addition, 32 ml of concentrated nitric acid was added dropwise and stirred for 30 minutes. The reaction mixture was poured onto ice and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and ethyl 6-chloro-7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 6.442 As a red-orange viscous substance, 5.201 g of ethyl 6-chloro-9-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was obtained as a pale yellow solid.\n\n\n\n\n\n\n \n\n製造例６\n\n　エチル　6-クロロ-7-ニトロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート6.431gにEtOH 120mlを加え、60℃にて攪拌して溶解させ、還元鉄12.15gおよび1M塩酸60mlを加えて1時間加熱還流した。反応混合物に1M水酸化ナトリウム水溶液を加えてアルカリ性とした後セライトにて濾過した後有機溶媒を減圧下留去し、残渣をクロロホルムにて抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮してエチル　7-アミノ-6-クロロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート 5.743gを赤橙色粘稠性物質として得た。\n\nProduction Example 6 \n Ethyl 6-chloro-7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate (6.431 g) was added with EtOH (120 ml) and stirred at 60 ° C to dissolve, and reduced iron 12.15 g and 60 ml of 1M hydrochloric acid were added and heated to reflux for 1 hour. The reaction mixture was made alkaline with 1M aqueous sodium hydroxide solution, filtered through celite, the organic solvent was evaporated under reduced pressure, the residue was extracted with chloroform, and the organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain 5.743 g of ethyl 7-amino-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a red-orange viscous substance .\n\n\n\n\n\n\n \n\n製造例７\n\n　エチル　7-アミノ-6-クロロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート5.74gのジクロロメタン100ml溶液に、N-ブロモスクシンイミド3.9gを氷冷下少量ずつ加えた後、40分間攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、エチル　7-アミノ-8-ブロモ-6-クロロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート5.769gを褐色固体として得た。\n\nProduction Example 7 \n Ethyl 7-amino-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 5.74g in dichloromethane 100ml solution, N-bromosuccinimide 3.9g in small portions under ice cooling After the addition, it was stirred for 40 minutes. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and ethyl 7-amino-8-bromo-6-chloro-1,2,4,5-tetrahydro- There was obtained 5.769 g of 3H-3-benzazepine-3-carboxylate as a brown solid.\n\n\n\n\n\n\n \n\n製造例８\n\n　エチル　7-アミノ-8-ブロモ-6-クロロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート4.37gのDMF 40ml溶液に、アクリル酸エチル2.1ml、トリス-o-トリルホスフィン230mg、酢酸パラジウム（II）85mgおよびトリエチルアミン3.6mlを加え、120℃にて3時間攪拌した。反応混合物をEtOAcにて希釈し、水、飽和食塩水にて洗浄し、無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮した。得られた黄色固体をジイソプロピルエーテル中攪拌洗浄し、エチル　7-アミノ-6-クロロ-8-[(1E)-3-エトキシ-3-オキソプロピ-1-エン-1-イル]-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート3.125gを淡黄色固体として得た。\n\nProduction Example 8 \n Ethyl 7-amino-8-bromo-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 4.37 g in DMF 40 ml solution, ethyl acrylate 2.1 ml, tris- 230 mg of o-tolylphosphine, 85 mg of palladium (II) acetate and 3.6 ml of triethylamine were added, and the mixture was stirred at 120 ° C. for 3 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The resulting yellow solid was washed with stirring in diisopropyl ether, and ethyl 7-amino-6-chloro-8-[(1E) -3-ethoxy-3-oxoprop-1-en-1-yl] -1,2, 3.125 g of 4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was obtained as a pale yellow solid.\n\n\n\n\n\n\n \n\n製造例９\n\n　エチル　7-アミノ-6-クロロ-8-[(1E)-3-エトキシ-3-オキソプロピ-1-エン-1-イル]-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート2.12gのクロロホルム20mlおよびMeOH 20ml溶液に、酸化白金(IV)65mgを加え、1気圧水素雰囲気下20時間攪拌した。反応混合物をセライトにて濾過し、濾液を減圧下濃縮してエチル　11-クロロ-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート2.256gを乳白色固体として得た。\n\nProduction Example 9 \n Ethyl 7-amino-6-chloro-8-[(1E) -3-ethoxy-3-oxoprop-1-en-1-yl] -1,2,4,5-tetrahydro-3H-3-benzazepine- To a solution of 3-carboxylate (2.12 g) in chloroform (20 ml) and MeOH (20 ml), platinum (IV) 65 mg was added, and the mixture was stirred at 1 atm under a hydrogen atmosphere for 20 hours. The reaction mixture was filtered through Celite, the filtrate was concentrated under reduced pressure, and ethyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5 -g] 2.256 g of quinoline-8-carboxylate was obtained as a milky white solid.\n\n\n\n\n\n\n \n\n製造例１０\n\n　11-クロロ-1,3,4,6,7,8,9,10-オクタヒドロ-2H-アゼピノ[4,5-g]キノリン-2-オン　1.403gのジオキサン15ml懸濁液に、トリエチルアミン12mlおよび二炭酸ジ-t-ブチル1.5gを加え、室温にて2時間攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行いt-ブチル　11-クロロ-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート1.779gを乳白色固体として得た。\n\nProduction Example 10 \n 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino [4,5-g] quinolin-2-one 1.403 g of dioxane in 15 ml suspension, 12 ml of triethylamine and Di-t-butyl dicarbonate (1.5 g) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9 , 10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate (1.779 g) was obtained as an opalescent solid.\n\n\n\n\n\n\n \n\n製造例１１\n\n　t-ブチル　11-クロロ-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート1.772gのTHF 10ml溶液に、氷冷下1Mボラン-THF錯体のTHF溶液10.1mlを加え、室温に昇温して3時間攪拌した。反応混合物にEtOH 10mlを滴下し、続いて1M水酸化ナトリウム水溶液10mlを滴下し攪拌した。混合溶液を水で希釈した後、EtOAcにて抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　11-クロロ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート2.0707gを無色粘稠性物質として得た。\n\nProduction Example 11 \n t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 1.772 g THF 10 ml To the solution, 10.1 ml of a 1M borane-THF complex THF solution was added under ice cooling, and the mixture was warmed to room temperature and stirred for 3 hours. To the reaction mixture, 10 ml of EtOH was added dropwise, followed by 10 ml of 1M aqueous sodium hydroxide solution and stirred. The mixed solution was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4, 2.0707 g of 5-g] quinoline-8-carboxylate was obtained as a colorless viscous substance.\n\n\n\n\n\n\n \n\n製造例１２\n\n　t-ブチル　11-クロロ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート205mgのアセトニトリル3ml溶液に36%ホルマリン0.077ml、シアノ水素化ホウ素ナトリウム58mgおよび酢酸0.5mlを加え、室温にて攪拌した。反応混合物に水を加え、EtOAcにて抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　11-クロロ-1-メチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート　96mgを橙色粘稠性物質として得た。\n\nProduction Example 12 \n t-Butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 205 mg in 3 ml acetonitrile in 36% formalin 0.077 ml, sodium cyanoborohydride 58 mg and acetic acid 0.5 ml were added and stirred at room temperature. Water was added to the reaction mixture, and the mixture was extracted with EtOAc. The organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 11-chloro-1-methyl-1,2,3,4,6,7,9,10-octahydro-8H- 96 mg of azepino [4,5-g] quinoline-8-carboxylate was obtained as an orange viscous substance.\n\n\n\n\n\n\n \n\n製造例１３\n\n　t-ブチル　11-クロロ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート193mgのトルエン2ml溶液に、イソ酪酸クロリド0.121mlを加え60℃にて攪拌した。反応混合物をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　1-アセチル-11-クロロ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート80mgを無色固体として得た。\n\nProduction Example 13 \n t-Butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 193 mg in toluene 2 ml solution with isobutyric acid 0.121 ml of chloride was added and stirred at 60 ° C. The reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 1-acetyl-11-chloro-1,2,3,4,6,7,9,10-octahydro-8H -80 mg of azepino [4,5-g] quinoline-8-carboxylate was obtained as a colorless solid.\n\n\n\n\n\n\n \n\n製造例１４\n\n　2,3,4,5-テトラヒドロ-1H-3-ベンゾアゼピン1.75gのジクロロメタン20ml溶液に、ピリジン2.884mlを加えた。反応混合物を氷冷し、ジクロロメタン5mlに溶解させたクロロギ酸エチル1.705mlを滴下し終夜攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、エチル　1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート2.15gを淡黄色油状物質として得た。\n\nProduction Example 14 \n To a solution of 2,3,4,5-tetrahydro-1H-3-benzazepine (1.75 g) in dichloromethane (20 ml), pyridine (2.884 ml) was added. The reaction mixture was ice-cooled, and 1.705 ml of ethyl chloroformate dissolved in 5 ml of dichloromethane was added dropwise and stirred overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to give ethyl 1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 2.15. g was obtained as a pale yellow oil.\n\n\n\n\n\n\n \n\n製造例１５\n\n　エチル　2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート287mgをDMF 5mlに溶解させ、氷浴下、60%水素化ナトリウム65mgを加えた後、1時間攪拌した。ヨウ化メチル0.3mlを加えた後、室温にて3時間攪拌後、飽和炭酸水素ナトリウム水溶液を加え、クロロホルムにて抽出した。溶媒を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、エチル　1-メチル-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート94mgを無色固体として得た。\n\nProduction Example 15 \n Ethyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate (287 mg) is dissolved in 5 ml of DMF and placed in an ice bath. 60% sodium hydride (65 mg) was added, and the mixture was stirred for 1 hour. After adding 0.3 ml of methyl iodide and stirring at room temperature for 3 hours, a saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The solvent was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc). Ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10 94 mg of octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate was obtained as a colorless solid.\n\n\n\n\n\n\n \n\n製造例１６\n\n　エチル　2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート5gにエチレングリコール40mlおよび4M水酸化ナトリウム水溶液28mlを加え、150℃で攪拌した。終夜攪拌後、反応混合物を氷冷後、濃塩酸を加え、液性を酸性にし、室温にて1時間攪拌した。反応混合物を減圧下濃縮後、残渣に1M水酸化ナトリウム水溶液を加え、液性を塩基性とし、クロロホルムで抽出した。溶媒を減圧下濃縮後、得られた茶褐色の残渣をジクロロメタンに溶解させ、二炭酸ジ-t-ブチル4gおよびトリエチルアミン3.5mlを加えた。室温にて終夜攪拌し、反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー（溶出溶媒：クロロホルム-MeOH）にて精製を行い、t-ブチル　2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート3.39gを得た。\n\nProduction Example 16 \n Ethyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 5g ethylene glycol 40ml and 4M aqueous sodium hydroxide 28 ml was added and stirred at 150 ° C. After stirring overnight, the reaction mixture was ice-cooled, concentrated hydrochloric acid was added to make the solution acidic, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, 1M aqueous sodium hydroxide solution was added to the residue to make the solution basic, and the mixture was extracted with chloroform. After concentrating the solvent under reduced pressure, the resulting brown residue was dissolved in dichloromethane, and 4 g of di-t-butyl dicarbonate and 3.5 ml of triethylamine were added. The mixture was stirred overnight at room temperature, the reaction mixture was concentrated under reduced pressure, the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH), and t-butyl 2-oxo-1,2,3,4,6 3,9,10-Octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 3.39 g was obtained.\n\n\n\n\n\n\n \n\n製造例１７\n\n　t-ブチル　1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート250mgのジクロロエタン2.5ml溶液に、塩化イソブチリル0.175ml及びトリエチルアミン0.4mlを加えた後、60℃に昇温し30分攪拌した。反応混合物をEtOAcで希釈し、1M塩酸、水、1M水酸化ナトリウム水溶液、飽和食塩水で洗浄し、溶媒を濃縮した。得られた残渣にTHF 2mlを加え、氷浴下、1Mボラン-THF錯体のTHF溶液3.5mlを加えた後、室温にて終夜攪拌した。反応混合物を氷冷し、EtOHを加え、室温にて30分攪拌した。反応混合物を濃縮し、得られた残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　1-イソブチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート213mgを得た。\n\nProduction Example 17 \n t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 250 mg in dichloroethane 2.5 ml, isobutyryl chloride 0.175 ml and After adding 0.4 ml of triethylamine, the temperature was raised to 60 ° C. and stirred for 30 minutes. The reaction mixture was diluted with EtOAc, washed with 1M hydrochloric acid, water, 1M aqueous sodium hydroxide solution and saturated brine, and the solvent was concentrated. 2 ml of THF was added to the resulting residue, and 3.5 ml of a 1M borane-THF complex THF solution was added in an ice bath, followed by stirring at room temperature overnight. The reaction mixture was ice-cooled, EtOH was added, and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and t-butyl 1-isobutyl-1,2,3,4,6,7,9,10 There was obtained 213 mg of -octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate.\n\n\n\n\n\n\n \n\n製造例１８\n\n　アルゴン雰囲気下、t-ブチル　11-ブロモ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート460mgのジオキサン9ml溶液に2M炭酸カリウム水溶液1.6mlを加え、続いてトリメチルボロキシン449mg、テトラキストリフェニルホスフィンパラジウム70mgを加え、90℃にて13時間攪拌した。反応混合物を放冷し、ろ過した後、減圧下濃縮、得られた残渣をEtOAcで希釈し、有機層を水、飽和食塩水で洗浄した。溶媒を減圧留去し、得られた残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　11-メチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート380mgを得た。\n\nProduction Example 18 \n T-butyl 11-bromo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 460 mg in dioxane 9 ml under argon atmosphere 1.6 ml of 2M potassium carbonate aqueous solution was added, 449 mg of trimethylboroxine and 70 mg of tetrakistriphenylphosphine palladium were added, and the mixture was stirred at 90 ° C. for 13 hours. The reaction mixture was allowed to cool, filtered, and concentrated under reduced pressure. The resulting residue was diluted with EtOAc, and the organic layer was washed with water and saturated brine. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain t-butyl 11-methyl-1,2,3,4,6,7,9, 380 mg of 10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例１９\n\n　t-ブチル　11-イソプロペニル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート670mgのMeOH 10ml溶液にパラジウム炭素200mgを加え、常圧で水素雰囲気下、室温にて3.5時間攪拌した。さらに4.5気圧水素雰囲気下、終夜攪拌後、反応混合物をセライトろ過し、溶媒を減圧留去した。得られた残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　11-イソプロピル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート512mgを得た。\n\nProduction Example 19 \n t-Butyl 11-isopropenyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 200 mg was added, and the mixture was stirred at room temperature under a hydrogen atmosphere at room temperature for 3.5 hours. Furthermore, after stirring overnight under a 4.5 atmosphere hydrogen atmosphere, the reaction mixture was filtered through Celite, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and t-butyl 11-isopropyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino. 512 mg of [4,5-g] quinoline-8-carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例２０\n\n　t-ブチル　11-エチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート140mgのアセトニトリル1.86ml溶液に、グリシジルメチルエーテル0.12mlを加え、アルゴン置換した。氷浴下、トリフルオロメタンスルホン酸イッテルビウム(III) 9mgを加えた後、室温にて2時間攪拌後、50℃に昇温し、終夜攪拌した。反応混合物にEtOAc及び重曹水を加え、有機層を水、飽和食塩水で洗浄した。溶媒を減圧留去し、得られた残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　11-エチル-1-(2-ヒドロキシ-3-メトキシプロピル)-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート147mgを得た。\n\nProduction Example 20 \n t-butyl 11-ethyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 140 mg of acetonitrile in 1.86 ml of acetonitrile 0.12 ml of methyl ether was added and the atmosphere was replaced with argon. After adding 9 mg of ytterbium (III) trifluoromethanesulfonate in an ice bath, the mixture was stirred at room temperature for 2 hours, then warmed to 50 ° C. and stirred overnight. EtOAc and aqueous sodium bicarbonate were added to the reaction mixture, and the organic layer was washed with water and saturated brine. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain t-butyl 11-ethyl-1- (2-hydroxy-3-methoxypropyl) -1 , 2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 147 mg was obtained.\n\n\n\n\n\n\n \n\n製造例２１\n\n　t-ブチル　7-ヒドロキシ-8-（テトラヒドロ-2H-ピラン-4-イルアミノ）-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート215mgのDMF 4ml溶液に、炭酸カリウム98mg、及びブロモ酢酸メチル0.062mlを加えて室温で6時間攪拌した。反応混合物に水を加えてEtOAcで2回抽出した。合わせた有機層を飽和食塩水で3回洗浄し、その後無水硫酸ナトリウムで乾燥後濾過して、溶媒を減圧留去した。得られた残渣259mgのEtOH 7ml溶液に、1M水酸化ナトリウム水溶液1.2mlを加えて50℃にて終夜攪拌した。さらに、氷冷下で1M塩酸水1.2mlを加えて、クロロホルムで2回抽出し、合わせた有機層を無水硫酸ナトリウムで乾燥後濾過し、溶媒を減圧留去した。得られた残渣239mgのDMF 4ml溶液に室温にて1‐エチル‐3‐(3‐ジメチルアミノプロピル)カルボジイミド塩酸塩120mg及びHOBt 84mgを加えて室温で終夜攪拌した。水を加えてEtOAcで2回抽出した。合わせた有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後濾過して、溶媒を減圧留去した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　3-オキソ-4-（テトラヒドロ-2H-ピラン-4-イル）-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート153mgを白色固体として得た。\n\nProduction Example 21 \n t-Butyl 7-hydroxy-8- (tetrahydro-2H-pyran-4-ylamino) -1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 215 mg in DMF 4 ml Potassium 98 mg and methyl bromoacetate 0.062 ml were added and stirred at room temperature for 6 hours. Water was added to the reaction mixture, and the mixture was extracted twice with EtOAc. The combined organic layers were washed 3 times with saturated brine, then dried over anhydrous sodium sulfate and filtered, and the solvent was evaporated under reduced pressure. To a solution of 259 mg of the resulting residue in 7 ml of EtOH, 1.2 ml of 1M aqueous sodium hydroxide solution was added and stirred at 50 ° C. overnight. Furthermore, 1.2 ml of 1M aqueous hydrochloric acid was added under ice-cooling, and the mixture was extracted twice with chloroform. The combined organic layers were dried over anhydrous sodium sulfate and filtered, and the solvent was distilled off under reduced pressure. To a solution of the obtained residue 239 mg in DMF 4 ml, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride 120 mg and HOBt 84 mg were added at room temperature and stirred at room temperature overnight. Water was added and extracted twice with EtOAc. The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate and filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain t-butyl 3-oxo-4- (tetrahydro-2H-pyran-4-yl) -3,4,6,7,9, 153 mg of 10-hexahydro [1,4] oxazino [2,3-h] [3] benzazepine-8 (2H) -carboxylate was obtained as a white solid.\n\n\n\n\n\n\n \n\n製造例２２\n\n　t-ブチル　7-ヒドロキシ-6-メチル-8-ニトロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート828mgのDMF 25ml溶液にブロモ酢酸メチル0.268mlおよび炭酸カリウム390mgを加えて55℃にて13時間攪拌した。反応混合物を放冷した後、水を加え、EtOAcで２回抽出した。合わせた有機層を飽和食塩水で洗浄し、有機層を無水硫酸ナトリウムで乾燥後濾過して、溶媒を減圧留去した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　7-(2-メトキシ-2-オキソエトキシ)-6-メチル-8-ニトロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート1.076gを黄白色固体として得た。\n\nProduction Example 22 \n t-Butyl 7-hydroxy-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 828 mg of DMF in 25 ml 390 mg was added and stirred at 55 ° C. for 13 hours. The reaction mixture was allowed to cool, water was added, and the mixture was extracted twice with EtOAc. The combined organic layers were washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 7- (2-methoxy-2-oxoethoxy) -6-methyl-8-nitro-1,2,4,5 -1.076 g of tetrahydro-3H-3-benzazepine-3-carboxylate was obtained as a pale yellow solid.\n\n\n\n\n\n\n \n\n製造例２３\n\n　t-ブチル　7-(2-メトキシ-2-オキソエトキシ）-6-メチル-8-ニトロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート967mgのEtOH 25ml混合物にアルゴン雰囲気下、10%パラジウム担持炭素97mgを加えて、水素雰囲気下常圧で2時間攪拌した。反応混合物にてTHF 200mlを加えた後、触媒をセライトを用いて除去し、溶媒を減圧留去した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　11-メチル-3-オキソ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート629mgを白色固体として得た。\n\nProduction Example 23 \n t-butyl 7- (2-methoxy-2-oxoethoxy) -6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 967 mg of EtOH in 25 ml mixture Under an argon atmosphere, 97 mg of 10% palladium-supported carbon was added, and the mixture was stirred at normal pressure under a hydrogen atmosphere for 2 hours. After adding 200 ml of THF in the reaction mixture, the catalyst was removed using celite, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography (eluent: HEX-EtOAc) and t-butyl 11-methyl-3-oxo-3,4,6,7,9,10-hexahydro [1,4] oxazino [ 629 mg of 2,3-h] [3] benzazepine-8 (2H) -carboxylate was obtained as a white solid.\n\n\n\n\n\n\n \n\n製造例２４\n\n　t-ブチル　2-メチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート120mgのDMF 4ml溶液に、室温でヨウ化メチル0.026ml及び炭酸カリウム104mgを加え13時間攪拌した。反応混合物にヨウ化メチル0.012mlと炭酸カリウム26mgを加えて更に3時間攪拌した。反応混合物に水を加えてEtOAcで2回抽出した。合わせた有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後濾過して、溶媒を減圧留去した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　2,4-ジメチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート55mgを茶色固体として得た。\n\nProduction Example 24 \n t-butyl 2-methyl-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzazepine-8 (2H) -carboxylate 120 mg DMF 4 ml To the solution, 0.026 ml of methyl iodide and 104 mg of potassium carbonate were added at room temperature and stirred for 13 hours. To the reaction mixture were added 0.012 ml of methyl iodide and 26 mg of potassium carbonate, and the mixture was further stirred for 3 hours. Water was added to the reaction mixture, and the mixture was extracted twice with EtOAc. The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate and filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (eluent: HEX-EtOAc) and t-butyl 2,4-dimethyl-3,4,6,7,9,10-hexahydro [1,4] oxazino [2, 55 mg of 3-h] [3] benzazepine-8 (2H) -carboxylate was obtained as a brown solid.\n\n\n\n\n\n\n \n\n製造例２５\n\n　t-ブチル　2-メチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート120mgのDMF 4ml溶液にヨウ化イソプロピル0.113mlおよびジイソプロピルエチルアミン0.197mlを加えて、100℃にて6.5時間攪拌した。さらに、反応混合物にヨウ化イソプロピル0.113ml及びジイソプロピルエチルアミン0.197mlを加え、100℃にて4時間攪拌した。さらに、反応混合物にヨウ化イソプロピル0.226mlおよびジイソプロピルエチルアミン0.394mlを加え、100℃にて19時間攪拌した。反応混合物を室温まで冷却して、水を加えてEtOAcで2回抽出した。合わせた有機層を飽和食塩水で洗浄し、有機層を無水硫酸ナトリウムで乾燥後濾過して、溶媒を減圧留去した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　4-イソプロピル-2-メチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート90mgを薄茶色固体として得た。\n\nProduction Example 25 \n t-butyl 2-methyl-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzazepine-8 (2H) -carboxylate 120 mg DMF 4 ml To the solution were added 0.113 ml of isopropyl iodide and 0.197 ml of diisopropylethylamine, and the mixture was stirred at 100 ° C. for 6.5 hours. Furthermore, 0.113 ml of isopropyl iodide and 0.197 ml of diisopropylethylamine were added to the reaction mixture, and the mixture was stirred at 100 ° C. for 4 hours. Furthermore, 0.226 ml of isopropyl iodide and 0.394 ml of diisopropylethylamine were added to the reaction mixture, and the mixture was stirred at 100 ° C. for 19 hours. The reaction mixture was cooled to room temperature, water was added and extracted twice with EtOAc. The combined organic layers were washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 4-isopropyl-2-methyl-3,4,6,7,9,10-hexahydro [1,4] oxazino [ 90 mg of 2,3-h] [3] benzazepine-8 (2H) -carboxylate was obtained as a light brown solid.\n\n\n\n\n\n\n \n\n製造例２６\n\n　t-ブチル　3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート130mgのジクロロメタン4ml溶液に氷冷下、メタンスルホニルクロリド0.036ml及びジイソプロピルエチルアミン0.089mlを加えて室温で16時間攪拌した。反応混合物にメタンスルホニルクロリド0.036ml及びジイソプロピルエチルアミン0.089mlを加えて室温にて更に9時間攪拌した。反応混合物に水を加えて、クロロホルムで抽出した。有機層を無水硫酸ナトリウムで乾燥後濾過して、溶媒を減圧留去した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　4-(メチルスルホニル）-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート152mgを無色固体として得た。\n\nProduction Example 26 \n t-Butyl 3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzazepine-8 (2H) -carboxylate 130 mg in dichloromethane 4 ml Then, 0.036 ml of methanesulfonyl chloride and 0.089 ml of diisopropylethylamine were added and stirred at room temperature for 16 hours. To the reaction mixture, 0.036 ml of methanesulfonyl chloride and 0.089 ml of diisopropylethylamine were added, and the mixture was further stirred at room temperature for 9 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 4- (methylsulfonyl) -3,4,6,7,9,10-hexahydro [1,4] oxazino [2 , 3-h] [3] Benzazepine-8 (2H) -carboxylate 152 mg was obtained as a colorless solid.\n\n\n\n\n\n\n \n\n製造例２７\n\n　水素化ホウ素ナトリウム5gと無水THF 30ml混合物に、氷冷下2-メチル-3-ニトロフェニル酢酸10.27gの無水THF60ml溶液を加えた後、メタンスルホン酸35mlの無水THF 10ml溶液を滴下した。反応混合物を70℃に加熱して30分攪拌した後、氷冷下3M塩酸80mlを加えて攪拌した。混合液をクロロホルムにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮し橙色粘稠性物質9.701gを得た。得られた物質9.53gのジクロロメタン100ml溶液に、ジイソプロピルエチルアミン22mlおよびクロロメチルメチルエーテル4.75mlを氷冷下滴下し24時間攪拌した。クロロメチルメチルエーテル10mlを追加し、さらに24時間攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、黄色油状物11.26gを得た。得られた物質11.26gのEtOH 200ml溶液に、二酸化白金(IV)340mgを加え、4気圧の水素雰囲気下、室温にて1時間攪拌した。反応混合物をセライトを用いて除去し、濾液を減圧下濃縮して橙色粘稠性物質9.21gを得た。残渣のジクロロメタン200mlおよびMeOH 40ml溶液に、炭酸カルシウム14.2gおよびベンジルトリメチルアンモニウムジクロロヨウ素酸塩36.5gを加え室温にて13時間攪拌した。不溶物を濾去し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、4,6-ジヨード-3-[2-(メトキシメトキシ）エチル]-2-メチルアニリン15.93gを暗赤色粘稠性物質として得た。\n\nProduction Example 27 \n To a mixture of 5 g of sodium borohydride and 30 ml of anhydrous THF, a solution of 10.27 g of 2-methyl-3-nitrophenylacetic acid in 60 ml of anhydrous THF was added under ice cooling, and then a solution of 35 ml of methanesulfonic acid in 10 ml of anhydrous THF was added dropwise. The reaction mixture was heated to 70 ° C. and stirred for 30 minutes, and then 80 ml of 3M hydrochloric acid was added and stirred under ice cooling. The mixture was extracted with chloroform, the organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain 9.701 g of an orange viscous substance. To a solution of 9.53 g of the obtained substance in 100 ml of dichloromethane, 22 ml of diisopropylethylamine and 4.75 ml of chloromethyl methyl ether were added dropwise under ice cooling and stirred for 24 hours. 10 ml of chloromethyl methyl ether was added, and the mixture was further stirred for 24 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (eluent: HEX-EtOAc) to give 11.26 g of a yellow oil. To a 200 ml EtOH solution of 11.26 g of the obtained substance, 340 mg of platinum dioxide (IV) was added, followed by stirring at room temperature for 1 hour in a hydrogen atmosphere of 4 atm. The reaction mixture was removed using celite, and the filtrate was concentrated under reduced pressure to obtain 9.21 g of an orange viscous substance. To a solution of the residue in 200 ml of dichloromethane and 40 ml of MeOH, 14.2 g of calcium carbonate and 36.5 g of benzyltrimethylammonium dichloroiodate were added and stirred at room temperature for 13 hours. The insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue is purified by silica gel chromatography (elution solvent: HEX-EtOAc), and 15.93 g of 4,6-diiodo-3- [2- (methoxymethoxy) ethyl] -2-methylaniline is obtained as a dark red viscous substance Got as.\n\n\n\n\n\n\n \n\n製造例２８\n\n　酢酸パラジウム(II)400mg、トリフェニルホスフィン934mg、テトラブチルアンモニウムクロリド9.91gおよび酢酸カリウム7gのDMF 150ml混合液に、4,6-ジヨード-3-[2-(メトキシメトキシ）エチル]-2-メチルアニリン15.93gのDMF 150ml溶液を加えた後、アクリル酸エチル16mlを加え、80℃にて3時間攪拌した。反応混合物をEtOAcにて希釈し、水および飽和食塩水にて洗浄し、減圧下濃縮した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、黄色固体を12.11g得た。得られた物質12.11gのEtOH 250mlおよびTHF 250ml溶液に、酸化白金(IV)701mgを加え 4気圧の水素雰囲気下、室温にて4時間攪拌した。反応混合物をセライトを用いて除去し、濾液を減圧下濃縮してエチル　3-｛7-[2-(メトキシメトキシ）エチル]-6-メチル-2-オキソ-1,2,3,4-テトラヒドロキノリン-6-イル｝プロナノエート11.39gを乳白色固体として得た。\n\nProduction Example 28 \n To a mixed solution of 400 mg of palladium (II) acetate, 934 mg of triphenylphosphine, 9.91 g of tetrabutylammonium chloride and 7 g of potassium acetate in 150 ml of DMF, 4,6-diiodo-3- [2- (methoxymethoxy) ethyl] -2-methyl A solution of 15.93 g of aniline in 150 ml of DMF was added, 16 ml of ethyl acrylate was added, and the mixture was stirred at 80 ° C. for 3 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 12.11 g of a yellow solid. To a solution of 12.11 g of the obtained substance in 250 ml of EtOH and 250 ml of THF, 701 mg of platinum (IV) oxide was added and stirred at room temperature for 4 hours under a hydrogen atmosphere of 4 atm. The reaction mixture was removed using celite, and the filtrate was concentrated under reduced pressure to give ethyl 3- {7- [2- (methoxymethoxy) ethyl] -6-methyl-2-oxo-1,2,3,4-tetrahydro. 11.39 g of quinolin-6-yl} pronanoate was obtained as a milky white solid.\n\n\n\n\n\n\n \n\n製造例２９\n\n　エチル　3-｛7-[2-(メトキシメトキシ）エチル]-6-メチル-2-オキソ-1,2,3,4-テトラヒドロキノリン-6-イル｝プロナノエート10.81gのEtOH 100mlおよびTHF 100ml溶液に、1M水酸化ナトリウム水溶液100mlを加え、室温にて1時間攪拌した。反応混合物に塩酸を加えて中和した後、減圧下、液量が3分の1程度になるまで濃縮し、残渣をクロロホルムにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。得られた残渣のt-ブタノール300ml溶液に、トリエチルアミン90mlおよびDPPA 70mlを加え、24時間加熱還流した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製した後、得られた固体をHEXにて洗浄し、t-ブチル　(2-｛7-[2-(メトキシメトキシ）エチル]-8-メチル-2-オキソ-1,2,3,4-テトラヒドロキノリン-6-イル｝エチル）カルバメート8.006gを乳白色固体として得た。\n\nProduction Example 29 \n Ethyl 3- {7- [2- (methoxymethoxy) ethyl] -6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl} pronanoate 10.81 g in 100 ml EtOH and 100 ml THF Then, 100 ml of 1M aqueous sodium hydroxide solution was added, and the mixture was stirred at room temperature for 1 hour. After neutralizing the reaction mixture by adding hydrochloric acid, the mixture was concentrated under reduced pressure until the liquid volume was reduced to about one third, the residue was extracted with chloroform, the organic layer was dried over anhydrous magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure. To a 300 ml solution of the obtained residue in t-butanol, 90 ml of triethylamine and 70 ml of DPPA were added and heated under reflux for 24 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc). The obtained solid was washed with HEX, and t-butyl (2- {7- [2- There was obtained 8.006 g of (methoxymethoxy) ethyl] -8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl} ethyl) carbamate as a milky white solid.\n\n\n\n\n\n\n \n\n製造例３０\n\n　t-ブチル　(2-｛7-[2-（メトキシメトキシ）エチル]-8-メチル-2-オキソ-1,2,3,4-テトラヒドロキノリン-6-イル｝エチル）カルバメート1.01gのTHF 10ml懸濁液に、6M塩酸10mlを加え、50℃にて1時間攪拌した。反応混合物に水酸化ナトリウムを加えてアルカリ性とした後、二炭酸ジ-t-ブチル675mgを加え、室温にて15時間攪拌した。反応混合物をクロロホルムにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮して、t－ブチル　｛2-[7-（2-ヒドロキシエチル）-6-メチル-2-オキソ-1,2,3,4-テトラヒドロキノリン-6-イル]エチル｝カルバメート1.105gを白色泡状物質として得た。\n\nProduction Example 30 \n t-butyl (2- {7- [2- (methoxymethoxy) ethyl] -8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl} ethyl) carbamate 1.01 g THF 10 ml To the suspension, 10 ml of 6M hydrochloric acid was added and stirred at 50 ° C. for 1 hour. Sodium hydroxide was added to the reaction mixture to make it alkaline, and then 675 mg of di-t-butyl dicarbonate was added and stirred at room temperature for 15 hours. The reaction mixture was extracted with chloroform, the organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give t-butyl {2- [7- (2-hydroxyethyl) -6-methyl- 1.105 g of 2-oxo-1,2,3,4-tetrahydroquinolin-6-yl] ethyl} carbamate was obtained as a white foam.\n\n\n\n\n\n\n \n\n製造例３１\n\n　t-ブチル　｛2-[7-(2-ヒドロキシエチル）-6-メチル-2-オキソ-1,2,3,4-テトラヒドロキノリン-6-イル]エチル｝カルバメート1.793gのTHF 30ml溶液に、氷冷下メタンスルホニルクロリド0.48mlおよびトリエチルアミン15mlを加え30分攪拌した。反応混合物にカリウム　t-ブトキシド1.8gを氷冷下少量ずつ加え、1.5時間攪拌した。反応混合物に飽和塩化アンモニウム水溶液を加え、EtOAcにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　11-メチル-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート1.06gを白色泡状物質として得た。\n\nProduction Example 31 \n To a solution of 1.793 g of t-butyl {2- [7- (2-hydroxyethyl) -6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl] ethyl} carbamate in 30 ml of THF, Under ice cooling, 0.48 ml of methanesulfonyl chloride and 15 ml of triethylamine were added and stirred for 30 minutes. To the reaction mixture, 1.8 g of potassium t-butoxide was added little by little under ice cooling, and the mixture was stirred for 1.5 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 11-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H- 1.06 g of azepino [4,5-g] quinoline-8-carboxylate was obtained as a white foam.\n\n\n\n\n\n\n \n\n製造例３２\n\n　t-ブチル　11-メチル-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート167mgのジクロロメタン2ml溶液に、トリエチルアミン0.221mlおよびイソシアン酸エチル0.062mlを加え室温にて15時間攪拌した。反応混合物にトルエン3mlおよびイソシアン酸エチル0.062mlを加え、60℃に加熱してさらに15時間攪拌後、反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、t-ブチル　1-（エチルカルバモイル）-11-メチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート200mgを無色粘稠性物質として得た。\n\nProduction Example 32 \n To a solution of 167 mg of t-butyl 11-methyl-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate in 2 ml of dichloromethane, 0.221 ml of triethylamine and 0.062 ml of ethyl isocyanate were added and stirred at room temperature for 15 hours. To the reaction mixture was added 3 ml of toluene and 0.062 ml of ethyl isocyanate, and the mixture was heated to 60 ° C. and further stirred for 15 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc). T-butyl 1- (ethylcarbamoyl) -11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxy A rate of 200 mg was obtained as a colorless viscous material.\n\n\n\n\n\n\n \n\n製造例３３\n\n　t-ブチル　11-メチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート201mgのピリジン2ml溶液に、クロロギ酸エチル0.1mlを加え室温にて30分攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製し、8-t-ブチル　1-エチル　11-メチル-3,4,6,7,9,10-ヘキサヒドロ-1H-アゼピノ[4,5-g]キノリン-1,8(2H)-ジカルボキシレート261mgを無色粘稠性物質として得た。\n\nProduction Example 33 \n t-Butyl 11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 201 mg in chloroform 2 ml Ethyl 0.1ml was added and it stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and 8-t-butyl 1-ethyl 11-methyl-3,4,6,7,9,10- Hexahydro-1H-azepino [4,5-g] quinoline-1,8 (2H) -dicarboxylate (261 mg) was obtained as a colorless viscous substance.\n\n\n\n\n\n\n \n\n製造例３４\n\n　3-(2-オキソ-1,2,3,4-テトラヒドロキノリン-7-イル）プロピオン酸2gのt-ブタノール40ml懸濁液に、DPPA 2.1mlおよびトリエチルアミン2.6mlを加え、100℃にて18時間加熱還流した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：クロロホルム-MeOH)にて精製を行い、t-ブチル　[2-(2-オキソ-1,2,3,4-テトラヒドロキノリン-7-イル）エチル]カルバメート1.832gを橙色固体として得た。\n\nProduction Example 34 \n To a 40 ml suspension of 2- (2-oxo-1,2,3,4-tetrahydroquinolin-7-yl) propionic acid in 40 ml of t-butanol, 2.1 ml of DPPA and 2.6 ml of triethylamine were added, and the mixture was stirred at 100 ° C. for 18 minutes. Heated to reflux for hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH) to give t-butyl [2- (2-oxo-1,2,3,4-tetrahydroquinoline-7 -Ill) ethyl] carbamate 1.832 g was obtained as an orange solid.\n\n\n\n\n\n\n \n\n製造例３５\n\n　t-ブチル　[2-(1,2,3,4-テトラヒドロキノリン-7-イル）エチル]カルバメート770mgのジクロロメタン15mlおよびMeOH 3ml混合溶液に、炭酸カルシウム420mgおよびベンジルトリメチルアンモニウムジクロロヨウ素酸塩970mgを加え、室温にて2時間攪拌した。不溶物を濾去し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　[2-(6-ヨード-1,2,3,4-テトラヒドロキノリン-7-イル）エチル]カルバメート595mgを赤褐色粘稠性物質として得た。\n\nProduction Example 35 \n To a mixed solution of t-butyl [2- (1,2,3,4-tetrahydroquinolin-7-yl) ethyl] carbamate 770 mg in dichloromethane 15 ml and MeOH 3 ml was added calcium carbonate 420 mg and benzyltrimethylammonium dichloroiodate 970 mg. The mixture was stirred at room temperature for 2 hours. The insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and 595 mg of t-butyl [2- (6-iodo-1,2,3,4-tetrahydroquinolin-7-yl) ethyl] carbamate was added. Obtained as a reddish brown viscous material.\n\n\n\n\n\n\n \n\n製造例３６\n\n　t-ブチル　[2-(6-ヨード-1,2,3,4-テトラヒドロキノリン-7-イル）エチル]カルバメート595mgのジクロロメタン3ml溶液に水3mlおよび炭酸水素ナトリウム376mgを加え、攪拌しながらクロロギ酸ベンジル0.273mlのジクロロメタン3ml溶液を氷冷下滴下した後、さらに5時間攪拌した。反応混合物をEtOAcにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮してベンジル　7-{2-[(t-ブトキシカルボニル)アミノ]エチル}-6-ヨード-3,4-ジヒドロキノリン-1(2H)-カルボキシレート877mgを赤橙色固体として得た。\n\nProduction Example 36 \n 3 ml of water and 376 mg of sodium bicarbonate are added to 3 ml of dichloromethane solution of 595 mg of t-butyl [2- (6-iodo-1,2,3,4-tetrahydroquinolin-7-yl) ethyl] carbamate and stirred with chloroformic acid A solution of benzyl 0.273 ml in dichloromethane 3 ml was added dropwise under ice cooling, and the mixture was further stirred for 5 hours. The reaction mixture was extracted with EtOAc, the organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give benzyl 7- {2-[(t-butoxycarbonyl) amino] ethyl} -6-iodo. 877 mg of -3,4-dihydroquinoline-1 (2H) -carboxylate was obtained as a red-orange solid.\n\n\n\n\n\n\n \n\n製造例３７\n\n　ベンジル　7-{2-[(t-ブトキシカルボニル)アミノ]エチル}-6-ヨード-3,4-ジヒドロキノリン-1(2H)-カルボキシレート793mgのTHF 10ml溶液に、氷冷下1MナトリウムビストリメチルシリルアミドのTHF溶液1.8mlを滴下し5分間攪拌後、臭化アリル0.166mlを加え、徐々に室温まで昇温しつつ18時間攪拌した。反応混合物に飽和塩化アンモニウム水溶液および水を加え、EtOAcにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製を行い、ベンジル　7-{2-[アリル(t-ブトキシカルボニル)アミノ]エチル}-6-ヨード-3,4-ジヒドロキノリン-1(2H)-カルボキシレート788mgを得た。\n\nProduction Example 37 \n Benzyl 7- {2-[(t-butoxycarbonyl) amino] ethyl} -6-iodo-3,4-dihydroquinoline-1 (2H) -carboxylate 793 mg in THF 10 ml solution under ice cooling with 1M sodium bistrimethylsilyl After 1.8 ml of amide in THF was added dropwise and stirred for 5 minutes, 0.166 ml of allyl bromide was added and stirred for 18 hours while gradually warming to room temperature. A saturated aqueous ammonium chloride solution and water were added to the reaction mixture, and the mixture was extracted with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluent: HEX-EtOAc) and benzyl 7- {2- [allyl (t-butoxycarbonyl) amino] ethyl} -6-iodo-3,4-dihydroquinoline-1 788 mg of (2H) -carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例３８\n\n　酢酸カリウム403mg、テトラブチルアンモニウムブロミド441mg、トリフェニルホスフィン9mgおよび酢酸パラジウム(II) 4mgの混合物にベンジル　7-｛2-[アリル（t-ブトキシカルボニル)アミノ]エチル}-6-ヨード-3,4-ジヒドロキノリン-1(2H)-カルボキシレート788mgのDMF 25ml溶液を加え、アルゴン置換した後に80℃にて4時間攪拌した。反応混合物をEtOAcにて希釈し、水および飽和食塩水にて洗浄し、減圧下濃縮した。得られた残渣のMeOH 25ml溶液に酸化白金(IV) 36mgを加え、4気圧水素雰囲気下室温にて終夜攪拌した。反応混合物をセライトにて濾過し、濾液を減圧下濃縮し、1-ベンジル　8-t-ブチル　6-メチル-3,4,6,7,9,10-ヘキサヒドロ-1H-アゼピノ[4,5-g]キノリン-1,8(2H)-ジカルボキシレート570mgを橙色泡状物質として得た。\n\nProduction Example 38 \n Benzyl 7- {2- [allyl (t-butoxycarbonyl) amino] ethyl} -6-iodo-3,4 in a mixture of potassium acetate 403 mg, tetrabutylammonium bromide 441 mg, triphenylphosphine 9 mg and palladium (II) acetate 4 mg -Dihydroquinoline-1 (2H) -carboxylate (788 mg) in DMF (25 ml) was added, and the mixture was purged with argon, followed by stirring at 80 ° C. for 4 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, and concentrated under reduced pressure. 36 mg of platinum (IV) oxide was added to a 25 ml solution of the obtained residue in MeOH, and the mixture was stirred overnight at room temperature in a 4 atmosphere hydrogen atmosphere. The reaction mixture was filtered through Celite, the filtrate was concentrated under reduced pressure, and 1-benzyl 8-t-butyl 6-methyl-3,4,6,7,9,10-hexahydro-1H-azepino [4,5- g] Quinoline-1,8 (2H) -dicarboxylate (570 mg) was obtained as an orange foam.\n\n\n\n\n\n\n \n\n製造例３９\n\n　塩化アルミニウム9.3gのジクロロメタン30ml混合液に、氷冷下塩化アセチル1.6mlを滴下し攪拌した後、7-メトキシ-1-メチル-3-(トリフルオロアセチル）-2,3,4,5-テトラヒドロ-1H-3-ベンゾアゼピン5gのジクロロメタン70ml溶液を加え、徐々に室温まで昇温しつつ13時間攪拌した。反応混合物を氷冷し、1M塩酸30mlを滴下した後さらに水を加え、クロロホルムにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をフラッシュクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、1-[8-ヒドロキシ-5-メチル-3-(トリフルオロアセチル）-2,3,4,5-テトラヒドロ-1H-3-ベンゾアゼピン-7-イル]エタノン5.137gを淡褐色固体として得た。\n\nProduction Example 39 \n 1.6 ml of acetyl chloride was added dropwise to 30 ml of dichloromethane mixed with 9.3 g of aluminum chloride under ice-cooling and stirred, then 7-methoxy-1-methyl-3- (trifluoroacetyl) -2,3,4,5-tetrahydro A solution of 5 g of -1H-3-benzoazepine in 70 ml of dichloromethane was added, and the mixture was stirred for 13 hours while gradually warming to room temperature. The reaction mixture was ice-cooled, 30 ml of 1M hydrochloric acid was added dropwise, water was further added, extracted with chloroform, the organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (elution solvent: HEX-EtOAc), and 1- [8-hydroxy-5-methyl-3- (trifluoroacetyl) -2,3,4,5-tetrahydro-1H- There was obtained 5.137 g of 3-benzoazepin-7-yl] ethanone as a light brown solid.\n\n\n\n\n\n\n \n\n製造例４０\n\n　1-[8-ヒドロキシ-5-メチル-3-(トリフルオロアセチル)-2,3,4,5-テトラヒドロ-1H-3-ベンゾアゼピン-7-イル]エタノン5.13gのMeOH 50ml懸濁液に、1M水酸化ナトリウム水溶液50mlを加え室温にて30分間攪拌した。反応混合物を減圧下半分量まで濃縮し、残渣にジオキサン50mlおよび二炭酸ジ-t-ブチル4.27gを加え、室温にて30分間攪拌した。反応混合物に1M塩酸を加えて中和し、クロロホルムにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　8-アセチル-7-ヒドロキシ-1-メチル-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート4.385gを黄色粘稠性物質として得た。\n\nProduction Example 40 \n 1- [8-Hydroxy-5-methyl-3- (trifluoroacetyl) -2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl] ethanone in 5.13 g of MeOH in 50 ml suspension Then, 50 ml of 1M aqueous sodium hydroxide solution was added and stirred at room temperature for 30 minutes. The reaction mixture was concentrated to half volume under reduced pressure, 50 ml of dioxane and 4.27 g of di-t-butyl dicarbonate were added to the residue, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was neutralized with 1M hydrochloric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and t-butyl 8-acetyl-7-hydroxy-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine. 3.385 g of 3-carboxylate was obtained as a yellow viscous substance.\n\n\n\n\n\n\n \n\n製造例４１\n\n　t-ブチル　8-アセチル-7-(2-エトキシ-2-オキソエトキシ）-1-メチル-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート1.715gのEtOH 20ml溶液に、ヒドロキシルアミン塩酸塩325mgを加え3時間加熱還流した。ヒドロキシルアミン塩酸塩500mgを加えてさらに2時間加熱還流後、反応混合物を減圧下濃縮し、残渣に水を加えクロロホルムにて抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮した。得られた残渣のアセトニトリル10ml溶液に、シアヌル酸クロリド24mgおよび塩化亜鉛(II) 33mgを加え、12時間加熱還流した。反応混合物を減圧下濃縮し、残渣をジオキサン10mlおよび1M水酸化ナトリウム水溶液 10ml混合液とし、二炭酸ジ-t-ブチル1.2gを加え室温にて24時間攪拌した。反応混合物を減圧下半分量まで濃縮し、1M塩酸を加えて弱酸性とした後クロロホルムにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。得られた残渣に17%硫酸水溶液60mlを加え、100℃にて1時間攪拌した。反応混合物を氷冷し、水酸化ナトリウム15gを加えてアルカリ性とした後、ジオキサン50mlを加え、二炭酸ジ-t-ブチル1.21gを加え室温にて3時間攪拌した。反応混合物を水で希釈し、EtOAcにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　6-メチル-3-オキソ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート735mgを淡黄色固体として得た。\n\nProduction Example 41 \n t-butyl 8-acetyl-7- (2-ethoxy-2-oxoethoxy) -1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 1.715 g EtOH 20 ml To the solution, 325 mg of hydroxylamine hydrochloride was added and heated to reflux for 3 hours. After adding 500 mg of hydroxylamine hydrochloride and heating under reflux for further 2 hours, the reaction mixture was concentrated under reduced pressure, water was added to the residue, extracted with chloroform, the organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was reduced under reduced pressure The bottom was concentrated. 24 mg of cyanuric chloride and 33 mg of zinc (II) chloride were added to a 10 ml solution of the resulting residue in acetonitrile, and the mixture was heated to reflux for 12 hours. The reaction mixture was concentrated under reduced pressure, the residue was mixed with 10 ml of dioxane and 10 ml of 1M aqueous sodium hydroxide solution, 1.2 g of di-t-butyl dicarbonate was added, and the mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated to half volume under reduced pressure, made weakly acidic with 1M hydrochloric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. 60 ml of a 17% sulfuric acid aqueous solution was added to the obtained residue, and the mixture was stirred at 100 ° C. for 1 hour. The reaction mixture was ice-cooled and made alkaline by adding 15 g of sodium hydroxide, 50 ml of dioxane was added, 1.21 g of di-t-butyl dicarbonate was added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 6-methyl-3-oxo-3,4,6,7,9,10-hexahydro [1,4] oxazino [ 735 mg of 2,3-h] [3] benzazepine-8 (2H) -carboxylate was obtained as a pale yellow solid.\n\n\n\n\n\n\n \n\n製造例４２\n\n　t-ブチル　6-メチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート704mgのジクロロメタン15ml溶液に、N-ブロモスクシンイミド438mgを氷冷下少量ずつ加え30分攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製し、淡黄色泡状物質を446mg得た。得られた化合物445mg、シクロプロピルボロン酸 144mg、リン酸カリウム724mg、トリシクロヘキシルホスフィン65mgおよび酢酸パラジウム(II) 28mgの混合物にトルエン10mlおよび水0.5mlを加え、110℃にて12時間攪拌した。反応混合物をセライトにて濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　5-シクロプロピル-6-メチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート379mgを淡褐色泡状物質として得た。\n\nProduction Example 42 \n t-butyl 6-methyl-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzazepine-8 (2H) -carboxylate 704 mg dichloromethane 15 ml To the solution, 438 mg of N-bromosuccinimide was added little by little under ice cooling, and the mixture was stirred for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 446 mg of a pale yellow foam. To a mixture of 445 mg of the obtained compound, 144 mg of cyclopropylboronic acid, 724 mg of potassium phosphate, 65 mg of tricyclohexylphosphine and 28 mg of palladium (II) acetate, 10 ml of toluene and 0.5 ml of water were added and stirred at 110 ° C. for 12 hours. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluent: HEX-EtOAc) and t-butyl 5-cyclopropyl-6-methyl-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] Benzazepine-8 (2H) -carboxylate (379 mg) was obtained as a light brown foam.\n\n\n\n\n\n\n \n\n製造例３３４\n\n　t-ブチル　3-オキソ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート500mgのDMF 10ml溶液に、1-（ブロモメチル）-3-フルオロベンゾエート250μlと炭酸セシウム800mgを加えてアルゴン雰囲気下、50℃で16時間攪拌した。反応混合物を室温まで冷却し、水を加えて酢酸エチルで2回抽出した。合わせた有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を留去し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　4-(3-フルオロベンジル)-3-オキソ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート609mgを得た。\n\nProduction Example 334 \n t-butyl 3-oxo-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate 500 mg in DMF 10 ml To the mixture, 250 μl of 1- (bromomethyl) -3-fluorobenzoate and 800 mg of cesium carbonate were added, and the mixture was stirred at 50 ° C. for 16 hours in an argon atmosphere. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted twice with ethyl acetate. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and t-butyl 4- (3-fluorobenzyl) -3-oxo-3,4,6,7,9 , 10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate 609 mg was obtained.\n\n\n\n\n\n\n \n\n製造例３３９\n\n　t-ブチル　2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート600mgのDMF 9ml溶液に、氷浴下カリウム　t-ブトキシド426mgおよびベンジルブロミド451μlを加え、室温にて3時間攪拌した。水、酢酸エチルを加え、有機層を減圧濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　1-ベンジル-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート644mgを淡黄色固体として得た\n\nProduction Example 339 \n t-Butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 600 mg in DMF 9 ml solution in an ice bath Lower potassium t-butoxide (426 mg) and benzyl bromide (451 μl) were added, and the mixture was stirred at room temperature for 3 hours. Water and ethyl acetate were added, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and t-butyl 1-benzyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H- 644 mg of azepino [4,5-g] quinoline-8-carboxylate was obtained as a pale yellow solid\n\n\n\n\n\n\n \n\n製造例３４４\n\n　t-ブチル　1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート3.83gのジクロロメタン40ml溶液に、氷冷下ピリジン1.3mlおよびトリホスゲン1.29gを加え3時間攪拌した。反応混合物を減圧下濃縮し、酢酸エチルにて希釈し、水および塩化アンモニウム水溶液にて洗浄し、無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣にヘキサンを加えて攪拌し、固体を濾取、乾燥してt-ブチル　1-（クロロカルボニル）-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート3.07gを白色固体として得た。\n\nProduction Example 344 \n t-Butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 3.83 g in dichloromethane 40 ml solution under ice cooling with pyridine 1.3 ml and 1.29 g of triphosgene were added and stirred for 3 hours. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, washed with water and aqueous ammonium chloride solution, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. Hexane is added to the residue and stirred, and the solid is collected by filtration and dried to give t-butyl 1- (chlorocarbonyl) -1,2,3,4,6,7,9,10-octahydro-8H-azepino [4 , 5-g] quinoline-8-carboxylate (3.07 g) was obtained as a white solid.\n\n\n\n\n\n\n \n\n製造例３４５\n\n　t-ブチル　1-(クロロカルボニル)-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート200mgのピリジン2ml溶液にフェネチルアルコール140μlを加え、100℃にて5.5時間攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、8-t-ブチル　1-（2-フェニルエチル）3,4,6,7,9,10-ヘキサヒドロ-1H-アゼピノ[4,5-g]キノリン-1,8(2H)-カルボキシレート68mgを黄色粘稠性物質として得た。\n\nProduction Example 345 \n t-Butyl 1- (chlorocarbonyl) -1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 200 mg in 2 ml of pyridine 140 μl of phenethyl alcohol was added and stirred at 100 ° C. for 5.5 hours. The reaction mixture was concentrated under reduced pressure, the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and 8-t-butyl 1- (2-phenylethyl) 3,4,6,7,9, 68 mg of 10-hexahydro-1H-azepino [4,5-g] quinoline-1,8 (2H) -carboxylate was obtained as a yellow viscous substance.\n\n\n\n\n\n\n \n\n製造例３４９\n\n　t-ブチル　1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート200mgおよび2-(2-メトキシフェニル)エチル　4-ニトロフェニルカルボネート318mgのジクロロエタン5ml溶液に、ピリジン0.11mlを加え室温にて2日間攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)及び塩基性シリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、8-t-ブチル　1-[2-(メトキシフェニル)エチル]-3,4,6,7,9,10-ヘキサヒドロ-1H-アゼピノ[4,5-g]キノリン-1,8(2H)-カルボキシレート243mgを淡黄色粘稠性物質として得た。\n\nProduction Example 349 \n t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 200 mg and 2- (2-methoxyphenyl) ethyl 4- To a solution of 318 mg of nitrophenyl carbonate in 5 ml of dichloroethane, 0.11 ml of pyridine was added and stirred at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and basic silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 8-t-butyl 1- [2 -(Methoxyphenyl) ethyl] -3,4,6,7,9,10-hexahydro-1H-azepino [4,5-g] quinoline-1,8 (2H) -carboxylate (243 mg) Obtained as material.\n\n\n\n\n\n\n \n\n製造例３６７\n\n　t-ブチル　11-クロロ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート150mgのテトラヒドロフラン3ml溶液に、1M炭酸水素ナトリウム水溶液1.5mlを加えて氷冷し、クロロギ酸エチル64μlを滴下して攪拌した。反応混合物を酢酸エチルにて希釈し、水および飽和食塩水にて洗浄し無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、8-t-ブチル　4-エチル-11-クロロ-2,3,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-4,8-ジカルボキシレート149mgを無色泡状物質として得た。\n\nProduction Example 367 \n t-butyl 11-chloro-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate 150 mg in tetrahydrofuran 3 ml To the mixture, 1.5 ml of 1M aqueous sodium hydrogen carbonate solution was added and ice-cooled, and 64 μl of ethyl chloroformate was added dropwise and stirred. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and 8-t-butyl 4-ethyl-11-chloro-2,3,6,7,9,10-hexahydro [1,4] 149 mg of oxazino [2,3-h] [3] benzazepine-4,8-dicarboxylate was obtained as a colorless foam.\n\n\n\n\n\n\n \n\n製造例３７５\n\n　t-ブチル　11-ブロモ-1-メチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート500mg、炭酸カリウム350mg、ヨウ化銅290mg、１H-ピラゾール173mgおよびN,N-ジメチルグリシン313mgにアルゴン下、ジメチルスルフォキシド6.25mlを加え、135℃にて36時間攪拌した。反応混合物に水、酢酸エチルを加え、攪拌後、固体をろ別した。有機層を重曹水にて洗浄し、減圧濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　1-メチル-11-（1H-ピラゾール-1-イル）-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート43mgを無色の粘凋性液体として得た。\n\nProduction Example 375 \n t-butyl 11-bromo-1-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 500 mg, potassium carbonate 350 mg Then, 6.25 ml of dimethyl sulfoxide was added to 290 mg of copper iodide, 173 mg of 1H-pyrazole and 313 mg of N, N-dimethylglycine under argon, followed by stirring at 135 ° C. for 36 hours. Water and ethyl acetate were added to the reaction mixture, and after stirring, the solid was filtered off. The organic layer was washed with aqueous sodium bicarbonate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and t-butyl 1-methyl-11- (1H-pyrazol-1-yl) -1,2,3,4,6,7, 43 mg of 9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate was obtained as a colorless viscous liquid.\n\n\n\n\n\n\n \n\n製造例３７６\n\n　t-ブチル　11-ブロモ-1-（2-メトキシエチル）1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート200mg、シアン化亜鉛34mg、ビス(トリ-t-ブチルホスフィン)パラジウム13mgおよび亜鉛末10mgのDMF 4ml溶液をアルゴン置換した後、100℃にて15時間攪拌した。反応混合物をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　11-シアノ-1-(2-メトキシエチル)-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート132mgを無色粘稠性物質として得た。\n\nProduction Example 376 \n t-Butyl 11-bromo-1- (2-methoxyethyl) 1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 200 mg A solution of 34 mg of zinc cyanide, 13 mg of bis (tri-t-butylphosphine) palladium and 10 mg of zinc powder in 4 ml of DMF was purged with argon, and then stirred at 100 ° C. for 15 hours. The reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain t-butyl 11-cyano-1- (2-methoxyethyl) -1,2,3,4,6,7,9, 132 mg of 10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate was obtained as a colorless viscous substance.\n\n\n\n\n\n\n \n\n製造例３７７\n\n　1-[11-ブロモ-1-(2-メトキシエチル)-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-イル]-2,2,2-トリフルオロエタノン1.1946g、トリフルオロ酢酸ナトリウム2.2395g及びヨウ化銅1.568gにをアルゴン雰囲気下、N-メチルピロリドン24mlを加え、170℃にて18時間攪拌した。反応混合物に水、酢酸エチルを加え、セライトろ過した。ろ液を分液し、有機層を飽和食塩水洗浄、無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：Hex-AcOEt)にて精製し、2,2,2-トリフルオロ-1-[1-(2-メトキシエチル)-11-(トリフルオロメチル)-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-イル]エタノン239mgを薄黄色固体として得た。\n\nProduction Example 377 \n 1- [11-Bromo-1- (2-methoxyethyl) -1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinolin-8-yl] Under an argon atmosphere, 24 ml of N-methylpyrrolidone was added to 1.1946 g of -2,2,2-trifluoroethanone, 2.2395 g of sodium trifluoroacetate and 1.568 g of copper iodide, and the mixture was stirred at 170 ° C. for 18 hours. Water and ethyl acetate were added to the reaction mixture, and the mixture was filtered through celite. The filtrate was separated, the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt), and 2,2,2-trifluoro-1- [1- (2-methoxyethyl) -11- (trifluoromethyl) -1,2 , 3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinolin-8-yl] ethanone 239 mg was obtained as a pale yellow solid.\n\n\n\n\n\n\n \n\n製造例３７９\n\n　3-(6-ヨード-2-オキソ-1,2,3,4-テトラヒドロキノリン-7-イル)プロパン酸7.87gにt-ブタノール25ml、トリエチルアミン1.1mlおよびアジ化ジフェニルホスホリル0.83mlを加え、70時間加熱還流した。反応混合物を室温まで冷却後、水を加えて希釈、撹拌し、固体を濾取、乾燥してt-ブチル[2-（6-ヨード-2-オキソ-1,2,3,4-テトラヒドロキノリン-7-イル）エチル]カルバメート1.40gを淡褐色固体として得た。さらに濾液から析出した固体を濾取し、t-ブチル[2-(6-ヨード-2-オキソ-1,2,3,4-テトラヒドロキノリン-7-イル)エチル]カルバメート665mgを白色固体として得た。\n\nProduction Example 379 \n To 7.87 g of 3- (6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl) propanoic acid was added 25 ml of t-butanol, 1.1 ml of triethylamine and 0.83 ml of diphenylphosphoryl azide. Heated to reflux for hours. The reaction mixture is cooled to room temperature, diluted with water and stirred, and the solid is collected by filtration and dried to give t-butyl [2- (6-iodo-2-oxo-1,2,3,4-tetrahydroquinoline). -7-yl) ethyl] carbamate 1.40 g was obtained as a light brown solid. Further, the solid precipitated from the filtrate was collected by filtration to obtain 665 mg of t-butyl [2- (6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl) ethyl] carbamate as a white solid. It was.\n\n\n\n\n\n\n \n\n製造例３８０\n\n　t-ブチル　1-[（ベンジルオキシ）メチル]-6-メチル-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート168mgを48%臭化水素酸水溶液中、室温にて3.5時間攪拌した。反応混合物をヘキサンにて抽出し副生するベンジルブロミドを除去した後、水層に1M水酸化ナトリウム水溶液を加えてアルカリ性とし、テトラヒドロフラン20mlを加えた。混合液に二炭酸ジ-t-ブチル500mgを加え室温にて2時間攪拌した。反応混合物を酢酸エチルにて抽出し、有機層を飽和食塩水にて洗浄し、無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮してt-ブチル　6-メチル-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート513mgを無色泡状物質として得た。\n\nProduction Example 380 \n t-Butyl 1-[(benzyloxy) methyl] -6-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline -8 mg of 8-carboxylate was stirred in a 48% aqueous hydrobromic acid solution at room temperature for 3.5 hours. The reaction mixture was extracted with hexane to remove by-produced benzyl bromide, and the aqueous layer was made alkaline with 1M aqueous sodium hydroxide solution, and 20 ml of tetrahydrofuran was added. To the mixture, 500 mg of di-t-butyl dicarbonate was added and stirred at room temperature for 2 hours. The reaction mixture was extracted with ethyl acetate, the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give t-butyl 6-methyl-2-oxo-1 , 2,3,4,6,7,9,10-Octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 513 mg was obtained as a colorless foam.\n\n\n\n\n\n\n \n\n製造例３８１\n\n　アルゴン雰囲気下、エチル　7-ブロモ-8-ヒドロキシ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート1.7gのDMF 30ml溶液に、氷冷下水素化ナトリウム283mgを加えてそのままの温度で10分撹拌後、t-ブチル　(4R)-4-メチル-1,2,3-オキサチアゾリジン-3-カルボキシレート1.54gを加え、室温で18時間撹拌した。反応を水を加えた後、1M塩酸水を加えて撹拌し、析出した固体をろ取した。得られた固体のエタノール20ml懸濁液に、氷冷下4M塩酸-酢酸エチル溶液10mlを加えた後、60℃にて1時間撹拌した。反応混合物を減圧留去し、残渣にクロロホルム、飽和重曹水を加えた。クロロホルムで抽出後、合わせた有機層を飽和食塩水にて洗浄、無水硫酸マグネシウムにて乾燥、ろ過、減圧濃縮し、エチル　7-{[(2R)-2-アミノプロピル]オキシ}-8-ブロモ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート2.26gを不透明なクリーム色油状物質として得た。\n\nProduction Example 381 \n Under an argon atmosphere, 283 mg of sodium hydride was added to a solution of 1.7 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 30 ml of DMF under ice-cooling. In addition, after stirring at the same temperature for 10 minutes, 1.54 g of t-butyl (4R) -4-methyl-1,2,3-oxathiazolidine-3-carboxylate was added and stirred at room temperature for 18 hours. After adding water to the reaction, 1M aqueous hydrochloric acid was added and stirred, and the precipitated solid was collected by filtration. 10 ml of 4M hydrochloric acid-ethyl acetate solution was added to a 20 ml suspension of the obtained solid ethanol under ice-cooling, followed by stirring at 60 ° C. for 1 hour. The reaction mixture was evaporated under reduced pressure, and chloroform and saturated aqueous sodium hydrogen carbonate were added to the residue. After extraction with chloroform, the combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. Ethyl 7-{[(2R) -2-aminopropyl] oxy} -8-bromo 1.26 g of -1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was obtained as an opaque cream oil.\n\n\n\n\n\n\n \n\n製造例３８３\n\n　アルゴン雰囲気下、エチル　7-{[(2R)-2-アミノプロピル]オキシ}-8-ブロモ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート1.64gのトルエン41ml溶液に、ナトリウム　t-ブトキシド509mg、2,2'-ビス(ジフェニルホスフィノ)-1,1'-ビナフチル275mg、トリス(ジベンジリデンアセトン)ジパラジウム(0) 202mgを順次加え、100℃にて24時間加熱した。さらにナトリウム　t-ブトキシド509mg、2,2'-ビス(ジフェニルホスフィノ)-1,1'-ビナフチル275 mg、トリス(ジベンジリデンアセトン)ジパラジウム(0) 202mgを追加し、100℃にてさらに24時間撹拌した。反応混合物を室温に戻した後、セライトろ過、酢酸エチルでの洗浄を行い、ろ液を減圧濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：Hex-AcOEt)にて精製し、エチル　(3R)-3-メチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレートを610 mg得た。\n\nProduction Example 383 \n Ethyl 7-{[(2R) -2-aminopropyl] oxy} -8-bromo-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 1.64 g toluene under argon atmosphere To a 41 ml solution, sodium tert-butoxide 509 mg, 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl 275 mg, tris (dibenzylideneacetone) dipalladium (0) 202 mg were sequentially added at 100 ° C. Heated for 24 hours. Further, sodium tert-butoxide 509 mg, 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl 275 mg, tris (dibenzylideneacetone) dipalladium (0) 202 mg were added, and further 24 at 100 ° C. Stir for hours. The reaction mixture was returned to room temperature, filtered through celite, washed with ethyl acetate, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt), and ethyl (3R) -3-methyl-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3 610 mg of -h] [3] benzazepine-8 (2H) -carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例３８５\n\n　アルゴン雰囲気下、エチル　7-[(3-メチルブテ-2-エノイル)アミノ]-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート1.032gのジクロロメタン10.5ml溶液に、室温で塩化アルミニウム870mgを加え、室温で3時間撹拌した。さらに塩化アルミニウム435mgを加え、室温にて2時間撹拌した。反応混合物を氷水に注ぎ、クロロホルムで抽出した。合わせた有機層を水、飽和炭酸水素ナトリウム水溶液、水、飽和食塩水にて洗浄、無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：Hex-AcOEt)にて精製し、エチル　4,4-ジメチル-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート431mgを白色固体として得た。\n\nProduction Example 385 \n Under argon atmosphere, ethyl 7-[(3-methylbut-2-enoyl) amino] -1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 1.032 g in dichloromethane 10.5 ml solution, 870 mg of aluminum chloride was added at room temperature, and the mixture was stirred at room temperature for 3 hours. Further, 435 mg of aluminum chloride was added and stirred at room temperature for 2 hours. The reaction mixture was poured into ice water and extracted with chloroform. The combined organic layers were washed with water, saturated aqueous sodium hydrogen carbonate solution, water and saturated brine, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt), and ethyl 4,4-dimethyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino 431 mg of [4,5-g] quinoline-8-carboxylate was obtained as a white solid.\n\n\n\n\n\n\n \n\n製造例３８６\n\n　アルゴン雰囲気下、エチル　7-アミノ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート1gと1,1,-ジメチルプロピ-2-イン-1-イルアセテート539mgのテトラヒドロフラン10ml溶液に、塩化銅43mgを加えて、90℃で5時間加熱した。反応混合物を減圧濃縮した後、酢酸エチルを加えて、飽和塩化アンモニウム水溶液、飽和食塩水で洗浄した。水層を酢酸エチルにて2回抽出し、合わせた有機層を飽和食塩水洗浄、無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣を分取薄層クロマトグラフィーを用いて精製を行い、エチル　2,2－ジメチル-1,2,6,7,9,10-ヘキサヒドロ-8H-アゼピン[4,5-g]キノリン-8-カルボキシレート272mgを得た。\n\nProduction Example 386 \n Under an argon atmosphere, 1 g of ethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate and 539 mg of 1,1, -dimethylprop-2-in-1-yl acetate To 10 ml of tetrahydrofuran was added 43 mg of copper chloride, and the mixture was heated at 90 ° C. for 5 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate was added, and the mixture was washed with a saturated aqueous ammonium chloride solution and saturated brine. The aqueous layer was extracted twice with ethyl acetate, and the combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified using preparative thin layer chromatography, and ethyl 2,2-dimethyl-1,2,6,7,9,10-hexahydro-8H-azepine [4,5-g] quinoline-8- 272 mg of carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例３８７\n\n　エチル　7-アミノ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレートに5%硫酸水溶液を加え氷冷下攪拌した。これに亜硝酸ナトリウム10.22gの水溶液（30ml）溶液を少しずつ滴下し、同温で0.5時間攪拌した後、60℃で3時間攪拌した。反応混合物を酢酸エチルで抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、エチル　7-ヒドロキシ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレートを主成分とする粗精製物を得た。粗精製物を酢酸エチルから再結晶を2回行い、エチル　7-ヒドロキシ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート15.66gを得た。\n\nProduction Example 387 \n A 5% aqueous sulfuric acid solution was added to ethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate, and the mixture was stirred under ice-cooling. An aqueous solution (30 ml) of 10.22 g of sodium nitrite was added dropwise thereto, and the mixture was stirred at the same temperature for 0.5 hour, and then stirred at 60 ° C. for 3 hours. The reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue is purified by silica gel chromatography (elution solvent: HEX-EtOAc) and contains ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as the main component. A crude product was obtained. The crude product was recrystallized twice from ethyl acetate to obtain 15.66 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate.\n\n\n\n\n\n\n \n\n製造例３８８\n\n　エチル　7-ニトロ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート30gのエタノール300ml溶液に、10%パラジウム炭素3gを加え、4気圧の水素雰囲気下、室温にて16時間攪拌した。反応混合物をセライトにて濾過し、濾液を氷冷した後無水酢酸21.6mlを滴下し16時間撹拌した。反応混合物を減圧下濃縮し、残渣にジエチルエーテルを加え、固体を洗浄し、エチル　7-アセトアミド-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート26.45gを白色固体として得た。\n\nProduction Example 388 \n Ethyl 7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 30 g of ethanol in 300 ml solution was added 10% palladium on carbon 3 g and brought to room temperature under 4 atm hydrogen atmosphere. And stirred for 16 hours. The reaction mixture was filtered through celite, the filtrate was ice-cooled, 21.6 ml of acetic anhydride was added dropwise, and the mixture was stirred for 16 hours. The reaction mixture was concentrated under reduced pressure, diethyl ether was added to the residue, the solid was washed, and 26.45 g of ethyl 7-acetamido-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was white. Obtained as a solid.\n\n\n\n\n\n\n \n\n製造例３８９\n\n　エチル　7-アセトアミド-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート12g、ヨウ化銅1.93g、1,10-フェナントロリン1.89gおよび炭酸セシウム33.12gのジオキサン240mlの混合液をアルゴン置換した後、100℃にて18時間攪拌した。反応混合物を酢酸エチルにて希釈し、不溶物をセライトを用いて除去し、濾液を減圧下濃縮しを乳白色固体として得た。得られた残渣をジオキサン240mlに懸濁し、ヨウ化銅1.93g、1,10-フェナントロリン1.89gと炭酸セシウム33.1gを加えて、100℃で3日間攪拌した。室温まで冷却し、反応混合物を酢酸エチルで希釈してセライト濾過して固体を除去し、ろ液を減圧濃縮してエチル　2-メチル-5,6,8,9-テトラヒドロ-7H-[1,3]オキサゾロ[4,5-h][3]ベンゾアゼピン-7-カルボキシレート9.245gを乳白色固体として得た。\n\nProduction Example 389 \n 12 ml of ethyl 7-acetamido-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate, 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline and 33.12 g of cesium carbonate in 240 ml of dioxane The mixture was purged with argon and stirred at 100 ° C. for 18 hours. The reaction mixture was diluted with ethyl acetate, insolubles were removed using celite, and the filtrate was concentrated under reduced pressure to give a milky white solid. The obtained residue was suspended in 240 ml of dioxane, 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline and 33.1 g of cesium carbonate were added, and the mixture was stirred at 100 ° C. for 3 days. Cool to room temperature, dilute the reaction mixture with ethyl acetate and filter through celite to remove solids, concentrate the filtrate under reduced pressure and ethyl 2-methyl-5,6,8,9-tetrahydro-7H- [1, 3] 9.245 g of oxazolo [4,5-h] [3] benzazepine-7-carboxylate was obtained as a milky white solid.\n\n\n\n\n\n\n \n\n製造例３９０\n\n　エチル　2-メチル-5,6,8,9-テトラヒドロ-7H-[1,3]オキサゾロ[4,5-h][3]ベンゾアゼピン-7-カルボキシレート7gのエタノール130ml溶液に、1M塩酸水130mlを加え16時間攪拌した。エタノールを減圧留去して乾固したのちに、クロロホルムに溶解し、水で洗浄した。有機層を無水硫酸ナトリウムで乾燥後溶媒を減圧留去し、エチル7-アセトアミド-8-ヒドロキシ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート6.84gを茶白色固体としてを得た。\n\nProduction Example 390 \n Ethyl 2-methyl-5,6,8,9-tetrahydro-7H- [1,3] oxazolo [4,5-h] [3] benzoazepine-7-carboxylate 130 ml was added and stirred for 16 hours. Ethanol was distilled off under reduced pressure to dryness, and then dissolved in chloroform and washed with water. The organic layer was dried over anhydrous sodium sulfate and the solvent was distilled off under reduced pressure to give 6.84 g of ethyl 7-acetamido-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as tea. Obtained as a white solid.\n\n\n\n\n\n\n \n\n製造例４０８\n\n　t-ブチル　4-エチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート860mgのジクロロメタン25ml溶液に、炭酸水素ナトリウム1.1gを加え、さらに、臭素200μlのジクロロメタン5ml溶液を30分程度かけて滴下して加えて室温で攪拌した。反応混合物に3%チオ硫酸ナトリウム水溶液をゆっくりと加えて激しく攪拌した後に、クロロホルムで2回抽出した。合わせた有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を留去し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　5-ブロモ-4-エチル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート490mgを得た。\n\nProduction Example 408 \n t-butyl 4-ethyl-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate 860 mg in dichloromethane 25 ml solution To the solution, 1.1 g of sodium hydrogen carbonate was added, and further a 5 ml solution of 200 μl bromine in dichloromethane was added dropwise over about 30 minutes, and the mixture was stirred at room temperature. A 3% aqueous sodium thiosulfate solution was slowly added to the reaction mixture and stirred vigorously, followed by extraction twice with chloroform. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and t-butyl 5-bromo-4-ethyl-3,4,6,7,9,10-hexahydro [ 490 mg of 1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例４０９\n\n　アルゴン雰囲気下、エチル　7-ヒドロキシ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート5.0gのジクロロメタン100ml及びメタノール20mlの混合溶液に、氷冷下N,N,N-トリメチルアニリニウムトリブロミド8.05gを少量ずつ加え、そのままの温度で1時間撹拌した。反応混合物を減圧濃縮し、残渣に酢酸エチル、水を加えて抽出後、有機層を1N塩酸水、飽和食塩水にて洗浄、無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮し、エチル　7-ブロモ-8-ヒドロキシ-1,2,4,5-テトラヒドロ-3H-3-ベンゾアゼピン-3-カルボキシレート6.67gをベージュ固体として得た。\n\nProduction Example 409 \n Under an argon atmosphere, a mixed solution of 5.0 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 100 ml of dichloromethane and 20 ml of methanol was added with N, N, N-trimethylanilinium tribromide (8.05 g) was added little by little, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was extracted with ethyl acetate and water. The organic layer was washed with 1N aqueous hydrochloric acid and saturated brine, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. 6.67 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was obtained as a beige solid.\n\n\n\n\n\n\n \n\n製造例４１１\n\n　t-ブチル　1-(3-メトキシプロピル)-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレートのアセトニトリル4.2ml溶液にN-ブロモスクシンイミド107mg及び硝酸アンモニウム3.7mgを加え、室温にて3.5時間攪拌した。反応混合物を1/4程度まで濃縮し、酢酸エチル、チオ硫酸ナトリウム水溶液、重曹水を加え、有機層を飽和食塩水にて洗浄後、無水硫酸マグネシウムにて乾燥した。溶媒を留去し、t-ブチル　11-ブロモ-1-(3-メトキシプロピル)-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート198mgを得た。\n\nProduction Example 411 \n t-Butyl 1- (3-methoxypropyl) -2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate To a 4.2 ml solution of acetonitrile, 107 mg of N-bromosuccinimide and 3.7 mg of ammonium nitrate were added and stirred at room temperature for 3.5 hours. The reaction mixture was concentrated to about 1/4, ethyl acetate, sodium thiosulfate aqueous solution, and sodium bicarbonate water were added, and the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off and t-butyl 11-bromo-1- (3-methoxypropyl) -2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4, 198 mg of 5-g] quinoline-8-carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例４２６\n\n　エチル　3-(6-ヨード-2-オキソ-1,2,3,4-テトラヒドロキノリン-7-イル)プロパネートのエタノール200ml溶液に、1M水酸化ナトリウム水溶液150mlを加え、室温にて2時間攪拌した。反応混合物に濃塩酸を滴下して弱酸性とし、さらに水を加えて希釈した。析出固体を濾取、乾燥して3-(6-ヨード-2-オキソ-1,2,3,4-テトラヒドロキノリン-7-イル)プロパン酸8.88gを淡褐色固体として得た。\n\nProduction Example 426 \n To a 200 ml ethanol solution of ethyl 3- (6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl) propanate was added 150 ml of 1M aqueous sodium hydroxide solution and stirred at room temperature for 2 hours. . Concentrated hydrochloric acid was added dropwise to the reaction mixture to make it weakly acidic, and further diluted with water. The precipitated solid was collected by filtration and dried to obtain 8.88 g of 3- (6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl) propanoic acid as a light brown solid.\n\n\n\n\n\n\n \n\n製造例４２７\n\n　エチル　8-アセトアミド-6-ブロモ-7-(2-エトキシ-2-オキソエトキシ)-1,2,4,5-テトラヒドロ-3H-ベンゾアゼピン-3-カルボキシレート3.421gに、酢酸30mlおよび8M塩酸30mlを加え、150℃にて16時間攪拌した。反応混合物を減圧下濃縮し、残渣をTHF 35mlに溶解させた後、1M水酸化ナトリウム水溶液35mlを加えてアルカリ性とし、二炭酸ジ-t-ブチル2gを加え室温にて1時間攪拌した。反応混合物を酢酸エチルにて抽出し、有機層を無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮しt-ブチル　11-ブロモ-3-オキソ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート1.373gを得た。\n\nProduction Example 427 \n Ethyl 8-acetamido-6-bromo-7- (2-ethoxy-2-oxoethoxy) -1,2,4,5-tetrahydro-3H-benzazepine-3-carboxylate 3.421 g, acetic acid 30 ml and 8M hydrochloric acid 30 ml was added and stirred at 150 ° C. for 16 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in 35 ml of THF. The mixture was made alkaline by adding 35 ml of 1M aqueous sodium hydroxide solution, 2 g of di-t-butyl dicarbonate was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain t-butyl 11-bromo-3-oxo-3,4,6,7,9, 1.373 g of 10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例４９５\n\n　t-ブチル　4-ベンジル-3-オキソ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート590mgのテトラヒドロフラン10ml溶液に、氷冷下1Mボラン-THF錯体のTHF溶液3.5mlを加え、室温にて14時間攪拌した。反応混合物を冷却し、MeOHおよび1M水酸化ナトリウム水溶液を加え、室温にて3時間攪拌した。反応混合物を濃縮し残渣に酢酸エチルおよび水を加え、有機層を飽和食塩水にて洗浄後、無水硫酸ナトリウムにて乾燥した。溶媒を留去し、得られた残渣578mgのジクロロメタン10ml溶液に、炭酸水素ナトリウム620mgを加え、さらに、臭素280mgのジクロロメタン5ml溶液を30分程度かけて滴下して加えて室温で攪拌した。反応混合物に3%チオ硫酸ナトリウム水溶液をゆっくりと加えて激しく攪拌した後に、クロロホルムで2回抽出した。合わせた有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　4-ベンジル-5-ブロモ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート518mgを得た。\n\nProduction Example 495 \n t-butyl 4-benzyl-3-oxo-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate 590 mg To a 10 ml tetrahydrofuran solution was added 3.5 ml of a 1M borane-THF complex THF solution under ice cooling, followed by stirring at room temperature for 14 hours. The reaction mixture was cooled, MeOH and 1M aqueous sodium hydroxide solution were added and stirred at room temperature for 3 hours. The reaction mixture was concentrated, ethyl acetate and water were added to the residue, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off, and 620 mg of sodium bicarbonate was added to a 10 ml dichloromethane solution of the obtained residue 578 mg. Further, 280 mg bromine in 5 ml dichloromethane was added dropwise over about 30 minutes, and the mixture was stirred at room temperature. A 3% aqueous sodium thiosulfate solution was slowly added to the reaction mixture and stirred vigorously, followed by extraction twice with chloroform. The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and t-butyl 4-benzyl-5-bromo-3,4,6,7,9,10-hexahydro [1,4] oxazino [ 518 mg of 2,3-h] [3] benzazepine-8 (2H) -carboxylate was obtained.\n\n\n\n\n\n\n \n\n製造例５４０\n\n　2,4,5-トリフルオロベンゾニトリル1.10gおよびt-ブチル　5-シクロプロピル-4-（2-ヒドロキシエチル）-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート500mgのTHF 15ml溶液に、カリウム　t-ブトキシド150mgを-30℃にて少量ずつ加え、2時間攪拌した。さらに反応混合物にMeOH 0.15mlを加えた後、カリウム　t-ブトキシド150mgを少量ずつ加え、-10℃に昇温して15時間攪拌した。さらに反応混合物にMeOH 0.15mlを加えた後、カリウム t-ブトキシド150mgを少量ずつ加え、0℃に昇温してさらに14時間撹拌後、酢酸エチルにて希釈し、水および飽和食塩水にて洗浄し、無水硫酸マグネシウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc))にて精製を行い、t-ブチル　４－[2-（4-シアノ-2-フルオロ-5-メトキシフェニル）エチル]-5-シクロプロピル-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート726mgを無色粘調性物質として得た。\n\nProduction Example 540 \n 1.10 g of 2,4,5-trifluorobenzonitrile and t-butyl 5-cyclopropyl-4- (2-hydroxyethyl) -3,4,6,7,9,10-hexahydro [1,4] oxazino [ To a solution of 2,3-h] [3] benzoazepine-8 (2H) -carboxylate 500 mg in THF 15 ml, potassium t-butoxide 150 mg was added little by little at −30 ° C. and stirred for 2 hours. Further, 0.15 ml of MeOH was added to the reaction mixture, 150 mg of potassium t-butoxide was added little by little, the temperature was raised to −10 ° C., and the mixture was stirred for 15 hours. Further, 0.15 ml of MeOH was added to the reaction mixture, 150 mg of potassium t-butoxide was added little by little, the temperature was raised to 0 ° C., the mixture was further stirred for 14 hours, diluted with ethyl acetate, and washed with water and saturated brine. The mixture was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and t-butyl 4- [2- (4-cyano-2-fluoro-5-methoxyphenyl) ethyl] -5-cyclopropyl- 726 mg of 3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate was obtained as a colorless viscous substance.\n\n\n\n\n\n\n \n\n製造例５４３\n\n　t-ブチル　5-シクロプロピル-4-[2-(2,6-ジフルオロ-4-フォルミルフェノキシ)エチル]-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート270mgのMeOH 6ml溶液に、水素化ホウ素ナトリウム30mgを加え室温にて4時間撹拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc))にて精製を行い、t-ブチル　5-シクロプロピル-4-{2-[2,6-ジフルオロ-4-(ヒドロキシメチル)フェノキシ]エチル}-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート220mg白色固体として得た。\n\nProduction Example 543 \n t-Butyl 5-cyclopropyl-4- [2- (2,6-difluoro-4-formylphenoxy) ethyl] -3,4,6,7,9,10-hexahydro [1,4] oxazino [2 , 3-h] [3] Benzoazepine-8 (2H) -carboxylate 270 mg of MeOH 6 ml solution was added sodium borohydride 30 mg and stirred at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc)), and t-butyl 5-cyclopropyl-4- {2- [2,6-difluoro-4- (Hydroxymethyl) phenoxy] ethyl} -3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate 220 mg white solid Got as.\n\n\n\n\n\n\n \n\n製造例５４５\n\n　t-ブチル　5-シクロプロピル-4-(2-ヒドロキシエチル)-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート400mgのジクロロメタン4ml溶液に、p-トルエンスルホニルクロリド217mg、トリエチルアミン0.22mlおよびN-メチルイミダゾール125μlを順次加え1時間撹拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　5-シクロプロピル-4-(2-{[(4-メチルフェニル)スルフォニル]オキシ}エチル)-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート541mgを白色固体として得た。\n\nProduction Example 545 \n t-butyl 5-cyclopropyl-4- (2-hydroxyethyl) -3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 ( To a solution of 2H) -carboxylate 400 mg in dichloromethane 4 ml, p-toluenesulfonyl chloride 217 mg, triethylamine 0.22 ml and N-methylimidazole 125 μl were sequentially added and stirred for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain t-butyl 5-cyclopropyl-4- (2-{[(4-methylphenyl) sulfonyl]. Oxy} ethyl) -3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate (541 mg) was obtained as a white solid .\n\n\n\n\n\n\n \n\n製造例５４９\n\n　t-ブチル　5-シクロプロピル-4-[(2R)-2-メトキシ-3-{[(4-メチルフェニル)スルフォニル]オキシ}プロピル]-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート400mgに、t-ブチルアンモニウムフルオリドの1M THF溶液7mlを加えて、アルゴン雰囲気下、60℃で13時間加熱撹拌した。反応混合物を室温まで冷却し、飽和炭酸水素ナトリウム水溶液を加えて、酢酸エチルで2回抽出した。合わせた有機層を無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　5-シクロプロピル-4-[(2R)-3-フルオロ-2-メトキシプロピル]-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンゾアゼピン-8(2H)-カルボキシレート257mgを白色泡状固体として得た。\n\nProduction Example 549 \n t-butyl 5-cyclopropyl-4-[(2R) -2-methoxy-3-{[(4-methylphenyl) sulfonyl] oxy} propyl] -3,4,6,7,9,10-hexahydro [ 1,4] Oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate (400 mg) was added with 7 ml of 1M THF solution of t-butylammonium fluoride, and the mixture was stirred at 60 ° C. under an argon atmosphere. Stir for hours. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted twice with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain t-butyl 5-cyclopropyl-4-[(2R) -3-fluoro-2-methoxypropyl] -3,4,6, 257 mg of 7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzazepine-8 (2H) -carboxylate was obtained as a white foamy solid.\n\n\n\n\n\n\n \n\n製造例５６５\n\n　t-ブチル　5-シクロプロピル-4-(2-ヒドロキシ-3-メトキシプロピル)-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート300mgのトルエン3ml溶液に、o-フルオロフェノール0.1mlおよびシアノメチレントリブチルホスホラン250mgを加え80℃にて20時間撹拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー(溶出溶媒：HEX-EtOAc)にて精製を行い、t-ブチル　5-シクロプロピル-4-[2-(2-フルオロフェノキシ)-3-メトキシプロピル]-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート277mgを淡黄色粘調性物質として得た。\n\nProduction Example 565 \n t-butyl 5-cyclopropyl-4- (2-hydroxy-3-methoxypropyl) -3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] To a solution of benzoazepine-8 (2H) -carboxylate 300 mg in toluene 3 ml, o-fluorophenol 0.1 ml and cyanomethylenetributylphosphorane 250 mg were added and stirred at 80 ° C. for 20 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain t-butyl 5-cyclopropyl-4- [2- (2-fluorophenoxy) -3-methoxy. Propyl] -3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H) -carboxylate 277 mg as a pale yellow viscous substance Obtained.\n\n\n\n\n\n\n \n\n　上記製造例の方法と同様にして、後記表に示す製造例の化合物を製造した。各製造例化合物の構造を表２～表８１に、製造法及び物理化学的データを表８２～表９６に示す。\n\n\nThe compounds of the production examples shown in the table below were produced in the same manner as in the above production examples. The structures of the respective production example compounds are shown in Tables 2 to 81, and the production methods and physicochemical data are shown in Tables 82 to 96.\n\n\n\n\n\n\n\n \n\n実施例１\n\n　エチル　1-メチル-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート1.865gにエチレングリコール20mLおよび40%水酸化カリウム水溶液20mLを加え、120℃に加熱して18時間攪拌した。反応混合物を氷冷し、濃塩酸を加えpHを1とした後、1時間攪拌した。反応混合物に1M水酸化ナトリウム水溶液を加えて塩基性とし、クロロホルムにて抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過した。濾液を減圧下濃縮して11-クロロ-1,3,4,6,7,8,9,10-オクタヒドロ-2H-アゼピノ[4,5-g]キノリン-2-オン1.451gを褐色固体として得た。11-クロロ-1,3,4,6,7,8,9,10-オクタヒドロ-2H-アゼピノ[4,5-g]キノリン-2-オン60mgにEtOAc1mlを加え、EtOHを加えて熱時溶解させた。析出固体を濾取し、11-クロロ-1,3,4,6,7,8,9,10-オクタヒドロ-2H-アゼピノ[4,5-g]キノリン-2-オン29.5mgを白色固体として得た。\n\nExample 1 \n Ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 1.865 g and ethylene glycol 20 mL and 20 mL of 40% aqueous potassium hydroxide solution was added, heated to 120 ° C. and stirred for 18 hours. The reaction mixture was ice-cooled, concentrated hydrochloric acid was added to adjust the pH to 1, and the mixture was stirred for 1 hr. The reaction mixture was basified with 1M aqueous sodium hydroxide solution, extracted with chloroform, and the organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give 1.451 g of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino [4,5-g] quinolin-2-one as a brown solid Obtained. 11-Chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino [4,5-g] quinolin-2-one 60mg, EtOAc 1ml, EtOH and hot dissolution I let you. The precipitated solid was collected by filtration and 29.5 mg of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino [4,5-g] quinolin-2-one as a white solid Obtained.\n\n\n\n\n\n\n \n\n実施例２\n\n　t-ブチル　11-クロロ-1-イソブチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート47mgに、4M塩化水素EtOAc溶液1mlを加え室温にて3時間攪拌した。反応混合物を減圧下濃縮し、残渣をシリカゲルクロマトグラフィー（溶出溶媒：クロロホルム-MeOH）にて精製を行い、得られた淡黄色粘稠性物質26mgをEtOHに溶解させ、フマル酸10.3mgを加えて攪拌した。析出固体を濾取し、11-クロロ-1-イソブチル-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン　モノフマル酸塩23.2mgを白色固体として得た。\n\nExample 2 \n t-Butyl 11-chloro-1-isobutyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 47 mg, 4M chloride 1 ml of hydrogen EtOAc solution was added and stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure, the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH), 26 mg of the pale yellow viscous substance obtained was dissolved in EtOH, and 10.3 mg of fumaric acid was added. Stir. The precipitated solid was collected by filtration, and 23.2 mg of 11-chloro-1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline monofumarate was added. Obtained as a white solid.\n\n\n\n\n\n\n \n\n実施例３\n\n　t-ブチル　2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート200mgのTHF 2mlの溶液に、氷冷下1Mボラン-THF錯体のTHF溶液1.9mlを加え、室温に昇温して6時間攪拌後、45℃に昇温した。3時間攪拌後、氷浴下、さらに1Mボラン-THF錯体のTHF溶液1.9mlを加えた。2時間後、MeOHを滴下し、20分攪拌した。混合溶液を水で希釈した後、クロロホルムにて抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮した。残渣をジクロロメタン1.6mlに溶解させ、トリフルオロ酢酸0.4mlを加えた、室温で1時間攪拌後、減圧下濃縮した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製し、得られた固体を熱EtOH 0.25mlに溶解させ、フマル酸21mgを加えた。攪拌させながら室温まで放冷し、析出した固体をろ過し、2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン　モノフマル酸塩36mgを淡黄色固体として得た。\n\nExample 3 \n t-Butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 200 mg of THF in a solution of 2 ml of ice Under cooling, 1.9 ml of 1M borane-THF complex in THF was added, the temperature was raised to room temperature, stirred for 6 hours, and then raised to 45 ° C. After stirring for 3 hours, an additional 1.9 ml of 1M borane-THF complex in THF was added in an ice bath. After 2 hours, MeOH was added dropwise and stirred for 20 minutes. The mixed solution was diluted with water and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in 1.6 ml of dichloromethane, 0.4 ml of trifluoroacetic acid was added, and the mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), the obtained solid was dissolved in 0.25 ml of hot EtOH, and 21 mg of fumaric acid was added. The mixture was allowed to cool to room temperature with stirring, and the precipitated solid was filtered, and 36 mg of 2,3,4,6,7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline monofumarate was added. Obtained as a pale yellow solid.\n\n\n\n\n\n\n \n\n実施例４\n\n　エチル　1-メチル-2-オキソ-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート150mgにエチレングリコール4mlおよび40%水酸化カリウム水溶液2mlを加え、120℃に加熱して18時間攪拌した。反応混合物を氷冷し、濃塩酸を加え 液性を酸性にした後1時間攪拌した。反応混合物を1M水酸化ナトリウム水溶液で中和した後、クロロホルムで抽出し、有機層を無水硫酸ナトリウムにて乾燥後濾過し、濾液を減圧下濃縮後、残渣をシリカゲルクロマトグラフィー（溶出溶媒：クロロホルム-MeOH-アンモニア水）で精製を行った。得られた残渣のEtOAc 2ml溶液に、4M塩化水素EtOAc溶液0.2mlを加えて攪拌した。溶媒を減圧下濃縮し、得られた固体をEtOH 2mlに熱時溶解させ、室温にて攪拌した。析出した固体を濾取し、1-メチル-1,3,4,6,7,8,9,10-オクタヒドロ-2H-アゼピノ[4,5-g]キノリン-2-オン　モノ塩酸塩43.7mgを淡黄色固体として得た。\n\nExample 4 \n Ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 150 mg ethylene glycol 4 ml and 40 2 ml of an aqueous potassium hydroxide solution was added, heated to 120 ° C. and stirred for 18 hours. The reaction mixture was ice-cooled, concentrated hydrochloric acid was added to make the solution acidic, and the mixture was stirred for 1 hour. The reaction mixture was neutralized with 1M aqueous sodium hydroxide solution and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the residue was chromatographed on silica gel (eluent: chloroform- Purification was performed with MeOH-ammonia water. To a solution of the obtained residue in 2 ml of EtOAc, 0.2 ml of 4M hydrogen chloride in EtOAc was added and stirred. The solvent was concentrated under reduced pressure, and the resulting solid was dissolved in 2 ml of EtOH with heating and stirred at room temperature. The precipitated solid was collected by filtration and 13.7-methyl-1,3,4,6,7,8,9,10-octahydro-2H-azepino [4,5-g] quinolin-2-one monohydrochloride 43.7 mg Was obtained as a pale yellow solid.\n\n\n\n\n\n\n \n\n実施例５\n\n　t-ブチル　11-シクロプロピル-1-(メトキシアセチル)-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート140mgのEtOH 1ml溶液に、4M塩化水素EtOAc溶液2mlを加え、室温にて3時間攪拌した。反応混合物を1M水酸化ナトリウム水溶液にあけ、水層をクロロホルムで抽出し、有機層を硫酸ナトリウムで乾燥させた。溶媒を減圧下濃縮し、得られた残渣を残渣をシリカゲルクロマトグラフィー（溶出溶媒：クロロホルム-MeOH-アンモニア水）で精製を行い、11-シクロプロピル-1-(メトキシアセチル)-2,3,4,6,7,8,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン102mgを薄黄色油状物として得た。\n\nExample 5 \n t-butyl 11-cyclopropyl-1- (methoxyacetyl) -1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 140 mg 2 ml of 4M hydrogen chloride in EtOAc was added to 1 ml of EtOH and stirred at room temperature for 3 hours. The reaction mixture was poured into 1M aqueous sodium hydroxide solution, the aqueous layer was extracted with chloroform, and the organic layer was dried over sodium sulfate. The solvent was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH-aqueous ammonia) to give 11-cyclopropyl-1- (methoxyacetyl) -2,3,4 , 6,7,8,9,10-Octahydro-8H-azepino [4,5-g] quinoline 102 mg was obtained as a pale yellow oil.\n\n\n\n\n\n\n \n\n実施例６\n\n　t-ブチル　1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート200mgのジクロロエタン2.13ml溶液に、トリエチルアミン0.553mlおよびクロロギ酸エチル0.19mlを加え、60℃にて2時間攪拌した。反応混合物を室温まで放冷後、反応混合物をEtOAcで希釈し、1M塩酸、水、1M水酸化ナトリウム水溶液および飽和食塩水にて洗浄、濃縮し、残渣をシリカゲルカラムクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製した。得られた物質をクロロホルムに溶解し、トリフルオロ酢酸0.005mlを加え、30分攪拌した。減圧濃縮後、EtOHに溶解しトリエチルアミンを加え中和した後、減圧濃縮後、残渣をシリカゲルカラムクロマトグラフィー（溶出溶媒：クロロホルム-MeOH-アンモニア水）にて精製した。得られた物質をEtOHに溶解し、フマル酸76mgを加え、生じた白色固体をろ取し、乾燥しエチル　2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4.5-g]キノリン-1-カルボキシレート　ヘミフマル酸塩79mgを得た。\n\nExample 6 \n t-Butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 200 mg of dichloroethane in 2.13 ml solution, triethylamine 0.553 ml and chloroform Ethyl acid 0.19ml was added and it stirred at 60 degreeC for 2 hours. The reaction mixture is allowed to cool to room temperature, and the reaction mixture is diluted with EtOAc, washed with 1M hydrochloric acid, water, 1M aqueous sodium hydroxide solution and saturated brine, concentrated, and the residue is subjected to silica gel column chromatography (elution solvent: HEX- Purified with EtOAc). The obtained substance was dissolved in chloroform, 0.005 ml of trifluoroacetic acid was added, and the mixture was stirred for 30 minutes. After concentration under reduced pressure, the residue was dissolved in EtOH and neutralized by adding triethylamine. After concentration under reduced pressure, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The obtained substance was dissolved in EtOH, 76 mg of fumaric acid was added, and the resulting white solid was collected by filtration, dried, and ethyl 2,3,4,6,7,8,9,10-octahydro-1H-azepino [ 4.5-g] quinoline-1-carboxylate hemifumarate 79 mg was obtained.\n\n\n\n\n\n\n \n\n実施例７\n\n　t-ブチル　1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート300mgのピリジン5.26ml溶液に塩化N,N‐ジメチルカルバモイル0.455mlを加え80℃にて3時間攪拌した。反応混合物に1M塩酸を加え、EtOAcで抽出した。有機層を飽和食塩水で洗浄し、溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフィー（溶出溶媒：HEX-EtOAc）で精製した。得られた物質をクロロホルム6mlに溶解し、トリフルオロ酢酸3mlを加え、30分攪拌した。減圧濃縮後、EtOH 4.5mlに溶解しトリエチルアミンを加え中和した後、減圧濃縮後、残渣をシリカゲルカラムクロマトグラフィー（溶出溶媒：クロロホルム-MeOH-アンモニア水）にて精製した。得られた物質をEtOH 4.5mlに溶解し、フマル酸115mgを加え、生じた白色固体をろ取し、乾燥しN,N-ジメチル-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン-1-カルボキサミド　フマル酸塩120mgを得た。\n\nExample 7 \n t-Butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 300 mg in pyridine 5.26 ml in N, N-dimethyl chloride 0.455 ml of carbamoyl was added and stirred at 80 ° C. for 3 hours. 1M hydrochloric acid was added to the reaction mixture, and the mixture was extracted with EtOAc. The organic layer was washed with saturated brine, and the solvent was distilled off. The obtained residue was purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The obtained substance was dissolved in 6 ml of chloroform, 3 ml of trifluoroacetic acid was added, and the mixture was stirred for 30 minutes. After concentration under reduced pressure, the residue was dissolved in 4.5 ml of EtOH and neutralized by adding triethylamine. After concentration under reduced pressure, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The obtained substance is dissolved in 4.5 ml of EtOH, 115 mg of fumaric acid is added, and the resulting white solid is collected by filtration, dried and N, N-dimethyl-2,3,4,6,7,8,9,10. -Octahydro-1H-azepino [4,5-g] quinoline-1-carboxamide fumarate 120 mg was obtained.\n\n\n\n\n\n\n \n\n実施例８\n\n　t-ブチル　1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート300mgのトルエン6ml溶液に、イソシアン酸エチル1.16mlを加え、90℃で終夜攪拌した。反応混合物を減圧濃縮後、シリカゲルカラムクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製した。得られた物質をクロロホルム7.5mlに溶解し、トリフルオロ酢酸3mlを加え、30分攪拌した。減圧濃縮後、EtOH 4.5mlに溶解しトリエチルアミンを加え中和した後、減圧濃縮後、残渣をシリカゲルカラムクロマトグラフィー（溶出溶媒：クロロホルム-MeOH-アンモニア水）にて精製した。得られた物質をEtOHに溶解し、フマル酸115mgを加え、生じた白色固体をろ取し、乾燥し、N-エチル-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン-1-カルボキサミド　モノフマル酸塩247mgを得た。\n\nExample 8 \n t-Butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 300 mg of toluene 6 ml solution with 1.16 ml of ethyl isocyanate In addition, the mixture was stirred at 90 ° C. overnight. The reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The obtained substance was dissolved in 7.5 ml of chloroform, 3 ml of trifluoroacetic acid was added, and the mixture was stirred for 30 minutes. After concentration under reduced pressure, the residue was dissolved in 4.5 ml of EtOH and neutralized by adding triethylamine. After concentration under reduced pressure, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The obtained substance was dissolved in EtOH, 115 mg of fumaric acid was added, the resulting white solid was collected by filtration, dried, and N-ethyl-2,3,4,6,7,8,9,10-octahydro- 247 mg of 1H-azepino [4,5-g] quinoline-1-carboxamide monofumarate was obtained.\n\n\n\n\n\n\n \n\n実施例９\n\n　t-ブチル　1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート200mgのジクロロメタン6ml溶液に氷冷下、トリエチルアミン0.148ml、エタンスルホニルクロリド0.093mlおよび1-メチルイミダゾール54mgを加えて室温で終夜攪拌した。反応混合物にEtOAcおよび飽和食塩水を加え、有機層を飽和食塩水にて洗浄後、減圧濃縮した。残渣をシリカゲルクロマトグラフィー（溶出溶媒：HEX-EtOAc）にて精製した。得られた物質をクロロホルム4mlに溶解し、トリフルオロ酢酸2mlを加え、30分攪拌した。減圧濃縮後、EtOH4.5mlに溶解しトリエチルアミンを加え中和した後、減圧濃縮後、残渣をシリカゲルカラムクロマトグラフィー（溶出溶媒：クロロホルム-MeOH-アンモニア水）にて精製した。得られた物質をEtOHに溶解し、フマル酸76mgを加え、生じた白色固体をろ取し、乾燥し、1-（エチルスルフォニル）-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン　モノフマル酸塩61mgを得た。\n\nExample 9 \n t-Butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline-8-carboxylate 200 mg in dichloromethane 6 ml solution under ice cooling 0.148 ml triethylamine , 0.093 ml of ethanesulfonyl chloride and 54 mg of 1-methylimidazole were added, and the mixture was stirred at room temperature overnight. EtOAc and saturated brine were added to the reaction mixture, and the organic layer was washed with saturated brine and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc). The obtained substance was dissolved in 4 ml of chloroform, 2 ml of trifluoroacetic acid was added, and the mixture was stirred for 30 minutes. After concentration under reduced pressure, the residue was dissolved in 4.5 ml of EtOH and neutralized by adding triethylamine. After concentration under reduced pressure, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting material is dissolved in EtOH, 76 mg of fumaric acid is added, the resulting white solid is filtered and dried, 1- (ethylsulfonyl) -2,3,4,6,7,8,9,10 61 mg of octahydro-1H-azepino [4,5-g] quinoline monofumarate was obtained.\n\n\n\n\n\n\n \n\n実施例１１２\n\n　t-ブチル　4-（3-クロロベンジル）-3-オキソ-3,4,6,7,9,10-ヘキサヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン-8(2H)-カルボキシレート283mgのテトラヒドロフラン1.8ml溶液に、1Mボラン-THF錯体のTHF溶液1.46mlを加えた後、50℃にて4時間攪拌した。反応混合物を氷冷し、MeOHを加え、室温にて30分攪拌した。反応混合物を減圧濃縮後、MeOHを加え、再び濃縮した。残渣をEtOH 2.8mlに溶解し、1M塩酸を加え、終夜攪拌した。減圧濃縮後、EtOHに溶解し、取りエチルアミンにて中和、減圧濃縮後、残渣をシリカゲルクロマトグラフィー(溶出溶媒：CHCl\n3\n-MeOH)にて精製を行った。残渣をエタノールに溶解し、フマル酸を加え、しばらく攪拌した。固体が生じた後、一度加熱して溶解し、室温にて3時間攪拌した。生じた白色固体をろ取し、乾燥した4-(3-クロロベンジル)-2,3,4,6,7,8,9,10-オクタヒドロ[1,4]オキサジノ[2,3-h][3]ベンソアゼピン　フマル酸塩23mgを得た。\n\nExample 112 \n t-Butyl 4- (3-chlorobenzyl) -3-oxo-3,4,6,7,9,10-hexahydro [1,4] oxazino [2,3-h] [3] benzoazepine-8 (2H After adding 1.46 ml of 1M borane-THF complex in THF to 1.8 ml of a solution of) -carboxylate 283 mg in tetrahydrofuran, the mixture was stirred at 50 ° C. for 4 hours. The reaction mixture was ice-cooled, MeOH was added, and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure, MeOH was added, and the mixture was concentrated again. The residue was dissolved in 2.8 ml of EtOH, 1M hydrochloric acid was added, and the mixture was stirred overnight. After concentration under reduced pressure, the residue was dissolved in EtOH, neutralized with ethylamine, concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: CHCl \n3\n -MeOH). The residue was dissolved in ethanol, fumaric acid was added and stirred for a while. After a solid was formed, it was heated once to dissolve, and stirred at room temperature for 3 hours. The resulting white solid was collected by filtration and dried 4- (3-chlorobenzyl) -2,3,4,6,7,8,9,10-octahydro [1,4] oxazino [2,3-h] [3] Benzoazepine fumarate 23 mg was obtained.\n\n\n\n\n\n\n \n\n実施例２８２\n\n　t-ブチル　11-ブロモ-1-（2-メトキシエチル）-10-メチル-1,2,3,4,6,7,9,10-オクタヒドロ-8H-アゼピノ[4,5-g]キノリン-8-カルボキシレート606mgのジクロロメタン6ml溶液に、トリフルオロ酢酸3mlを加え室温にて1時間攪拌した。反応混合物を減圧下濃縮し、残渣を塩基性シリカゲルクロマトグラフィー(溶出溶媒：CHCl\n3\n-MeOH)にて精製を行った。得られた残渣150mgをDAICEL CHIRALPAK AD-H (2cmφ×25cm)を用いて分取し、低極性物質51mg、および高極性物質45mgを得た。それぞれをエタノールに溶解させ、フマル酸を加えて造塩し、析出固体をエタノールより再結晶して11-ブロモ-1-(2-メトキシエチル)-10-メチル-2,3,4,6,7,8,9,10-オクタヒドロ-1H-アゼピノ[4,5-g]キノリン　フマル酸塩の鏡像体をそれぞれ42 mgおよび36mgを白色固体として得た。\n\n　なお、実施例２８２、及び、実施例２８２に同様に製造した実施例２８０と実施例２８１の化合物については、後記表中、生成物が１つの平面構造で示されているが、上記と同様に、２種類の鏡像体をそれぞれ単離し、取得したが、その立体化学の特定は行っていない。\n\nExample 282 \n t-butyl 11-bromo-1- (2-methoxyethyl) -10-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino [4,5-g] quinoline- To a solution of 8-carboxylate 606 mg in dichloromethane 6 ml, trifluoroacetic acid 3 ml was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified by basic silica gel chromatography (elution solvent: CHCl \n3\n -MeOH). 150 mg of the obtained residue was fractionated using DAICEL CHIRALPAK AD-H (2 cmφ × 25 cm) to obtain 51 mg of a low polarity substance and 45 mg of a high polarity substance. Each was dissolved in ethanol, salted by adding fumaric acid, and the precipitated solid was recrystallized from ethanol to give 11-bromo-1- (2-methoxyethyl) -10-methyl-2,3,4,6, The enantiomers of 7,8,9,10-octahydro-1H-azepino [4,5-g] quinoline fumarate were obtained as 42 mg and 36 mg, respectively, as a white solid. \n In addition, about the compound of Example 280 and Example 280 manufactured similarly to Example 282, the product is shown by one plane structure in the postscript table | surface, but it is the same as the above. Two types of enantiomers were isolated and obtained, but their stereochemistry was not specified.\n\n\n\n\n\n\n \n\n　上記実施例の方法と同様にして、後記表に示す実施例の化合物を製造した。各実施例化合物の構造を表９７～表１４７に、製造法及び物理化学的データを表１４８～表１８１に示す。\n\n\nIn the same manner as in the above Examples, the compounds of Examples shown in the table below were produced. The structure of each example compound is shown in Table 97 to Table 147, and the production method and physicochemical data are shown in Table 148 to Table 181.\n\n\n\n\n\n\n\n \n\n　また、表１８２～表１９０に本発明の別の化合物の構造を示す。これらは、上記の製造法や実施例に記載の方法及び当業者にとって自明である方法、又はこれらの変法を用いることにより、容易に合成することができる。\n\n\nTables 182 to 190 show the structures of other compounds of the present invention. These can be easily synthesized by using the above-described production methods, the methods described in the Examples, methods obvious to those skilled in the art, or variations thereof.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n　式（Ｉ）の化合物又はその塩、あるいは、式（ＩＩ）の化合物又はその塩は、5-HT\n2C\n受容体アゴニスト作用を有し、5-HT\n2C\n受容体に関係する疾患の予防及び又は治療剤として使用できる。\n\n　ここで、5-HT\n2C\n受容体に関係する疾患としては、腹圧性尿失禁、切迫性尿失禁、混合型尿失禁等の尿失禁、勃起不全症等の性機能障害、肥満等が挙げられる。\n\nThe compound of formula (I) or a salt thereof, or the compound of formula (II) or a salt thereof has a 5-HT \n2C\n receptor agonistic action and prevents and / or treats a disease related to 5-HT \n2C\n receptor Can be used as an agent. \n Here, diseases related to 5-HT \n2C\n receptor include urinary incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, sexual dysfunction such as erectile dysfunction, obesity and the like."
  }
]